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Abstract 
Introduction: Preterm birth is the leading cause of perinatal morbidity and 
mortality and rates are rising. The UK now has the highest rate of premature 
birth in Europe with 5.3% of overall births in Scotland occurring spontaneously 
before 37 weeks gestation (1, 2) .Preterm babies have higher rates of perinatal 
mortality and morbidity and those that survive are at risk of multiple conditions 
including respiratory distress syndrome, central nervous system abnormalities, 
necrotising enterocolitis and sepsis. The mechanisms of preterm birth are poorly 
understood. Preterm birth can be spontaneous or induced and spontaneous 
preterm labour has multiple aetiologies. Current evidence suggests that 
prolonged treatment with progesterone and 17 α-hydroxyprogesterone caproate  
(17OHPC) may reduce the incidence of premature delivery in high risk patients 
with a history of spontaneous preterm birth (3) or with a short cervix.  However, 
progesterone is not uniformly effective in preventing preterm labour and at 
present its principal mode of action on myometrium is unknown. I aimed to 
determine some of the specific mechanisms of action of progesterone. 
Aims:  I hypothesised that progesterone has a direct inhibitory effect on 
spontaneous myometrial contractility, induces increased sensitivity to tocolytic 
agents and decreases sensitivity to contractile agonists such as oxytocin. I also 
hypothesised that progesterone has inhibitory effects on endogenous uterine 
stimulants, stimulatory effects on endogenous uterine relaxants, induces 
upregulation of endogenous receptors that inhibit uterine contractions and 
inhibits contraction associated proteins both in vitro and in vivo. 
Methods: I recruited women already enrolled in the STOPPIT (a double blind 
randomised placebo controlled study of progesterone for the prevention of 
preterm birth in twins) who were given vaginal progesterone, or placebo and 
who were scheduled for caesarean section. I also recruited women with healthy 
twin or singleton pregnancies undergoing elective caesarean section. Myometrial 
biopsies were obtained from the upper border of the lower uterine segment 
incision during caesarean section. Samples were divided and used for 
contractility measurements, or subsequent mRNA, protein and 
immunohistochemical analysis.  
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Myometrial strips were cut and suspended under resting tension within organ 
baths. Concentration-response curves were carried out in response to oxytocin, 
levcromakalim, nifedipine and ritodrine to ascertain any reduction in effect by 
progesterone on oxytocics or enhancement of tocolytic effects. I also carried out 
concentration-response curves to progesterone alone and in the presence of 
potassium channel blocking agents.  I then assessed ex vivo, the inherent 
contractility of the placebo versus progesterone groups from myometrium 
sampled from the STOPPIT cohort of patients. 
I carried out cell culture experiments on myometrium from healthy singleton 
women who were not in labour at the time of sampling. Myometrial explants 
were placed in cell culture medium, cultured for 1, 4 and 24 hours, and the 
supernatants were then analysed using Bio-Plex array technology to ascertain 
cytokine release. I selected time points and concentrations conditions to 
incubate myometrial tissue using progesterone and 17OHPC and was able to 
assess cytokine release.The myometrial explants were used for subsequent 
molecular studies. I performed real time-polymerase chain reaction (RT-PCR) 
(Abi,Taqman) to quantitate endogenous inhibitors of uterine contractility 
(cGRPR, EP2,NOS), cytokines (interleukins- IL6, IL8, IL1β), uterine stimulants 
COX-2 and gap junction components ( connexin 26 and connexin 43) expressed 
relative to housekeeping gene 18s.  
Lastly, I analysed the STOPPIT cohort of myometrial samples for to determine 
the in vivo effect of progesterone. We carried out RT-PCR (Abi,Taqman) to 
quantitate endogenous inhibitors of uterine contractility (cGRPR, EP2,NOS, 
PGDH), cytokines (IL6, IL8, IL1β) and gap junction components (connexin 26 and  
43).I performed immunohistochemistry, staining for localisation of pro-
inflammatory cytokines. I then carried out protein expression analysis using 
Western blot for contraction associate protein, connexin 43. 
The project was approved by North Glasgow University Hospitals Research Ethics 
Committee ref no. 05/S0705/18. All patients gave written informed consent to 
participate. 
Results: I found that progesterone, exerted consistent, rapid and sustained 
inhibition of the amplitude of spontaneous myometrial contractions in vitro at 
high concentrations however, this affect was not achieved through the principal 
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potassium channels. Levcromakalim, a KATP channel opener, produced a 
concentration-dependent inhibition of the amplitude and frequency of 
spontaneous contractions. These effects were antagonised by the KATP channel 
blocker, glibenclamide. In contrast, glibenclamide had no effect on the 
progesterone-induced inhibition of myometrial contractility. Charybdotoxin 10 
nM (which blocks IKCa, BKCa and Kv channels), iberiotoxin 100 nM (which blocks 
BKCa channels) and apamin 100 nM (which blocks SKCa channels) failed to affect 
the ability of progesterone to inhibit myometrial contractility.  
 In contrast, 17OHPC did not exert any inhibitory effect on myometrial activity 
in vitro. Results indicated, at the selected pharmacological doses used in vitro 
that progesterone did not increase sensitivity to tocolytic agents tested. There 
was no decrease in sensitivity to the uterotonin oxytocin. Lastly, from our 
STOPPIT patient cohort I demonstrated no difference between the progesterone 
and placebo groups in either spontaneous contractility, response to tocolytics as 
above or response to oxytocin. One main conclusion of this arm of the study is 
that in vivo progesterone therapy to prevent pre-term labour does not appear to 
modify contractility ex vivo. 
I demonstrated that administration of progesterone but not 17OHPC for up to 24 
hours in vitro does not appear to modify mRNA expression of uterine stimulants 
such as cytokines, COX-2  or endogenous uterine relaxants such as NOS and 
PGDH. Progesterone but not 17OHPC inhibited production of gap junction 
component connexin 43. This modification of contraction associated protein is in 
agreement with other literature presented on human myometrial data in vitro 
(4) .  
I used STOPPIT patients as a potential example of the myometrial effects of 
progesterone in vivo with a placebo treated control group. Prolonged maternal 
administration of progesterone appeared to inhibit expression of gap junction 
components connexin 26 and 43 in myometrium. Connexin 43 importantly, was 
also modified in vitro within the progesterone treated arm. However, ex-vivo 
assessment of the functional impact on human myometrium does not 
demonstrate a long-term inhibitory impact on myometrial function with down 
regulation of endogenous contractile inhibitors such as eNOS and EP2. The 
connexins play an essential role in regulating synchronous myometrial 
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contractions. If progesterone has been of benefit in those at risk of preterm 
labour with a history of spontaneous preterm birth, it is possible therefore that 
this is by reducing connexin expression, which prevents the development of 
these synchronous contractions whilst on progesterone therapy.  
In summary, I have demonstrated putative mechanisms by which progesterone 
(and its analogue 17OHPC) might prevent preterm birth. Further studies 
characterising these pathways might inform the design of other agents which 
could provide additional efficacy in preventing preterm delivery.  
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Definitions 
AKAP membrane associated A kinase anchoring protein 
ANOVA analysis of variance 
ATP adenosine triphosphate 
BK ca large conductance calcium activated potassium channel 
BMI body mass index 
bNOS neuronal ( brain) nitric oxide synthase 
Ca  calcium 
cAMP cyclic adenosine monophosphate 
cGMP cyclic guanosine monophosphate 
cGRP calcitonin gene related peptide 
cGRPR calcitonin gene related peptide receptor 
CNS central nervous system 
COX cyclooxygenase 
CRH corticotrophin releasing hormone 
Cx Connexin 
Da  Daltons 
DAG diacylglycerol 
DEPC diethyl procarbonate 
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DES diethylstilboestrol 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
EC50 half maximal effective concentration 
ELISA enzyme linked immunoassay 
ELLUCS elective lower uterine segment caesarean section 
eNOS endothelial nitric oxide synthase 
EP2 endothelial phosphate prostaglandin 2 receptor   
ETOH ethanol 
GABA gamma amino butyric acid 
HBSS Hank's buffered salt solution 
HCl hydrochloric acid 
IFNγ interferon gamma 
IK ca intermediate conductance calcium activated potassium channel 
IL interleukin 
iNOS inducible nitric oxide synthase 
IP3 inositol triphosphate 
IU international Units 
K potassium 
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K ATP ATP sensitive potassium channel 
kDa kilo Daltons 
Kv voltage operated potassium channel 
LDH lactate dehydrogenase 
LPS lipopolysaccharide 
M moles 
MCP-1 monocyte chemoattractant protein-1 
MLCK myosin light chain kinase 
mM milliMoles 
mN millinewtons 
mPR membrane progesterone receptor 
mRNA messenger ribonucleic acid 
N newtons 
NAD nicotinamide adenine dinucleotide 
NFκB nuclear factor kappa B 
nM nanomoles 
NO nitric oxide 
nPR nuclear progesterone receptor 
PGDH 15-Hydroxyprostaglandin dehydrogenase 
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PGF-2α prostaglandin F-2 alpha 
PIP2 phosphatidylinositol biphosphate 
PKA protein kinase A 
PPROM  preterm premature rupture of membranes 
PRA progesterone receptor A 
PRB progesterone receptor B 
PRC progesterone receptor C 
PRR pattern recognition receptor 
RCOG Royal College of Obstetricians and Gynaecologists 
RCT randomised controlled trial 
RNA ribonucleic acid 
rpm revolutions per minute 
RT-PCR real time-polymerase chain reaction 
SEM standard error of the mean 
SK ca small conductance calcium activated potassium channel 
StAR steroidgenic acute regulatory protein 
STOPPIT  study of the prevention for preterm labour in twins 
TLR toll like receptor 
TNFα tumour necrosis factor alpha 
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◦C degrees centigrade 
µM micromoles 
17OHPC 17 α-hydroxyprogesterone caproate 
AKAP membrane associated A kinase anchoring protein 
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Chapter 1 
Introduction and Literature Review 
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Introduction 
Adaptive change of the uterus and myometrium during pregnancy is vital – 
initially this incorporates alteration of structure and size to accommodate the 
growing fetus, but then a change in phenotype to facilitate synchronous 
contractions to allow labour and delivery to occur. The mechanisms of this are 
still not fully understood in humans, and consequently the predicting and 
prevention of preterm labour remains one of the greatest obstetric challenges. 
Progesterone is thought to play a pivotal role in maintaining uterine quiescence. 
We have tried to expand our knowledge of the myometrial effects of 
progesterone and their role in labour both at term and preterm. 
Preterm Birth and preterm labour 
 
Preterm birth is the largest cause of perinatal morbidity and mortality; with 
rates of preterm birth rising. In the USA, the preterm delivery rate is 12–13% and 
in Europe and other developed countries, reported rates are generally 5–9% (5). 
The UK now has the highest rate of premature birth in Europe with 7.8% of 
overall births in Scotland occurring before 37 weeks gestation (6). Preterm birth 
is defined as birth before 37 completed weeks gestation by the World Health 
Organisation and has a multifactorial aetiology (7). Preterm birth is one of the 
largest contributors to mortality in the neonatal period and infancy and to 
morbidity later in life (8) and it accounts for 5–10% of all births in developed 
countries (9). In longer term, the morbidity amongst survivors of preterm birth 
has been noted to lead to poorer health and reduced achievement in school and 
beyond into adulthood. There are also significant economic costs and 
implications to both the health service and individuals affected as well as there 
families(10).  
There is a degree of overlap within the definitions of preterm birth and labour. 
Preterm birth can be spontaneous or induced and medical intervention may 
determine a preterm delivery in indicated cases. Preterm labour is responsible 
for the majority, approximately 70% of preterm births (11). It may be 
appropriate to deliver a patient by caesarean section at 35 weeks with 
fulminating pre eclampsia due to the increased risk of maternal and fetal 
complications if no action is taken. Preterm labour however is when parturition 
Laurie Anderson, 2009  25 
occurs prior to the 37 completed weeks of pregnancy. Our understanding of 
parturition as a normal physiological process is not yet complete and how this 
then becomes a pathological process prior to the 37 completed weeks of 
pregnancy is even less well understood. It is possible that preterm labour 
represents idiopathic activation of normal parturition process however the same 
triggers may not always be the initiating factor and it has been referred to as 
the “preterm parturition syndrome” in view of multiple aetiologies (12) .  
The obstetric precursors which lead to preterm birth are 1) delivery for maternal 
or fetal indications, in which labour is either induced or the infant is delivered 
by prelabour caesarean section; 2) spontaneous preterm labour with intact 
membranes; and 3) preterm premature rupture of the membranes (PPROM), 
irrespective of whether delivery is vaginal or by caesarean section (5). 
Approximately 30–35% of preterm births are indicated, 40–45% follows 
spontaneous preterm labour, and 25–30% follows PPROM. 
In general terms infants delivering at  less than 24 weeks are considered pre-
viable, under 28 weeks is extremely preterm, 28–31 weeks very preterm and 32–
36 weeks moderately preterm (13).The percentage of deliveries according to the 
relative classifications of preterm birth are approximately 5% born less than 28 
weeks, 15% between 28 and 31 weeks, 20% between 32 and 33 weeks and 60-70% 
at 34-36 weeks gestation (5).  Preterm babies are at risk of multiple conditions 
including respiratory distress syndrome, central nervous system abnormalities, 
necrotising enterocolitis and sepsis. The prognosis for the preterm infant varies 
with presence and severity of complications, but usually mortality and likelihood 
of complications decrease greatly with increasing gestational age and birth 
weight. Preterm labour is associated with preterm rupture of membranes, 
cervical incompetence, polyhydramnios, fetal and uterine anomalies, infections, 
social factors, stress, smoking, heavy work and other risk factors. There is also a 
genetic link as women who experienced an early preterm birth less than 32 
completed weeks in their first pregnancy have the highest rate of recurrent 
preterm birth in subsequent pregnancies (14).The diagnosis is made on the 
patients presenting symptoms, clinical findings and of progressive effacement 
and dilatation of the cervix (9). 
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There are multiple risk factors for preterm labour including African-American 
race, low body mass index (BMI), previous preterm birth or previous miscarriage, 
cervical abnormalities after colposcopic procedures as well as cervical or uterine 
anomalies can increase the potential for preterm labour. Fetal risk factors 
include fetal abnormalities, multiple pregnancy and polyhydramnios.  Infection 
is often linked to preterm labour however many cases are simply idiopathic with 
no determining factors. Clinically once preterm labour is diagnosed by 
confirmation of regular uterine contractions and evidence of cervical change; it 
is managed with tocolytics thereby providing time for maternal corticosteroid 
administration  which is known to reduce preterm morbidity and mortality 
(15).Notably, there is no effective long term management option to stop uterine 
contractions once they have established. This may however only be part of the 
preterm parturition problem as once the parturition process has commenced it 
may not be possible to stop the cascade of events that follow such as 
inflammation. Uterine contractions may therefore be a late event of parturition 
and we need to intervene at a far earlier point to succeed in stopping or 
preventing this process in the preterm. This suggests that to avoid preterm 
labour we must establish an effective mechanism to avoid the initial trigger and 
cause where appropriate. 
Romero et al categorise several pathological processes that may well be 
implicated in preterm labour. These include intrauterine infection, inflammation 
as a mechanism or preterm labour, uterine ischemia, uterine over distension, 
cervical disease and hormonal disorders (12). I will utilise these subheadings to 
assess underlying mechanisms of preterm labour however our main focus will be 
on hormonal disorders and in particular progesterone and its mechanism of 
action. 
Intrauterine Infection 
The association between infection and preterm birth is well established and 
thought to be the underlying cause of preterm birth in up to 40% of all cases(16). 
Importantly, there is a gestational link between preterm labour and infection 
effect as around 24 weeks, nearly all spontaneous deliveries show evidence of 
intrauterine infection, however between 34 and 36 weeks, only about 15% show 
this relationship (17). Consistent with this amniotic fluid is normally sterile and 
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isolation of bacteria within the amniotic fluid is a pathological finding. The 
majority of these preterm births are caused by bacterial infections of the 
amnion and chorion, with organisms likely originating in the vagina. Bacterial 
infections within the uterus can occur between the maternal tissues and the 
fetal membranes (i.e. within the choriodecidual space), within the fetal 
membranes (the amnion and chorion), within the placenta, within the amniotic 
fluid, or within the umbilical cord or the fetus (18).The most common organisms 
present are a common pathogens implicated in the infection of the lower female 
genital tract, caused by heavy concentrations of a mixed group of organisms 
(19). The most commonly identified bacteria are Ureaplasma urealyticum, 
Mycoplasma hominis, Gardnerella vaginalis, peptostreptococci, and bacteroides 
species (18). Many of these organisms are present in small numbers in the vagina 
normally as commensals, and although there is a strong association between the 
presence of bacterial vaginosis and preterm delivery it is not absolute (20).  The 
mechanisms that convert a subclinical infection to actual preterm labour and 
rupture of membranes are thought to involve an inflammatory response including 
increased production of cytokines, prostaglandins, and metalloproteases – which 
can all have a direct effect on the myometrium and cervix. 
Extrauterine Infection 
There is also evidence that infection from extrauterine sites is linked to 
causality of preterm birth. Specifically, urinary tract infections (21) as well as 
periodontal disease may have implications as extrauterine sources of infection 
leading to preterm birth. It has been hypothesized that in the presence of severe 
periodontal disease, oral organisms can spread hematogenously to target the 
placenta, membranes, and fetus (22). 
Inflammation 
Human parturition is increasingly recognised to be an inflammatory event. It is 
therefore possible therefore that preterm labour may be due to a prematurely 
triggered inflammatory response. There is evidence to a suggesting that labour 
involves an inflammatory process and this involves myometrium, cervix, fetal 
membranes and placenta via a cascade of events (23-25). Broadly inflammation 
can either be acute or chronic. Acute inflammation is characterised by its short 
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duration, blood vessel dilatation and leakiness, exudation of fluid and plasma 
proteins and emigration of leucocytes (26). Many of these features have been 
seen in conjunction with human labour. Pro-inflammatory cytokines are thought 
to be closely involved in the parturition process and these cytokines may 
contribute to the onset of labour by stimulating interleukin-8 (IL8) production 
and prostaglandins (27). Cytokines such as IL1β, IL6 and IL8 can induce cervical 
remodelling and weakening and rupture of membranes via synthesis of inducible 
nitric oxide synthase, cyclo-oxygenase-2 (COX-2) and matrix metalloproteinases 
(28, 29). In both term and preterm labour there is evidence to show increased 
levels of IL1β, IL6 and tumour necrosis factor-alpha (TNFα)  within amniotic fluid 
(30-32).  
Previous research carried out within our laboratory was able to demonstrate a 
massive influx of inflammatory cells (neutrophils and macrophages) into both 
lower and upper segment of myometrium in association with labour (23). They 
found that parturition was associated with a significant increase in IL1-β, IL-6 
and IL-8 messenger ribonucleic acid (mRNA) expression in cervix and 
myometrium, IL-6 and IL-8 mRNA expression in chorio-decidua and IL1-β and IL-8 
mRNA expression in amnion. Histological analysis demonstrated that leukocytes 
(predominantly neutrophils and macrophages) infiltrate the uterine cervix 
coincident with the onset of labour. (24).These results suggested that 
inflammatory cell infiltration was part of the underlying physiological 
mechanism that occurred in myometrium during parturition. 
Nuclear factor-kappa B (NF-κB) is a transcription factor which is classically 
associated with inflammation. Importantly, many pro-inflammatory and labour-
associated genes are regulated by NF-κB and there is suggestion that it plays a 
central role in parturition both at term and preterm. TNFα has been shown to 
stimulate NF-kB activity in uterine tissues. In addition, many genes which 
encode pro-inflammatory cytokines, such as TNFα , IL1-β, IL-8 and IL-6, contain 
NF-kB recognition elements within their promoters and NF-kB is known to 
promote the formation of cytokines in many cell types (27). 
Pattern recognition Receptors (PRRs) is a group of molecules which detect the 
presence of microorganisms and can trigger a host response to limit tissue 
invasion. One subclassification of these are transmembrane PRRs which include 
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toll like receptors (TLRs).These TLRs are important components of the innate 
immune system and initiate an immune response to bacterial, viral and fungal 
pathogens by activating signal transduction pathways that induce expression of 
pro-inflammatory cytokines and chemokines (12) . TLR2 and TLR4 expression has 
also been shown to increase in human decidua and amnion in preterm labour 
(33). TLR activation therefore may be important in inflammation and infection 
associated preterm birth. 
Data from a Swedish study by Hagberg et al shows evidence of infection related 
to PPROM before 34 weeks gestation. They found microorganisms detected 
within the amniotic fluid in 25% of women with PPROM and in 16% of those in 
preterm labour. Nearly half of these women had intra-amniotic inflammation 
defined as elevated IL6 and IL8, and there was a high degree of correlation 
between cytokine levels and preterm birth or the presence of microbial 
colonisation (34). 
The current view is that during the course of ascending intrauterine infection, 
microorganisms may reach the decidua, where they can stimulate a local 
inflammatory reaction and the production of proinflammatory cytokines and 
inflammatory mediators (platelet-activating factor, prostaglandins, leucotrienes, 
reactive oxygen species, nitric oxide etc). If these pro-inflammatory cytokines 
are implicated in labour and preterm labour this offers one possible target site 
for treatment or prevention of preterm labour. To date however the use of 
antibiotics to treat infection related preterm birth has shown inconsistent 
results and they are of little benefit. This may be related to the different 
outcome parameters, antibiotic regimes as well as the dose and duration of 
administration and the route, whether vaginal or systemic (16).  
Uterine Ischaemia 
Maternal vascular lesions could lead to preterm labour by causing uteroplacental 
ischaemia. There is evidence that  changes in the maternal vascular 
compartment of the placenta in patients with preterm labour and premature 
rupture of membranes are similar to those found in patients with preeclampsia 
(35). Abruptio placenta is also implicated in preterm delivery (36). The precise 
mechanisms responsible for premature labour in women with evidence of utero 
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uteroplacental ischaemia remains unclear however, the poor survival of the 
fetus in such a hostile environment may initiate parturition in such cases. One 
potential mechanism is via thrombin, a coagulation protein which possesses 
potent uterotonic activity in vitro and in vivo. This activity has been proposed to 
play a role stimulating uterine contractions which occur after delivery and also 
in preterm birth related to intrauterine haemorrhage (37, 38). 
Uterine Overdistension 
It has been established that multiple pregnancy and polyhydramnios are classical 
risk factors for preterm birth (5). The size of the uterus itself can be considered 
as a predisposing factor for preterm labour and in addition, PPROM is observed 
more frequently in twin pregnancies than in singletons (39). Uterine stretch can 
initiate myometrial contractions and lead to expression of gap junction protein  
connexin 43 (40) and increased oxytocin receptor (41) in pregnant myometrium. 
The hypertrophy of uterine myocytes is one of the earliest responses to steroid 
hormones and may modify the cellular responses to stretch and pressure (42). 
Within smooth muscle tissues, including myometrium, stretch has been shown to 
induce the depolarization of the cell membrane and increase action potential 
frequency and contractions. 
Within cell culture, myometrium has shown increased IL8 mRNA expression, COX-
2 activation and an increase in Prostacyclin (PGI2), a potent smooth muscle 
relaxant production in response to stretch (43, 44). Similar cell culture 
experiments demonstrated an increase in oxytocin receptor mRNA expression in 
response to stretch (41).  It is possible that myometrium may respond and adapt 
to gradual stretch to accommodate a growing fetus whilst maintaining 
quiescence, however as labour approaches the uterus may become primed and is 
more responsive to lesser stimuli such as inflammatory cytokines, allowing a 
contractile phenotype to take over. 
Cervical Disorders 
Cervical insufficiency is usually linked to midtrimester miscarriage however some 
forms of preterm labour present with bulging membranes in the absence of 
uterine contractions, a form of precipitous labour at term or preterm (12) . 
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Measuring cervical length by transvaginal ultrasonography has been postulated as 
a predictor of preterm labour. Cervical studies may be useful in the prediction of 
preterm delivery, both a shortened cervical length identified on transvaginal 
ultrasound examination and an increased level of fetal fibronectin in cervico-
vaginal secretions are associated with an increased risk of preterm delivery (45). 
These investigations may be useful to identify women at high risk in order to 
take appropriate action prior to the event.  
The cervix plays a key role in normal and abnormal labour and nitric oxide (NO) 
is believed to be the final mediator in the mechanisms that allow ripening of the 
cervix (46). 
A recognised congenital abnormality in cervical function is seen in women 
exposed in utero to the synthetic oestrogen diethylstilboestrol (DES). More 
commonly, women may have a potentially weakened cervix because of previous 
medical or surgical treatment. The commonest reasons for this are previous 
mechanical cervical dilation (commonly at termination of pregnancy or surgical 
evacuation at the time of miscarriage) or cervical biopsy or destruction during 
treatment for cervical neoplasia. It is these women that may well be identified 
as high risk of preterm labour and be suitable for further investigation. 
Hormonal Changes  
Progesterone maintains the pregnant state and promotes myometrial relaxation, 
but levels remain constant unlike many animal models in which a fall in 
progesterone pre-empts labour (47) . Parturition is also associated with 
oestrogen activation and a combination of progesterone withdrawal and 
oestrogen activation allows the myometrium to change from a quiescent state to 
a contractile state in order to trigger labour. Progesterone is considered vital for 
pregnancy maintenance in humans because inhibition of progesterone via 
administration of progesterone receptors antagonists such as RU486 
(Mifepristone) given to pregnant women can induce labour (48). This will be 
discussed in more detail later within the introduction. 
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Current identification and treatment strategies for preterm labour 
Labour is characterised by changes in the myometrium, cervix and other 
gestational tissues both at term and preterm. 
Detection and diagnosis of preterm labour 
 Unfortunately, clinical detection of these early changes is limited and 
subsequently uterine contractions and cervical dilatation are used as indicators 
of labour. So far measuring biochemical markers to predict preterm labour is 
limited, although measuring fetal fibronectin, an extracellular matrix 
glycoprotein, in cervicovaginal fluid has shown some promising data towards 
improving the diagnostic accuracy of preterm labour (49). 
Treatment of Preterm labour 
Current treatment strategies tend to focus on the basis that a regularly 
contracting uterus before 37 weeks gestation is the most recognisable indicator 
of preterm labour. Uterine contractions therefore have become the most 
common area to commence treatment and thus by inhibition of contractions 
with tocolysis. There are several tocolytic agents used clinically but since their 
introduction to clinical practice they have not been shown to improve perinatal 
or neonatal outcomes and have adverse effects on women in preterm labour. 
They usually maintain the pregnancy for a further 48 hours allowing 
corticosteroid administration within a therapeutic window (50). Current tocolysis 
is likely to have limited success as the available drugs do not alter fundamental 
processes leading to the initial myometrial activation, instead they target one 
aspect of contractions , which due to inherent redundancy of the process 
accommodates this and preterm birth still occurs (51).   
β- adrenergic-receptor agonists 
The β-adrenergic-receptor agonists cause myometrial relaxation by binding to 
β2- adrenoreceptors which subsequently increase the levels of intracellular 
cAMP. This in turn activates protein kinase which inactivates myosin-light chain 
kinase and reduces myometrial contractility (52). All 4 main types of adrenergic 
receptor appear to be present on the uterus. This will effect neuronal 
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modulation and therefore uterine smooth muscle contraction. Ritodrine had 
been used for many years but is unpleasant and has infrequent but potentially 
life threatening maternal side effects. In general high progesterone levels 
increase the numbers of β-receptors and produce the formation of high affinity 
state β-adrenoreceptors. It does produce a short term delay in delivery however 
should not be used as a first line treatment for preterm labour. A review of β2 
agonists (53) looked at 11 RCTs involving over a thousand women. There was a 
significant decrease in the number of women giving birth within 48 hours of 
administration (RR 0.63, 95% confidence intervals 0.53 to 0.75) but no reduction 
on deliveries before 37 weeks (RR 0.95, 95% confidence intervals 0.88 to 1.03). 
There were significant increases in maternal adverse effects but no significant 
effects on perinatal deaths, respiratory distress, cerebral palsy, neonatal death 
and necrotising enterocolitis. 
Calcium channel blocker 
Drugs that target calcium channels do so by directly inhibiting the influx of 
calcium ions through the cell membrane and the release of intracellular calcium 
from the sarcoplasmic reticulum. The reduction on intracellular calcium leads to 
the inhibition of MLCK mediated phosphorylation which is calcium dependent 
and results in myometrial relaxation (54). Nifedipine is a smooth muscle relaxant 
which inhibits the intracellular influx of calcium ions. It acts via L-type voltage 
sensitive gated channels. It is currently recommended first line use as a tocolytic 
by the RCOG green top guidelines, despite not being licensed for this use in the 
UK (55). King et al carried out a systematic review of 12 randomized, controlled 
trials involving over a thousand women (55). In this meta-analysis, compared 
with other tocolytic agents, calcium-channel blockers reduced the number of 
women giving birth within 7 days after receiving treatment (relative risk, 0.76; 
95% confidence intervals, 0.60 to 0.97) and before 34 weeks of gestation 
(relative risk, 0.83; 95% confidence intervals, 0.69 to 0.99). They also noted that 
calcium-channel blockers appeared to reduce the frequency of the neonatal 
respiratory distress syndrome, necrotizing enterocolitis, intraventricular 
haemorrhage, and neonatal jaundice.  
Laurie Anderson, 2009  34 
Magnesium sulphate 
Magnesium sulphate is the most commonly used first-line tocolytic in North 
America (56). It inhibits the contractile response and decreases the intracellular 
concentration of calcium in myometrial strips obtained from pregnant women 
that is consistent with both extracellular and intracellular mechanisms of action. 
This agent hyperpolarises the plasma membrane and inhibits myosin light-chain 
kinase activity by competing with intracellular calcium, which in turn reduces 
myometrial contractility (51). A Cochrane review of the world’s randomized 
controlled trials, encompassing more than 2,000 women in 23 trials, concluded 
that magnesium sulphate tocolysis is ineffective at delaying birth or preventing 
preterm birth, and its use is associated with an increased mortality for the 
infant (57). Grimes et al suggest further use of this agent is inappropriate unless 
in the context of a formal clinical trial with informed consent for participants 
(58). 
Oxytocin-receptor antagonists 
Atosiban is a synthetic analogue of oxytocin and therefore a competitive 
antagonist. It competes with oxytocin for binding to the receptors in 
myometrium and decidua and prevents the increase in intracellular free 
calcium. Within a Cochrane review of oxytocin receptor antagonists for 
inhibiting preterm labour six trials (1695 women) were included. Compared with 
placebo, atosiban did not reduce the incidence of preterm birth or improve 
neonatal outcome and failed to demonstrate the superiority of atosiban over β-
agonists or placebo in terms of tocolytic efficacy or infant outcomes (59). 
 Nitric Oxide Donors  
Nitric oxide is a vasodilator essential for the maintenance of normal smooth-
muscle tone. Nitric oxide is synthesized during the oxidation of L-arginine (an 
essential amino acid) to L-citrulline. This reaction is catalyzed by the enzyme 
nitric oxide synthase, which exists in several isoforms. For all three nitric oxide 
synthase isoforms, nitric oxide synthesis depends upon the enzyme's binding of 
the calcium regulatory protein, calmodulin. For eNOS and bNOS , increases in 
intracellular calcium concentrations are required for their binding to calmodulin, 
and consequently for their full activation. By contrast, iNOS appears able to bind 
Laurie Anderson, 2009  35 
calmodulin with extremely high affinity, even at the low intracellular calcium 
concentrations. In contrast to iNOS, the activity of eNOS and bNOS may be 
closely regulated by changes in intracellular calcium concentration (60).Both 
inducible (type 2) or iNOS and brain (type 1) nitric oxide synthases or bNOS are 
expressed in myometrial cells and blood-vessel endothelial cells, whereas 
endothelial (type 3) nitric oxide synthase (eNOS) is expressed exclusively in 
blood vessel endothelial cells. A Cochrane review of nitric oxide donors for the 
treatment of preterm labour included five randomised controlled trials (466 
women) .Nitroglycerine was the nitric oxide donor used in all these trials. Nitric 
oxide donors did not delay delivery nor improve neonatal outcome when 
compared with placebo, no treatment or alternative tocolytics. There was, 
however, a reduction in number of deliveries less than 37 weeks (relative risk 
0.69, 95% confidence interval 0.53-0.88).when compared with alternative 
tocolytics but the numbers of deliveries before 32 and 34 weeks were not 
influenced. Women were significantly more likely to experience headache when 
NO donors had been used (61). 
Cyclooxygenase Inhibitors  
Cyclooxygenase (COX, or prostaglandin synthase), which exists in two isoforms, 
COX-1 and COX-2, converts arachidonic acid to prostaglandin H2 (PGH2). PGH2 
serves as a substrate for the production to the alternative prostaglandins and 
prostacyclins. COX-1 is expressed in human decidua, myometrium, and fetal 
membranes, whereas COX-2 dramatically increases in the decidua and 
myometrium during term and preterm labour (51). Pharmacologic blockade of 
prostaglandin production with COX inhibitors using nonsteroidal anti-
inflammatory drugs such as aspirin is widespread within medicine (62). 
Indomethacin was the most commonly used tocolytic agent in this group. A 
Cochrane review of COX inhibitors for treating preterm labour (indomethacin 
only) demonstrated a reduction in birth before 37 weeks gestation. Numbers 
were small however within the clinical trials and the review suggested the 
information available was insufficient to form reliable conclusions (63).  
Potassium Channel Openers 
Myocytes maintain an electrochemical potential gradient across the plasma 
membrane, with the interior of the cell negative to the exterior, through the 
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action of the sodium–potassium exchange pump. A component of this process is a 
potassium channel, which is calcium and voltage regulated and allows efflux of 
potassium, thereby increasing the potential difference across the cell membrane 
and making it less likely to depolarize.  Repolarisation of the cell is brought 
about by inactivation of the calcium current and a 4-aminorpyridine sensitive 
potassium efflux. The smooth muscle relaxation is caused by opening potassium 
channels and hyperpolarising the cells. Levcromakalim, a potassium channel 
opener, causes relaxation of smooth muscle cells. Although this drug is not used 
directly in obstetrics it has been used in the treatment of hypertension and 
asthma. It is widely used for smooth muscle relaxation in pharmacological 
experiments and has in the past been suggested as a potential tocolytic agent 
(64). 
Parturition 
Human parturition is still not fully comprehended and although some areas have 
been determined there are still missing pieces of the jigsaw. Within research 
animal models are often used however, human parturition is unique and 
therefore animal models cannot answer all the remaining questions.  Some of 
the main differences in gene analysis between humans and animals are in the 
genes related to reproduction. The study of pregnant women therefore is 
paramount to further developments in our understanding of parturition.  
Timing of birth 
Corticotrophin releasing hormone (CRH) of placental origin levels increase as 
pregnancy gestation advances. They peak at the time of delivery suggesting that 
a placental clock determines the timing of delivery. In women with preterm 
labour the levels of CRH rise rapidly and also peak at the time of delivery (65). 
The levels of placental CRH are also modified by steroid hormones such as 
progesterone (66). Not all cases of preterm birth however, are related to 
changes in placental CRH production. In particular, intrauterine infection is not 
associated with elevated placental CRH production. Low levels of maternal 
plasma CRH does not therefore, rule out preterm birth. A single CRH 
measurement has relatively low sensitivity for predicting preterm birth, although 
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in an individual woman, a high CRH level has a relatively specific association 
with a greatly increased risk of preterm birth (67). 
Placental CRH is also released into the fetus, and although the concentrations 
are lower in the fetal than in the maternal circulation, they still rise with 
increasing gestation. Stimulation of the fetal pituitary by CRH increases 
corticotropin production and, consequently, the synthesis of cortisol by the fetal 
adrenal gland and maturation of the fetal lungs. The maturation of the fetal 
lungs as a result of increasing cortisol concentrations is associated with 
increased production of surfactant protein A and phospholipids. These are 
critical for lung function. 
There appears to be coordination between rising CRH production, fetal lung 
maturation and potential myometrial activation which initiates labour. 
Fetal membranes 
It is becoming more evident that rupture of the fetal membranes, term or 
preterm, is not solely due to stretch and forces of uterine contractions, but may 
also be the consequence of a programmed weakening process. In the majority of 
patients that labour at term contractions are initiated prior to the rupture of 
membranes. In general, artificially rupturing membranes in women will augment 
labour once it has started. 
Labour associated pro-inflammatory cytokines, TNFα and IL-1β, normally 
increase towards the end of pregnancy and during labour and can cause 
significant fetal membrane weakening.  This mechanism is via a process 
involving collagen remodelling and apoptosis (programmed cell death) (68). Rises 
in cortisol, CRH can stimulate COX-2 within the amniotic fluid and in turn 
increase prostaglandin E2 production with other inflammatory mediators in the 
amnion (27). PGDH, a potent inactivator of prostaglandins produced from the 
underlying chorion becomes less active towards term and underlying decidua, 
cervix and myometrium are in turn, exposed to rising levels of prostaglandin E2  
(67).These prostaglandins will promote release of matrix metalloproteases ( 
which can degrade extracellular matrix proteins)  and weaken the membranes 
leading to membrane rupture .  
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Oestrogen 
Oestrogens (mainly estradiol) oppose the relaxatory actions of progesterone and 
augment myometrial contractility and excitability. The balance between the 
relaxatory actions of progesterone and the stimulatory actions of oestrogen is 
may well determine the contractile state of the myometrium and the timing and 
process of parturition (48). 
The role of oestrogens in human parturition was studied by Pinto et al in the 
sixties and they found by administrating a large amount of 17β-estradiol to non-
labouring pregnant women at term that estradiol treatment increased uterine 
contractility and the response to oxytocin. Those findings were consistent with 
the stimulatory actions of estrogens on myometrial contractility and showed that 
the progesterone block was not absolute and could be overcome by estrogenic 
drive (69). 
There is consistent data which demonstrates the role of oestrogen as the active 
hormone required for myometrial transformation into a contractile state. In 
humans the circulating oestrogen levels increase around mid gestation and rise 
up until birth. There is also the developing concept that as for the functional 
progesterone withdrawal, oestrogens and the parturition process involve 
functional oestrogen activation. The term gestation myometrium is thereby 
more oestrogen responsive (48). Mesiano also showed that oestrogen receptor-α 
(ERα) mRNA levels correlated positively with cyclooxygenase type 2 and oxytocin 
receptor mRNA levels in non-labouring myometrium, indicating that the increase 
in ERα expression is directly associated with the activation of contraction-
associated genes and estrogen responsiveness (70). 
 The current functional progesterone withdrawal theory (discussed within next 
section) that progesterone via its interaction with progesterone receptor B 
inhibits myometrial (ERα) expression and causes the myometrium to be 
unresponsive to circulating estrogens. This subsequently will increase 
contraction associated proteins and enable myometrial transformation into a 
contractile state which precedes labour. 
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Oxytocin 
Oxytocin is a small peptide hormone with multiple sites of action in human body 
and in particular it is able to stimulate uterine contractions. This is achieved by 
multiple mechanisms involving sarcoplasmic reticulum calcium release and 
sensitization of the contractile apparatus to calcium. Its role within the 
parturition process is certainly established and it is evident within the second 
stage of labour allowing forceful uterine contractions to aid delivery of the 
baby. The role within the lead up and initiation of labour is less comprehensive.  
Towards term it is thought that the uterus and therefore myometrium, 
transforms into an active contracting form from a quiescent one and this is via 
the action of various contraction associated proteins. It is now thought that the 
nonapeptide hormone oxytocin has a fundamental role in the stimulation process 
of converting myometrial tissue to an active from and stimulates co-ordinated 
powerful contractions of labour (71). Oxytocin has been shown to be vital for the 
expulsive contractile part of labour and, although there is less evidence a role 
for oxytocin in the initiation of labour is likely. 
 The concentration of oxytocin receptors increased in the myometrium of 
pregnant women and reach maximum levels in early labour. In vitro, 
prostaglandin production by the decidua, but not by the myometrium, was 
increased by the addition of oxytocin. Oxytocin may therefore stimulate uterine 
contractions by acting both directly on the myometrium and indirectly on 
decidual prostaglandin production (72).  
The effects of oxytocin are mediated by tissue-specific oxytocin receptor 
expression, which leads directly to contraction in the myometrium and 
prostaglandin formation in the decidua. There is a significant increase in 
oxytocin receptor expression in these tissues in late pregnancy and 
pharmacological inhibition with oxytocin receptor antagonist delays delivery. 
This would suggest that, in contrast to oxytocin, the oxytocin receptor is 
essential for normal labour (73). 
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Progesterone 
This is essential within normal pregnancy and parturition and a functional 
progesterone withdrawal is now thought to instigate labour in humans. I will 
discuss this in much greater detail as this forms the basis of this thesis project. 
Progesterone and its structure 
Progesterone (4-pregnene-3, 20-Dione) (Figure 1) is a C-21 carbon steroid that 
plays a vital role in life as well as an integral role in pregnancy. It is often 
referred to as the hormone of pregnancy and its name derived from “pro 
gestational steroid hormone” encouraging pregnancy to develop with the corpus 
luteum at the early stages of pregnancy until the placenta takes over this role at 
7 to 9 weeks gestation. Progesterone like all other steroid hormones is converted 
from pregnenolone, a cholesterol derivative and is produced in the adrenal 
glands, brain, corpus luteum and the placenta. Like other steroids, progesterone 
consists of four interconnected cyclic hydrocarbons. Progesterone contains 
ketone and oxygenated functional groups, as well as two methyl branches. Like 
all steroid hormones, it is hydrophobic. Ultimately, it is an essential hormone for 
reproduction, involved in the menstrual cycle, implantation and pregnancy 
maintenance. During the menstrual cycle the corpus luteum produces 
progesterone which stimulates secretory activity from the endometrium. If 
fertilisation occurs, then implantation, the corpus luteum will continue to 
produce progesterone under the tropic stimulation of human chorionic 
gonadotrophin (hCG) produced by the synctiotrophoblasts of the conceptus 
(74).Placental trophoblasts take over production of progesterone at around 6-8 
weeks gestation and luteal progesterone production decreases as the amount of 
hCG produced by the placenta diminishes (75). Progesterone production in 
pregnancy continues to increase until the placenta is delivered at parturition 
and at term the placenta can produce up to 250mg of progesterone each day. 
Placental progesterone synthesis starts with the conversion of cholesterol to 
pregneneolone by cytochrome P450scc in the placenta. Progesterone synthesis 
by the human placenta however differs from steroid synthesis in other steroid 
producing tissues such as the adrenal cortex and corpus luteum. The human 
placenta is distinct from other steroid producing tissues in that it does not 
express the steroidgenic acute regulatory (StAR) protein. Within the placenta 
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pregneneolone is then converted to progesterone by type 1 3β-hydroxysteroid 
dehydrogenase located in the mitochondrion. Progesterone synthesis is 
stimulated by cAMP in the human placenta but uncertainty remains regarding 
the key hormones that control cyclic AMP levels (74). 
17-Hydroxyprogesterone caproate (17-α-Hydroxypregn-4-ene-3, 20-dione 
hexanoate) (Figure 2) is a synthetic hormone that is similar in structure to 
medroxyprogesterone acetate. This however, is not the same progestin as 17-
Hydroxyprogesterone (a metabolite of progesterone). There is supporting 
evidence that 17OHPC is no better than progesterone at binding to PR-A or PR-B 
isoforms and is no better than progesterone in eliciting gene expression of 
progestin-responsive genes (76).As well as progesterone, 17OHPC is being used 
within clinical trials as a potential progestin to prevent preterm labour. 
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Figure 1 : Structure of progesterone (4-pregnene-3, 20-Dione)  
 
Figure 2 : Structure of 17 hydroxyprogesterone caproate (17-α-Hydroxypregn-4-ene-3, 20-dione 
hexanoate) 
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Progesterone and the functional progesterone withdrawal 
Progesterone exerts its effects through both genomic and non genomic 
pathways, genomic pathways being mediated through nuclear progesterone 
receptors nPRs (77).The progesterone receptor isoforms are PR-A, PR-B, and PR-
C. It has long been established that progesterone is a pre-requisite for a 
successful pregnancy outcome, with functional withdrawal of progesterone now 
thought to underlie human labour. This is regulated via the progesterone 
receptors, the full length PR-B and truncated (164 N-terminal amino acids) PR-A 
under the control of separate promoters. PR-B is suggested to be the principal 
mediator of progesterone actions and PR-A represses the activity of PR-B. As PR-
A and PR-B have opposing actions the progesterone response is thought to be 
related to the ratio of PR-A to PR-B. At parturition PR-A expression increases 
until the PR-A/PR-B ratio reaches a point whereby the relaxatory actions 
mediated through PR-B are inhibited i.e., functional progesterone withdrawal 
and this may preclude labour in humans (48, 77, 78). The increase in myometrial 
PR-A expression with advancing gestation decreases PR-B and eventually 
eliminates the PR-B-mediated inhibition of ERα expression. The third 
progesterone receptor isoforms PR-C does not have the ability to bind DNA but 
can bind progesterone. There is some evidence to suggest that PR-C can bind to 
the PR-B isoforms thereby reducing the ability of PR-B to bind to progesterone 
receptor response elements and inducing loss of the progesterone quiescence. 
There is also a proposed association with upregulation of PR-B and PR-C 
expression associated with activation of the transcription factor nuclear factor- 
kappa B(NF-κB) in fundal myometrial samples (79). NF-κB is classically 
associated with inflammation and thought to be a key step within the parturition 
pathway (80). The role and presence of PR-C however, is somewhat controversial 
and there is disagreement between research groups regarding its existence as a 
naturally occurring isoform (81, 82). Further clarity on the progesterone 
receptor C and its role within parturition is still required. 
Progesterone may inhibit myometrial contractility via a number of mechanisms 
and this forms part of the main focus of this thesis. 
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Genomic actions of progesterone 
These genomic pathways alter the expression of specific contraction associated 
genes in order to modify the contractile phenotype. The contraction associated 
proteins which are of importance within the parturition process include the 
oxytocin receptor, prostaglandin F-2 alpha receptor (PGF-2α), the gap junction 
component connexin 43( Cx43) and the prostaglandin-metabolising enzyme,15-
hydroxy-prostaglandin-dehydrogenase (PGDH).  
Progesterone can be inhibited by administering RU486 in rat myometrium and as 
a result, an increase in expression of myometrial oxytocin receptor was observed 
(83). Myometrial PGF2α receptor mRNA levels significantly increased during 
labour at term and during ovariectomy-induced preterm labour in rats and this 
increase was blocked by progesterone (84). Progesterone can also promote 
inactivation of prostaglandins via increased PGDH (85). 
Synchronous activity of myometrial cells in normal labour culminates in uterine 
contractions which are necessary to expel the fetus. Equally important are the 
periods of relaxation between contractions, which permit blood flow to the 
fetus. The uterus lacks a pacemaker that regulates these contractions however 
there is clearly evidence of synchronous activity in labour. The synchrony is 
achieved by electrical conduction through connected myofibrils, which transmit 
the electrical activity to nearby muscle fibres. The activated myocytes produce 
prostaglandins, which act in a paracrine fashion to depolarise their neighbouring 
myocytes. This process progresses as more myocytes are recruited into the 
contraction (67). Gap junctions are transmembrane proteins that serve to 
synchronise contractions within the uterus and a major component of 
myometrial gap junctions is connexin 43 (Cx43) (Figure 3).  
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Figure 3 : Myocytes in Labour. During labour the myometrium converts from a low connectivity 
state (A) to a high connectivity state (B). The connections occur through gap junctions formed from 
s in particular Cx 43. Connections are also formed from the paracrine release of prostaglandins 
and local calcium concentrations. ( Figure reproduced from Smith et al review on Parturition, with 
permission (67)). 
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These are upregulated with the onset of labour (86, 87). Progesterone represses 
the expression of Cx 43 within cultured human myometrial cells (4) and estrogen 
can upregulate expression (88). It is thought that Cx 43 is synthesised days prior 
to parturition but accumulates within the cytoplasm until labour when it is 
transported to the plasma membrane and forms part of the gap junction plaques 
present at the cell surface (89).  
The assembly of gap junction protein into functional gap junction plaques is the 
last point in a stepwise process that begins with oestrogen-dependent expression 
of the Cx 43 gene and continues with synthesis of Cx 43 in the rough endoplasmic 
reticulum and transport to the Golgi, followed by its trafficking to the plasma 
membrane and its assembly into functional gap junctions. Hendrix et al found 
that the trafficking of myometrial Cx 43 from the Golgi and assembly into gap 
junctions at the plasma membrane was suppressed in progesterone treated rats 
but suggested that it may be the trafficking of  to the plasma membrane and its 
assembly into functioning gap junctions which is important to the synchronous 
activity rather than just its synthesis (90). 
Progesterone is known to up regulate endogenous inhibitors of uterine 
contractility such as calcitonin gene related peptide (91) and nitric oxide 
synthase (92) as well as inhibition of contraction associated proteins. 
Receptor-coupled pathways that promote uterine relaxation involve activation of 
cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate 
(cGMP) that phosphorylate proteins regulating calcium homeostasis. cGMP is the 
second intracellular messenger of several hormones whose main effect is 
relaxation of smooth muscle. cAMP is the second intracellular mediator of a 
significant number of hormone substances such as prostaglandins and caltitonin 
gene related peptide. The end result of these hormones is smooth muscle 
relaxation and therefore suggests a possible role in myometrial quiescence 
(93).cAMP has inhibitory effects on myometrial contractile activity and some of 
these effects require association of protein kinase A (PKA) with a plasma 
membrane-associated A-kinase-anchoring-protein (AKAP)(94) . Sanborn et al also 
demonstrated that PKA was associated with the myometrial plasma membrane 
and declined towards the end of pregnancy and that this decline was attenuated 
by progesterone and promoted by an antiprogestin (95). 
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Non-genomic actions of progesterone 
More rapid non-genomic pathways are less well understood and act via a variety 
of ways including membrane progesterone receptors (48).The non genomic 
actions are characterised by a rapid time course , i.e. minutes rather than 
hours, no nuclear progesterone receptor activity and  no requirement for RNA or 
protein synthesis (77) . 
The non genomic effects of progesterone have been identified in other organs 
and systems including inducing the acrosome reaction in sperm (96) as well as its 
effects on the central nervous system, reducing CNS excitability by its 
neuroprotective properties (97). 
Myometrial strips can be examined in vitro in order to ascertain the effects of 
progesterone. Generally studies have shown progesterone and its metabolites 
exert rapid inhibitory and concentration-dependent effects on spontaneous 
myometrial contractions, excluding 17α-hydroxyprogesterone caproate( 17OHPC) 
which had no effect in vitro  (98-100). Some however, have reported an increase 
in contractile frequency (101, 102). There is some variation between studies 
regarding the specific progestin, the doses used and the original contraction 
method used whether oxytocin induced or spontaneous. The data however is 
consistent that the affects seen are rapid, and sustained, suggesting a non 
genomic mechanism.  
The myometrium is not highly innervated and does not contain pacemaker cells 
but myometrial function is influenced by both steroid and polypeptide hormones 
as well as cytokines and other signalling molecules(103) . One hypothesised 
mechanism is that progesterone inhibits myometrial contractility directly and or 
sensitises the uterus to other tocolytics. Several lines of evidence support this. 
For example, a recent clinical trial using vaginal progesterone in vivo reported 
that patients in the progesterone arm of the study responded more favourably to 
tocolysis with β-mimetics than the placebo group (104). In vitro studies have 
also shown that progesterone sensitises  the uterus to tocolytic agents such as 
ritodrine a β-2 agonist (99). This has been suggested to operate via a non-
genomic pathway. In vivo animal studies suggest that this may be via increased 
myometrial β-adrenoreceptor density. They also reported a concentration 
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dependant relaxant effect of myometrial contractility using progesterone (105, 
106).  
Another suggested non-genomic pathway is by interacting with other receptors 
such as gamma amino butyric acid A (GABAA). In rat myometrial models, using 
GABAA antagonists they were able to demonstrate a blocked inhibition of 
contractility with progesterone, suggesting that progesterone mediated its 
action via this receptor (107). More recently however, Perusqia et al showed 
that the relaxation produced by progesterone and its 5-reduced metabolites was 
not blocked by the GABAA receptor antagonists but was reversed by calcium. 
They suggest that the relaxant action of the sex steroids is not mediated by an 
interaction with GABAA receptors and  instead a blockade of calcium influx 
appears to be responsible (108).  
The non-genomic pathways by which progesterone itself  inhibits myometrial 
contractility in vitro may operate through the cell membrane progesterone 
receptors α, β and γ, which are similar to G-protein coupled receptors (109). 
Mesiano et al details explanations of these membrane receptors and their role 
within progesterone’s mechanism of action and the functional withdrawal, this is 
summarised below. These membrane receptors have been identified recently 
and their exact role within human pregnant myometrium is not yet known. 
Several studies have shown that mPRα and -β are expressed in the human 
pregnancy myometrium and activation of mPRα and mPRβ in cultures of human 
myometrial cells decreased cAMP levels and increased phosphorylation of 
myosin. They proposed that these effects (decreased cAMP and activation of 
myosin) augment contractility. It is also evident that mPRα and mPRβ increased 
the transcriptional activity of PR-B, which would be expected to decrease 
contractility via the genomic pathway. This proposed that for most of pregnancy 
the genomic actions of PR-B dominate to relax the myometrium and that mPRα 
and mPRβ augment this pathway by augmenting PR-B activity. At parturition, 
functional progesterone withdrawal decreases PR-B actions, allowing non-
genomic actions mediated by mPRα and -β to become dominant, and therefore 
increase contractility by decreasing cAMP and increasing myosin 
phosphorylation. This suggests during pregnancy non-genomic and genomic 
actions of progesterone relax the myometrium, whereas after the functional 
progesterone withdrawal occurs prior to labour non-genomic pathways mediated 
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by mPRα and mPRβ may prevail and promote contraction (48, 77). This may 
explain why in myometrial tissues the response to progesterone can sometimes 
vary and an increase in frequency observed. If the tissues tested were sampled 
at a time after the functional progesterone withdrawal and converted to a 
contractile phenotype then these may be less responsive to progesterone and 
still able to contract. 
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Progesterone and the prevention of Preterm labour 
It has long been established that progesterone is a pre-requisite for a successful 
pregnancy outcome with functional withdrawal of progesterone now thought to 
underlie human labour as described above. In the 1956 Csapo published new 
data from rabbit models which proposed his “progesterone block hypothesis”. He 
suggested that progesterone maintained pregnancy by actively blocking labour 
and that removal of this block or a fall in progesterone preceded parturition 
(110). In the majority of animals this theory is upheld however in humans, 
parturition occurs without a fall in systemic progesterone levels. This has proven 
the subject of extensive research amongst many groups since the initial 
proposed hypothesis by Csapo. More recently progesterone and other progestins 
have been advocated as a supplementary treatment in order to prevent preterm 
birth. Consistent with this theory recent clinical trials have demonstrated a 
beneficial effect of supplementation with either progesterone or the synthetic 
progestin 17 α-hydroxyprogesterone caproate (17OHPC) in the prevention of 
preterm labour (104, 111). However, progesterone is not uniformly effective in 
preventing preterm labour and at present its principal mode of action on 
myometrium is unknown (112).  
The clinical trials carried out recently have differed in the form of progesterone 
used, its method of administration, the gestation at commencement of 
treatment and the order of pregnancy, whether singleton or multiple. Although 
no teratogenic effects have been described with most progestins, there is little 
data regarding its long term safety. Maternal side-effects from progesterone 
therapy include headache, breast tenderness, nausea, cough and local irritation 
if administered intramuscularly. Current data regarding the optimal dose of 
progesterone, mode of administration, gestation to commence therapy, or 
duration of therapy is limited and continually under scrutiny (113, 114).  
Dodd et al (114) published a meta-analysis of randomised controlled trials 
reviewing progesterone for the prevention preterm birth. In summary the 
primary outcome measures were perinatal mortality, preterm birth less than 34 
weeks gestation and major neurodevelopmental handicap at childhood follow 
up. They also considered secondary outcomes such as threatened preterm labour 
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and PPROM. Their analysis of the following six publications (104, 111, 115-118) 
involved 988 women. The routes of administration varied with da Fonseca et al 
using vaginal progesterone 100 milligrams (mg) daily and the other 5 trials using 
intramuscular (IM) 17OHPC, administered doses varying from 250mg once weekly 
to a maximal 1000mg once weekly. The gestational age for commencement of 
progestin started at 20 weeks and finished at 32-37 weeks depending on the 
trial. Hatikainen et al was a twin study and the remaining were singleton 
patients identified at high risk of preterm labour.  The results of the meta-
analysis indicated that progesterone administration is associated with a 
reduction in the risk of preterm birth less than 37 weeks' gestation (six studies, 
988 participants, relative risk (RR) 0.66, 95% confidence interval 0.54 to 0.79), 
and in infant birthweight less than 2500 grams (four studies, 763 infants, RR 
0.63, 95% confidence interval 0.49 to 0.81).They concluded that intramuscular 
progesterone was associated with a reduction in the risk of preterm birth less 
than 37 weeks' gestation, and infant birthweight less than 2500 grams. They 
suggest however that further information was required about the use of vaginal 
progesterone and the potential long term effects of progestogens on maternal 
and infant health.  
More recently data published on triplet pregnancies reported no reduction in the 
rate of preterm birth with IM 17OHPC (119). Furthermore in 2007, a randomised 
controlled trial reported no reduction in the frequency of recurrent preterm 
birth under 32 weeks, with prophylactic progesterone in women with a history of 
spontaneous preterm birth. They used a 90mg vaginal progesterone preparation 
from 18-22 weeks until 37 weeks gestation. They suggest that patients with a 
history of previous spontaneous preterm delivery constitute a heterogenous 
population and that a subset of these patients may benefit from progestin 
prophylaxis (responders) while others would not (non-responders) (120). This 
may explain the conflicting results amongst studies of progesterone to prevent 
preterm labour. In contrast , a similar regime of progesterone to O’Brien et al 
used in women with a short ultrasonographic cervical length les than 28 
millimetres(mm) concluded that the rate of preterm birth under 32 weeks was 
significantly lower for those receiving progesterone than it was for those 
receiving the placebo (121). Another paper which examined progesterone use in 
women with a short cervix demonstrated that spontaneous delivery before 34 
weeks of gestation was less frequent in the progesterone group than in the 
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placebo group. The criteria differed from the above study with cervical length of 
15 mm or less and vaginal progesterone, 200 mg daily or placebo from 24 to 34 
weeks of gestation (122). 
Progesterone and the prevention of Preterm labour is a continually developing 
and evolving field of research. The most recent meta-analysis available at the 
time of writing this chapter was published in December 2008 by Tita et al. This 
review focuses on data from 2000 onwards and identified 8 randomised 
controlled trials, 6 meta-analyses and 3 national guidelines using the search 
terms “preterm” and “progesterone”. Overall, they suggest the data indicates 
that prophylactic use of progesterone does lead to a reduction in preterm birth 
and low birth weight. However, the data are less conclusive that progesterone 
improves neonatal morbidity and mortality.  They make the following 
suggestions for guidelines in the use of progesterone for the prevention of 
preterm labour. In high risk women with a history of spontaneous preterm birth, 
weekly IM 17OHPC (250 mg) commenced at 16-20 weeks, or daily vaginal 
progesterone (at least 100 mg) beginning before 24 weeks should be given. In 
twin pregnancy, progesterone is not routinely indicated, although its use may be 
considered in women with a history of spontaneous preterm birth or short cervix 
of 15mm or less. Finally, in women with a singleton pregnancy and a short cervix 
of 15 mm or less, 200 mg of vaginal progesterone suppositories may be 
appropriate (3).  
Progesterone and the prevention of Preterm labour: STOPPIT 
The clinical trial upon which this study was partly based, STOPPIT (A 
randomised, double blind placebo controlled STudy of Progesterone for the 
Prevention of Preterm Birth In Twins) was carried out in the UK and submitted 
for publication in April 2009 (123). Five hundred women with twin pregnancy 
were recruited from UK NHS clinics specialising in the management of twin 
pregnancy. Women were randomised either to daily vaginal progesterone 90mg 
(Crinone®) or to placebo, given double blind for ten weeks from 24 weeks 
gestation. The primary outcome was delivery (or intrauterine death) prior to 34 
weeks gestation (ISRCTN 35782581). 
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The findings indicated that the combined proportion of intrauterine death or 
delivery prior to 34 weeks of pregnancy was 24.7%  in the progesterone and 
19.4% in the placebo group, odds ratio [95% confidence intervals] of 1.36 [0.89 
to 2.09]. Norman et al concluded that progesterone, administered vaginally, 
does not prevent preterm birth in women with twin pregnancy. The data are in 
agreement with those of Rouse (124) who showed that 17OHPC, administered 
intramuscularly, failed to prevent preterm birth in twin pregnancy. In conclusion 
different pathophysiological mechanisms may account for the apparent 
difference in efficacy of progesterone in high risk singleton and twin pregnancy 
and progestogens are not indicated in twin pregnancy to prevent preterm birth. 
Progesterone potential mechanisms of action 
Although there are some data which suggest that progesterone may not be of 
benefit to prevent preterm labour, due to the multifactorial background of 
preterm labour it appears likely that there are subgroups of patients for which a 
supplementary progestin may be beneficial. The outcomes of further clinical 
trials are awaited and evolving clinical data may support current trial guidelines. 
The consensus statement arising from the 46th Study Group of preterm birth 
within the Royal College of Obstetricians and Gynaecologists (RCOG) state that 
the role for progesterone in the management of preterm birth needs to be 
further critically evaluated. This research should address the dose, mode of 
administration and potential benefits and or risks of using progesterone in 
pregnancy. Its current use should be restricted to randomised controlled trials 
and further clinical trials need to be adequately powered to address neonatal 
and infant outcome (125).  
This study, in particular focuses on the myometrial effects of progesterone. We 
aimed in particular to look at both in vivo and in vitro effects of progesterone 
upon pregnant human myometrium. The data on myometrial effects of 
progesterone in pregnancy are limited and further understanding of its 
mechanism of action is required in order to enable the efficacy of progesterone 
in the prevention of preterm delivery to be maximised. We aimed to examine 
the effects of progesterone on myometrium in vitro. We were also uniquely able 
to examine progesterone effects in vivo with access to the cohort of women 
participating within the STOPPIT clinical trial. We then aimed to compare the 
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effects of progesterone in vivo and in vitro.  We therefore examined the 
following hypotheses. 
Progesterone has a direct inhibitory effect on spontaneous myometrial 
contractility 
Prolonged in vivo treatment with progesterone may directly inhibit myometrial 
contractions and in vitro treatment with progesterone or 17OHPC may inhibit 
contractions. Progesterone weakly inhibited myometrial contractions in vitro 
and other metabolites such as 5-β dihydroprogesterone were more efficacious in 
reducing myometrial contractile activity (98, 126). The study of myometrial 
strips under organ bath settings within progesterone conditions either added in 
vitro or from STOPPIT participants aims to determine any direct effects of 
progestins on myometrial contractility. 
Progesterone induces increased sensitivity to tocolytic agents 
Prolonged in vivo administration of progesterone may sensitise the uterus to 
tocolysis. In vitro, incubation with progesterone increased the efficacy of the 
tocolytic agent, ritodrine (99). Within one clinical trial of women receiving 
vaginal progesterone versus placebo that presented in preterm labour, the 
progesterone treatment group appeared to respond more favourably to tocolytic 
treatment with β- mimetics (104). We aimed to look at in vivo progesterone 
compared to placebo within the STOPPIT group and the efficacy of tocolytics 
examined ex vivo within organ baths. We also hypothesised this increased 
sensitivity would be seen with in vitro progesterone.  
Progesterone induces decreased sensitivity to contractile agonist oxytocin 
In a similar manner as above, we hypothesised that progesterone may decrease 
the sensitivity of myometrium to oxytocin, a potent uterotonin. A limited 
number of patients given a large bolus of progesterone in vivo into amniotic fluid 
decreased the frequency of contractions and weakened the response to oxytocin 
(127). 
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Progesterone utilises the potassium channel 
Progesterone exerts its effects through both genomic and non genomic 
pathways, genomic pathways being mediated through nuclear progesterone 
receptors nPR’s(77). Potassium also has a major  role in maintaining uterine 
quiescence (128). Potassium channels are widely expressed on the myocyte 
membrane surface (129); specifically adenosine triphosphate sensitive-potassium 
channels (KATP), BKCa (large conductance channel), IKCa (intermediate 
conductance channel), KV (voltage-operated channel) and SKCa (small 
conductance channel) are all present in pregnant myometrium (128).  
Additionally, levcromakalim, a KATP opener, has been shown to exert a 
concentration-dependent inhibition of spontaneous myometrial activity in vitro 
(64, 92). The opening of potassium channels or closure of calcium channels by 
progesterone could either hyperpolarise or prevent depolarisation of the cell 
respectively and would thereby potentially directly inhibit contractile activity.   
It remains unclear, however, by which mechanism progesterone causes rapid 
myometrial relaxation. It has an instant non genomic effect and we hypothesised 
that this may have some impact by acting through potassium channels as these 
also maintain uterine quiescence.  By using specific potassium channel blocking 
agents such as glibenclamide (blocks voltage gated potassium channels KATP), 
apamin (blocks small channels SKCA), charybdotoxin (blocks intermediate 
channels IKCA, BKCA, Kv) and Iberiotoxin (large conductance channels BKCA) we 
aimed to answer this hypothesis. 
Progesterone has inhibitory effects on endogenous uterine stimulants and 
stimulatory effects on endogenous inhibitors of uterine contractions 
The onset of parturition, both term and preterm is associated with increased 
myometrial prostaglandin concentrations via both increased synthesis and 
decreased breakdown (130, 131).There is also good evidence of increased pro-
inflammatory cytokine expression (24). Prostaglandins and cytokines both are 
able to stimulate myometrial contractions (129, 132). We hypothesised that the 
mechanism of action of progesterone may include the suppression of endogenous 
myometrial prostaglandin and cytokine production. In addition to these 
inhibitory effects of progesterone on uterine stimulants, progesterone may 
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potentially upregulate endogenous inhibitors of uterine contractility such as 
calcitonin gene related peptide (91) and nitric oxide synthase (92). 
Progesterone induces upregulation of endogenous receptors that inhibit 
uterine contractions 
In addition to the direct effects on stimulators and inhibitors of uterine 
contractility, we hypothesised that progesterone may alter receptor 
concentration. In rat models, progesterone has upregulated expression of the 
prostaglandin EP2 receptor (133) and calcitonin gene related peptide receptor, 
both of which promote uterine quiescence (134). 
Progesterone inhibits contraction associated proteins 
Connexins 26 and 43 are major components of gap junctions within the 
myometrium. They serve to electrically couple adjacent cells and allow the 
uterus to function synchronously. Progesterone inhibits both hormonal and 
stretch induced  expression in rat myometrium in vivo and in vitro (40, 49). We 
hypothesised that the mechanism of action of treatment with progesterone may 
include the inhibition of gap junction formation in vivo and in vitro. 
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Myometrial contractility 
In order to understand the mechanism of preterm labour it is also important to 
consider the underlying mechanism of uterine contractility. Uterine contraction 
and its physiological mechanisms of modulation highlight the importance of 
control of the smooth muscle, myometrium, during pregnancy and parturition. 
(135)  
The myometrium is composed of interlacing bundles of long, spindle shaped 
smooth muscle fibres, they are surrounded by collagen fibres, fibroblasts and 
bone marrow derived cells. In pregnancy myometrium grows with hypertrophy 
and there is an increase in the overall number of smooth muscle cells. 
Contractions occur through sliding of actin and myosin filaments. 
Smooth muscle can develop spontaneous activity with or without hormonal and 
neuronal control. An isolated piece of pregnant of non pregnant myometrium 
will produce regular spontaneous contractions. These must be preceded by 
action potentials and the basis of this follows spontaneous depolarisation of 
pacemaker cells in the myometrium. These pacemaker cells are not in a specific 
anatomical site as in cardiac muscle. Changes in the permeability of the cell 
membrane to potassium (increase) and sodium (decrease) occur to give slow 
depolarisation of the membrane potential preceding the action potential. In 
human myometrium we know that resting membrane potential is between -45 
and -50mV (136). In general the upstroke of the action potential is related to 
calcium entry and repolarisation due to inactivation of calcium channels and 
potassium efflux. Calcium entry is via voltage gated channels which are opened 
by spontaneous pacemaker activity, hormonal and neuronal control. The 
contractile activity is highly dependant on extracellular calcium concentration. 
This can be blocked by dihydropyridine derivatives, such as nifedipine, 
suggestive therefore that these are L-type channels. Repolarisation is brought 
about by inactivation of the calcium current and a potassium efflux. 
Levcromakalim, a potassium channel opener, causes relaxation in smooth 
muscles including the uterus and in a dose dependant manner. In other smooth 
muscles the drug exerts this effect by opening potassium channels and 
hyperpolarising the cell. In the uterus relaxation is usually only accompanies by 
a small hyperpolarisation i.e. their mechanisms may differ. Different hormones 
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and neurotransmitters may change electrical activity within these cells. Agonists 
can bring about uterine contraction by membrane potential-independent 
mechanisms such as the release of calcium from the sarcoplasmic reticulum  by 
a chemical messenger, 1, 4, 5-triphosphate (IP3) .This is well known to be 
initiated not by depolarisation, but by agonist-receptor interaction which and is 
described as pharmacomechanical coupling. Another such pathway involving 
calcium entry via voltage operated channels after depolarisation can arise 
spontaneously within the myometrial membrane. The entry of calcium then 
leads to further depolarisation. Another such mechanism is an increase in 
intracellular calcium concentration produced by the agonist binding to its 
receptor, stimulating receptor operated channels, causing depolarisation which 
then activates voltage operated channels allowing more calcium to enter. An 
increase in the intracellular calcium concentration produced by an agonist 
induced calcium release from internal stores is another method by which activity 
can be enhanced. The agonist stimulates a G protein (secondary messenger) 
which inactivates phosphoinositidase C which produces 1, 4, 5-triphosphate (IP3) 
and diacylglycerol (DAG) from phosphatidyl 4, 5-inositol biphosphate (PIP2) in 
membrane. IP3 causes release of calcium from the sarcoplasmic reticulum. DAG 
will stimulate protein kinase C which is further hydrolysed to phosphatidic acid 
and arachidonic acid. This can in turn be used for prostaglandin synthesis. The 
rise in intracellular calcium results in the formation of an active compound 
between calcium, calmodulin and myosin light chain kinase (MLCK). Calcium 
binds to the calmodulin forming a calcium-calmodulin complex, which allows the 
activation of enzyme myosin light chain kinase. This phosphorylates light chains 
on myosin allows actin binding and increases actin-activated myosin MG-ATPase 
concentration, a contraction may then occur with the hydrolysis of ATP. The 
phosphorylation of the myosin light chain causes the generation of ATPase 
activity, which promotes the sliding of myosin over the actin filaments and the 
movement that constitutes a contraction. Relaxation will occur as intracellular 
calcium lowers by uptake into internal stores and extrusion across the 
sarcolemma. The calcium calmodulin-MLCK complex is then inactivated. 
There does appear to be a lack of overall understanding concerning uterine 
contractility and there are many modulators of control. The uterus has 
autonomic innervation via parasympathetic fibres. All 4 main types of adrenergic 
receptors are present on the uterus. In general α-activation stimulates 
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contraction and β-activation mediates relaxation. β-2 receptors are 
predominantly responsible for relaxation (137). Progesterone appears to produce 
the formation of high affinity state β-adrenoreceptors. β -adrenoreceptor 
agonists, such as ritodrine, have therefore been used to try to control preterm 
labour as this is linked with uterine relaxation. 
Activation of the uterus and myometrium 
The regulation of uterine activity during pregnancy and labour take place over 
several stages.  During pregnancy, the uterus is maintained in a state of 
functional quiescence through the action of various mediators, including 
progesterone, prostacyclin, nitric oxide, parathyroid hormone–related peptide, 
corticotropin-releasing hormone, and calcitonin gene–related peptide. Before 
term, the uterus undergoes activation and stimulation perhaps as a result of the 
functional progesterone withdrawal. Activation then occurs in response to 
uterotonins, including estrogen, and is characterized by increased expression of 
a series of contraction-associated proteins (including myometrial receptors for 
prostaglandins and oxytocin), activation of certain ion channels, and an increase 
in connexin 43 (a key component of gap junctions). An increase in gap junctions 
between adjacent myometrial cells leads to electrical synchrony within the 
myometrium and allows effective coordination of contractions.  Once activated, 
the "primed" uterus can be stimulated to contract by the actions of uterotonins 
such as oxytocin and the stimulatory prostaglandins. Preterm labour may 
represent an early activation of this normal term process due to various trigger 
factors. 
Summary 
Despite research efforts so far, the molecular mechanisms responsible for the 
onset of labour in humans, both at term and preterm, remain unclear. By 
utilising human myometrium from pregnant patients and focussing on its 
function and response to progesterone we aimed to elucidate some of these 
functional and molecular mechanisms. It is evident that progesterone plays a 
central role within this process however, the fundamental differences between 
animal models and humans have left unexplained questions.   
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There is much evidence about animal models and the role of progesterone in 
vitro however little evidence is available about the effects of progesterone on 
human myometrium in vivo. We aimed to try and ascertain some of the 
myometrial effects of progesterone by investigating women actively 
participating in a clinical trial of progesterone versus placebo to prevent 
preterm labour. It is this in vivo aspect that is unique to our study and an 
important aspect of the parturition pathway that has yet to be fully explained 
with appropriate supporting evidence.  
Progesterone is integral to the parturition process. The prevention of preterm 
labour therefore, is a much more achievable research goal if its underlying 
mechanisms of action are clarified within human myometrium.  
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CHAPTER 2  
Materials and methods 
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Patient Selection  
Experiments were carried out on patients undergoing elective caesarean section 
at or greater than 37 weeks. These patients had clinical indications for an 
elective caesarean section such as previous caesarean, breech presentation, 
maternal request. All patients were consented prior to theatre and myometrial 
biopsies were collected by the operating obstetrician. I was able to perform all 
consents personally to give a full and detailed explanation to the patient 
allowing time to consider participation in the trial and also to fill out the 
appropriate paperwork. In order to maintain the same conditions each specimen 
was taken after delivery of the baby but prior to administration of 5 IU 
syntocinon. Anaesthetists administering the drug were informed prior to theatre 
to withhold syntocinon until the biopsy had been taken. This took approximately 
5 minutes following delivery of the baby. At the time of caesarean section a 
myometrial biopsy (measuring 10mm wide by 10 deep by 20 mm length) was 
taken from the upper border of the incision into the lower uterine segment and 
closed routinely as required for caesarean section providing minimum risk to the 
patient. I was present in theatre at each biopsy in order to place the sample in 
the correct medium as soon as possible and to check each sample was biopsied 
correctly and from the same part of the lower uterine segment. The tissue for 
contractility, cell culture and molecular studies was immediately placed in 
separate buffers (Krebs Henseleit buffer, HBSS) prior to transportation to the 
laboratory. All tissue for functional contractility and tissue culture experiment 
data was placed immediately in Krebs or HBSS buffer respectively for use within 
12 hours. 
Women recruited to the in vivo study of placebo versus progesterone were 
patients included in the “STOPPIT” trial. This is a double blind randomised 
placebo controlled study of progesterone for the prevention of preterm birth in 
twins and was taking place within Scotland. Within the clinical trial, participants 
were randomised either to daily progesterone gel (90mg) (Crinone®) or placebo 
gel both administered vaginally by the participant and starting at 24 weeks + 0 
days gestation. Drugs were supplied in a sealed opaque covering. Each cover 
contained a single use, one piece, white polyethylene applicator with a twist-off 
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top, designed for intravaginal insertion. Each applicator contained 1.45 g of gel 
and delivered 1.125g of gel, containing either 8% progesterone or excipients 
(glycerin, light liquid paraffin, hydrogenated palm oil glyceride, carbopol 974P, 
sorbic acid, polycarbophil, sodium hydroxide and purified water) only. Patients 
were required to administer the gel at the same time each day and also asked to 
keep a diary of any symptoms or added information. They generally attended the 
antenatal clinic between every two to four weeks and were seen by a designated 
STOPPIT midwife. They were also contacted by telephone at regular intervals to 
ensure compliance and general wellbeing. If patients were subsequently 
scheduled for caesarean section for obstetric clinical reasons such as twin 1 
breech presentation, then they were selected and consented for this sub study. 
We collected samples form both elective and emergency caesarean section .All 
information, regarding STOPPIT placebo or progesterone treatment was blinded 
at the time of collection and the myometrial biopsy was taken as described 
above. Once the myometrial biopsy was obtained it was divided into 5 small 
sections. One placed in a Krebs buffer for functional contractility analysis and 
use within 12 hours. Another was placed in formalin for subsequent paraffin 
embedding and immunohistochemistry. The final 3 were placed in “RNA Later” 
(in view of multiple site location with trial based in several Scottish hospitals) 
for 4 weeks and then snap frozen in liquid nitrogen. These were then stored at -
80◦C for subsequent protein and molecular analysis. 
Laurie Anderson, 2009  64 
Chemicals used in functional studies 
 
All concentrations stated are final bath concentrations. All drugs were obtained 
from Sigma (Poole) except for iberiotoxin and charybdotoxin which were 
obtained from Latoxan (France). All drugs were dissolved in saline except 
levcromakalim ( DMSO solvent), oxytocin ( acetic acid), nifedipine ( ethanol), 
non water soluble progesterone ( 70% ethanol), 17OHPCC ( 70% ethanol)and  
glibenclamide ( DMSO).Water soluble progesterone, Sigma (Poole) is contained 
within a cylclodextrin compound. This enables hydrophobic molecules to be 
incorporated into the cavity of the cylclodextrin by displacing water, when the 
water soluble complex is dissolved in a larger volume of aqueous solvent the 
process is reversed thereby releasing the molecule into the solvent .Stock 
solutions of each chemical were made in advance and stored at -20ºC. Fresh 
solutions were made on the day of each experiment. 
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Lower uterine segment versus upper segment myometrium 
Myometrium can be collected from the lower uterine segment at the incision site 
for caesarean section. Collection from this site involves the least risk to the 
patients since it is already the site of incision and could be performed by the 
operating obstetrician with competence in caesarean section. Upper segment 
biopsies require more senior obstetricians to obtain and are more likely to 
provoke extra bleeding and are therefore less acceptable to participants. 
Previous works within the group have directly compared upper and lower 
myometrium and have observed changes seen in labour in both upper and lower 
tissues (23). Other studies compared the contractile characteristics of 
myometrium taken from upper and lower uterine segments. Biopsies obtained 
from women undergoing classical caesarean section therefore upper and lower 
segment samples were available. Myometrial strips were dissected and mounted 
in an organ bath, and contractions recorded. There were no significant 
differences in the contractile rate and force produced by myometrium from 
upper and lower segments therefore demonstrating that for contractile studies, 
the use of lower segment is appropriate and there is little regional functional 
difference (138). 
Lower segment tissues still give adequate results and that extra risks and 
difficulties of obtaining upper segment tissue was not justifiable. All biopsies 
therefore are from the lower uterine segment. 
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Contractility studies 
Subject and preparation of tissue 
 
Ethical approval for sample collection was obtained from the North Glasgow 
University Hospitals Research Ethics Committee Reference number 05/S0705/18( 
STOPPIT sub study)  and Glasgow Royal Infirmary Ethics Committee number 
08/S0704/41 .All patients gave written informed consent to participate.  
Women recruited to the in-vivo study of placebo versus progesterone were 
patients included in the “STOPPIT” trial 
Women recruited to all other aspects of the research were singleton patients 
undergoing elective caesarean section at 37 weeks or greater for the following 
clinical indications, previous caesarean section, breech presentation and 
maternal request. Patients were excluded if they were undergoing elective 
caesarean for placenta praevia, history of fibroids or had previously had a post 
partum haemorrhage greater than 1L. 
 Myometrial biopsies 2cm long, 1cm wide and 1cm thick were taken from the 
middle portion of the upper lip of the lower segment caesarean section incision. 
This was done following delivery of the baby and prior to administration of 
syntocinon 5IU. All biopsies were immediately placed in a buffered Krebs 
solution (NaCl 133nM, KCl 4.7nM, glu 11.1nM, MgS04 1.2nM, KH2PO4 1.2nM, CaCl2 
1.2nM, TES 10nM). Tissues were stored at 4°c and used within 12 hours of 
collection. Strips of myometrium 15mm long, 2mm wide and 2mm deep were cut 
under no tension. There was no stretch applied to tissue prior to its attachment 
to the rig for equilibration. The strips were secured with silk and placed under 
isometric conditions with a 20mN resting tension.  Contractility data was 
recorded via a tension transducer (FT03, Grass Technologies, Slough, UK) and 
the signal amplified and stored in a commercial data acquisition system (Octal 
ML228 Bridge Amplifier; PowerLab ML870/P, Chart, version 3.6, all AD 
Instruments. Each tissue strip was suspended in a separate 10ml organ bath 
filled with Krebs-Henseleit solution, gassed with 95% O2/5% CO2, and maintained 
at 37 oC. Tissues were equilibrated for a minimum of 2 hours prior to adding any 
substances. When suspended in this manner strips developed rhythmic activity 
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which stabilised within 90 minutes to 3 hours. Once stable activity had 
developed with the amplitude and frequency having less than 5% variation 
between contractions then we were added drugs as relevant for each 
experiment. Each biopsy from a participant was divided into identical strips. One 
a strip from each participant was used to test each drug and a further strip was 
used as a control strip. Additionally multiple drugs were tested in parallel from 
each participant.  No participant provided more than one strip for each drug (or 
control).  All analysis of amplitude and frequency was read in real time and 
inserted into the CHART® datapad software. This was then transferred to 
Microsoft Excel for further analysis. If a strip did not develop stable activity then 
this arm of the experiment was excluded. If more than 1 strip failed to contract 
then the subsequent experimentation and analysis was not possible so this 
patient would be excluded. 
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Organ bath experiments 
Oxytocin 
 
At the end of the 2 hour equilibration period rhythmic contractile activity was 
assessed in each myometrial strip. 6 organ baths were available within this 
protocol and a control strip was used for each patient. Oxytocin was used to 
stimulate contractions. A concentration-response curve was carried out between 
10 pM and 100µM. 20 minute time intervals were used for each concentration to 
allow drug interface interaction.  
Tocolysis 
Three separate tocolytic agents were tested, nifedipine a calcium channel 
blocker, levcromakalim a potassium ATP channel opener and ritodrine a β2- 
agonist. Concentration-response curves were obtained from nifedipine and 
levcromakalim 10 pM-1µM and 0.01µM to 100µM for ritodrine hydrochloride. Each 
drug was tested on separate myometrial strips in a cumulative fashion. 6 organ 
baths in total were available. This allowed a separate strip from the same 
patient to be treated with oxytocin, levcromakalim, nifedipine and ritodrine as 
well as 2 control strips. 
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STOPPIT trial 
 
After stable activity had developed in myometrial tissues from the specific 
STOPPIT myometrial samples collected we added oxytocin 100 picoM -100 µM 
and derived a full concentration response curve. In separate baths each of the 
tocolytics nifedipine 1nM-100 µM, levcromakalim 10nM-10 µM and ritodrine 
10nM-0.1mM were added in cumulative fashion to individual myometrial strips. A 
control strip was included for all experiments to examine the inherent amplitude 
and frequency of the placebo vs. progesterone group. We recorded amplitude 
and frequency as described before at the time of each experiment whilst still 
blinded to the groups to minimise bias. 
The STOPPIT codes were unlocked for the specified patients after the 
experiments were completed, and analysis performed as comparison of in-vivo 
placebo vs. progesterone tested under in-vitro conditions. 
Progesterone incubation in vitro 
 
We carried out concentration-response curves with oxytocin (stimulates 
myometrial contractions 10 pM-10 µM), levcromakalim (a KATP channel opener, 
100 pM -10 µM), nifedipine (a calcium channel blocker, 100 pM-10 µM) and 
ritodrine (a β-2 agonist, 0.01 µM-1 mM) all final bath concentrations, on separate 
strips from patients, n≥6. We then carried out concentration-response curves to 
oxytocin, levcromakalim, nifedipine and ritodrine as described above, following 
an incubation of each myometrial strip with progesterone 1 µM from a separate 
group of patients n≥6. This concentration was selected as it became clear that 
ethanol had a tocolytic effect itself and therefore we wished to minimise this. 
Progesterone 1 µM (dissolved in 70% ethanol) with an appropriate ethanol vehicle 
control (0.07% final bath concentration) was added to the myometrial strips at 
the end of the equilibration period for a 60 minute time period before carrying 
out each concentration-response in the second group and  we recorded 
amplitude and frequency as before. 
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Progesterone and 17-α hydroxyprogesterone caproate 
 
Progesterone and 17OHPC were dissolved in 70% ethanol stock. Water soluble 
progesterone was dissolved in distilled water. All potassium channel blockers 
other than glibenclamide were made into saline solution. DMSO solution was 
used for gliblenclamide. Oxytocin was dissolved in 2% acetic acid solution and 
tocolytic substances were made in saline solution. All drugs were obtained from 
Sigma (Poole), iberiotoxin and charybdotoxin from Latoxan, France. Each drug 
was measured into stock concentrations and fresh solutions were made for each 
separate experiment. Progesterone (10nM-100µM) was added in a cumulative 
manner at 20-minute intervals, amplitude and frequency were recorded at the 
end of each time period. Similar experiments were then carried out with 
17OHPC. Each of progesterone and 17OHPC were dissolved in a 70% ethanol 
vehicle, 10-3 M stock. Vehicle controls were included in all experiments. In view 
of ethanol having a significant tocolytic effect all progesterone experiments 
were repeated using water soluble progesterone. Both concentration-response 
curves and time point analyses were carried out for water soluble progesterone 
and the same concentrations. For time plot experiments a single dose of 
progesterone 10µM, 30µM and 100µM was added to organ baths after the 
equilibration period. The amplitude and frequency was recorded as before, after 
stable rhythmic activity achieved around 2 hours and then measured at 30 
minute intervals noting both amplitude and frequency. This was recoded for 4 
hours after addition of the progesterone. 
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Potassium channels blocking functional studies 
 
Given the demonstrable inhibitory effect of ethanol at higher concentrations 
that we observed on contractions, all subsequent experiments were conducted 
with only water soluble progesterone. Each of the potassium channel blocking 
agents, glibenclamide 1.5 µM (blocks KATP channels), charybdotoxin 100 nM 
(blocks intermediate channels IKCa, BKCa, Kv), iberiotoxin 100 nM (blocks large 
conductance BKCa channels)  or apamin 100 nM (blocks small SKCa channels) were 
added to myometrial strips at the end of the equilibration period. 
Concentration-response curves were then carried out adding water soluble 
progesterone as described above. Experiments were performed on separate 
strips with n≥6 for each agent.  Time matched controls were included for all 
agents and a DMSO vehicle control was also included for glibenclamide. Time 
course experiments were also repeated with progesterone 100 µM after the 
addition of each potassium channel blocking agent. If no spontaneous activity 
developed in an organ bath then this arm of the experiment was excluded.  
Potassium channel 
blocker 
KATP BKCa IKCa SKCa Kv 
Glibenclamide +     
Charybdotoxin  + +  + 
Apamin    +  
Iberiotoxin  +    
Table 1: Potassium channel blocking agents 
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Contractile analysis 
Spontaneous contraction amplitude was taken as the mean amplitude of three 
consecutive contractions recorded prior to the addition of drug. Stable activity is 
defined as a series of at least 3 contractions reaching the same amplitude and 
frequency after the 2 hour equilibration period. The response to drug was 
defined as the effect on a single contraction at the time point of interest and 
recorded in milliNewtons (mN).  Frequency was recorded in Hertz (number of 
events occurring per second) by measuring the interval between the peaks of 
two consecutive contractions occurring at the time point of interest. This was 
subsequently converted to contractions/h-1. For time point analysis, contraction 
amplitude and frequency were analysed following the development of stable 
rhythmic activity, immediately prior to addition of drug, time 0, and at every 30 
minute periods thereafter. An integral measure of contractile activity was 
determined by the area under the tension curve for each contraction and 
recorded for 60 minutes after the addition of each substance.  
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Contractility statistical Analysis 
 
The tension (amplitude of contraction) of the myometrial strips was recorded in 
millinewtons (mN). A reduction in the magnitude of the contractions was 
expressed as a percentage inhibition (mean ± SEM) of the contraction obtained 
immediately before the first addition of the drug. The frequency of contractions 
was defined as the number of contractions h-1. Each data set from each 
myometrial strip was transferred from the Chart® datapad onto Excel 
spreadsheets. Statistical analysis was carried out using one-way analysis of 
variance with Bonferoni correction and Kruskall-wallis test for non parametric 
data as well as paired t test for parametric data (Graph Pad prism, Minitab). A 
value of p< 0.05 was considered to indicate statistical significance. 
Laurie Anderson, 2009  74 
Cell Culture  
Patients were selected and were asked for informed consent as described 
previously. Myometrial biopsies were obtained each morning from non-labouring 
elective caesarean section patients. These were placed into HBSS (Sigma) 
immediately after delivery. They were then transferred to the laboratory and in 
tissue culture hood washed 3 times in Dulbeccos PBS (Sigma) to remove any 
excess blood. The biopsy was then dissected into small pieces (10-30mg weight). 
Three myometrial explants of known weight were then placed into each of a 24 
well plate containing 1ml of Isocoves medium supplemented with 100µl/ml 
penicillin,100µg/ml streptomycin(500µl in 50ml) and 250ng/ml fungizone( 
amphoterocin 50Vl in 50ml). After a pre-incubation at 37ºC for 45 minutes in a 
humidified chamber the explants were transferred to a new well containing 
fresh culture medium. Tissue samples were incubated with nil ( control) , 
Progesterone(water soluble) at 10-6M, 10-5M, 10-4M concentration and 17-α 
hydroxyprogesterone caproate 10-6M,10-5M,10-4M . DMSO controls were carried 
out for 17 hydroxyprogesterone caproate as it was made in stock solution at 10-
1M with 100% DMSO. Each well was carried out in duplicate and separate wells 
were used for the LDH assay to check tissue viability. After incubations periods 
of 1hour, 4hours and 24 hours supernatants were collected in duplicate and 
stored at -20 ºC. Myometrial explants were frozen in liquid nitrogen at the end 
of the 24 hour period and these were stored at -80 ºC for subsequent RT-PCR 
analysis. LDH assays were performed on the supernatants and a standard curve 
was performed using LDH to quantify results. This allowed us to confirm tissue 
viability for the 24 hours of the tissue culture experiment. 
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LDH Assay 
The LDH (lactate dehydrogenase) assay was used as a means of determining 
membrane integrity as a function of the amount of cytoplasmic LDH released 
into the medium. The assay is based on the reduction of NAD by the action of 
LDH. The resulting reduced NAD (NADH) is utilized in the stoichiometric 
conversion of a tetrazolium dye. The resulting coloured compound is measured 
spectrophotometrically. If cells are lysed prior to assaying the medium, an 
increase or decrease in cell numbers results in a change in the amount of 
substrate converted. This indicates the degree of inhibition of cell growth 
(cytotoxicity) caused by the test material. With myometrial explants we were 
unable to determine the actual cell number so weights were noted for each 
experiment. We also used LDH to make standards 1000, 750, 500, 250, 125, 62.5, 
31.25, 15.625 mU/ml) in order to quantify the LDH in vitro toxicology assay kit 
(Sigma). We used both methods as described by the manufacturer, the first 
providing a measure of total cell LDH and the second assessing the membrane 
integrity of cells as a function of the amount of LDH leakage into the 
supernatant. We also left tissue culture explants for greater than 24 hours and 
measured LDH release into the supernatant over time.  We prepared a tissue 
culture experiment as described above and collected the supernatants to 
measure LDH with the different conditions of progesterone, 17OHPC and DMSO. 
We also performed a separate group of cell cultures in order to ascertain LDH 
release. Using 4 time points 0, 1, 4 and 24 hours we wanted to clarify LDH 
release at time 0 with and without the lysis buffer. This gives us a comparison of 
levels of LDH spontaneously released from untreated cells and maximum LDH 
activity that can be released in response to lysis. At time 0 we incubated tissue 
in duplicate with Isocoves medium and lysis buffer and then froze samples at -20 
ºC to perform LDH assay together with other time points. Using 3 separate 24 
well plates for the 1, 4 and 24 hour time points we performed duplicate cell 
culture for myometrial explant tissue alone (in Isocoves medium) and also 
incubated tissues with a lysis buffer and isocoves medium. The lysis solution was 
added in a 1/10 volume and incubated for 45 minutes at the end of each time 
point. Supernatants were then collected at each time point and frozen at -20 ºC.  
For the LDH assay we used a 96 well plate, and carried out eight standards for 
LDH in combination to clarify the kit was detecting LDH correctly.  We 
transferred the all supernatants and standards and centrifuged this at 1100rpm 
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for 4 minutes. Two wells containing medium (isocoves) only were included as 
blanks. Every sample was measured in duplicate neat and at a 1: 10 dilution. We 
prepared the LDH assay mixture by adding equal amounts of LDH substrate, 
enzyme and dye adding this in an amount equal to half of the volume of culture 
medium. This was then incubated (covered in foil to protect from light) for 30 
minutes. 15µl (a 1/10 volume) of 1N HCl was added to each well to terminate 
the reaction. We then measured absorbance spectrophotometricallly at a 
wavelength of 490nM and measured the background absorbance of the plate at 
690nM and subtracted from the primary wavelength measurement ( Ascent 
software®). This allowed us to compare LDH release at time 0 from all other 
timepoints used within the cell culture experiments and indicating the degree of 
LDH release over time. The medium (blank) wavelength could then be 
subtracted from all of the results and points compared to our standards and also 
over time.  
In another LDH assay we measured supernatant LDH release over time at 24, 48, 
72, 96, 120, 144 hours to determine cell membrane integrity over time. 
BIO-PLex  
Cytokine quantification was carried out with Bio-Plex (BIO-RAD®) system and 
suspension array technology. Supernatant samples were defrosted and 
centrifuged at 10,000rpm for 1 minute. 100% beads and neat supernatants were 
selected from a test bioplex experiment with duplicate samples. A pre-designed 
selection of cytokines were analysed using the BIO-RAD system .This is a 
multiplexed, particle based, flow cytometric assay which utilises anti-cytokine 
monoclonal antibodies linked to microspheres incorporating distinct proportion 
of two fluorescent dyes. Each of the 100 spectrally addressed bead sets can 
contain a captive antibody specific for a unique target protein. Fluorescent 
intensity of the bead identifies the reaction.  Our assay was customised to 
detect and measure IL1β, IL6, IL8, IL10, IFN γ, MCP and TNF α. Cytokine assays 
were performed as per the manufacturer’s protocol (BIO-RAD®) system. 
Following completion of the cell culture step we then stored supernatants at -20 
ºC. The samples were then selected using each control, progesterone and 
17OHPCC concentration as well as standards according to the Bio-Plex protocol. 
We used a labelled 96 well plate with corresponding key for each concentration 
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and drug. All weights of initial tissue were recorded and taken into account for 
the final analysis of results. The results were expressed as picograms per 
ml/1gm wet weight. 
BIO-PLex cytokine assay from BIO-RAD® 
Sample preparation 
We centrifuged the supernatants at 10,000 rpm for 1 minute and then tested 
dilute samples up to 1:20 if required –test first. A neat solution was decided as 
optimum conditions. All samples were kept on ice for the duration of the 
experiment. With the Bio-Plex kit a standard is available; this was diluted in the 
same medium as cell culture supernatants. A 96 well plate was suitable for 2 
patients using a total of 3 separate kits for 6 patients in total. Adding 500ul of 
appropriate matrix then vortexing gently and incubated on ice for 30 minutes. 
We prepared multiplex bead working solution from 25 x beads Bio-Plex (BIO-
RAD®) and protected beads from light by wrapping in foil. We filled 96 wells of 
the filter plate with 100ul Bio-Plex assay buffer each time removing the buffer 
by vacuum filtration and drying the bottom of filter plate thoroughly with a 
clean paper towel (lint free). The multiplex beads are vortexed for 15-20 
seconds at medium speed and 50ul pipetted into each well and again removing 
the buffer by vacuum filtration each time. 100ul of Bioplex wash buffer was 
added to each well and then removed by vacuum filtration and this step 
repeated.  50ul of each diluted standard and supernatant sample was then 
added into each well and covered with sealing tape. The plates were covered 
with foil and then shaken at 1,100rpm for the first 30 seconds then 300rpm for 
30 minutes at room temperature. We removed the buffer by vacuum filtration 
and wash 3 times with 100ul Bio-Plex wash buffer blotting the bottom of filter 
plate with clean paper towel after every wash to prevent cross-contamination. 
The detection antibody solution 25ul was then added to each well. It was 
covered with sealing tape and with foil and shaken as described before. The 3 
washes were repeated as. Streptavidin-PE 50ul was added to each well covered 
and shaken as before. The 3 washes were then repeated.  We then resuspended  
beads in each well with 125ul Bio-Plex assay buffer covered with sealing tape 
and shaken at 1100rpm for 30secs and stored at 4 ºC overnight before analysing 
the plate the following day .  
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Immunohistochemistry 
Immunohistochemistry was performed on paraffin-embedded myometrial 
samples from STOPPIT patients using antibodies against IL- 1b, IL-6, IL-8, TNFa, 
and CD45. These were selected in view of previous works published on these 
antibodies within our laboratory ad their importance in the role of parturition. 
Sections 5 mm thick were cut from the paraffin-embedded tissues, mounted on 
silane-coated slides, heated to 60◦C for 35 min, depariffinized in xylene, and 
rehydrated in a graded alcohol series. Endogenous peroxidise activity was 
quenched using 0.5% hydrogen peroxide in methanol. Sections were washed in 
PBS, and antigen was retrieved by microwaving in a pressure cooker (Lakeland 
Plastics Ltd., Cumbria, UK) at full power for 5 min in citrate buffer (10 mM, pH 
6.0).All sections to be incubated with antibodies against interleukins were 
washed in PBS with 0.1% saponin (Sigma-Aldrich Co. Ltd., Poole, Dorset, UK) 
then blocked with 20% rabbit/20% human serum. Sections to be incubated with 
CD45 were washed in PBS then blocked in 20% horse/20% human serum for 30 
minutes at room temperature. Sections were then incubated overnight for 16 
hours at 4◦C with the primary antibody diluted either in 2% rabbit serum with 
0.1% saponin (cytokines) or in 2% horse serum (CD45). Sections were washed in 
either PBS/0.1% saponin or PBS alone and then incubated for 30 min with 
biotinylated rabbit anti-goat (Vector Laboratories, Peterborough, UK) (cytokines) 
or biotinylated horse anti-mouse (Vector) (CD45) diluted 1:200 in 2% rabbit 
serum in PBS/0.1% saponin or 2% horse serum in PBS both with 5% human serum 
added. Sections were washed in PBS/0.1% saponin or PBS alone and then 
incubated with avidin DH/biotinylated horseradish peroxidase H reagent (Vector) 
in PBS for 30 min before final washing. The antigen was localized using 1 mg/ml 
diaminobenzidine tetrahydrochloride (Sigma-Aldrich), 0.2% hydrogen peroxide in 
50 mM Tris HCl, pH 7.6, and appeared as a brown end product. Sections were 
counterstained with Harris hematoxylin (Sigma-Aldrich). Negative controls 
included slides incubated without the primary antibody.  
For analysis we looked at each stained section for all STOPPIT myometrial 
biopsies obtained. We stained the tissue for cytokine localisations however we 
did not attempt to analyse staining intensity semi-quantitatively for these. We 
described each slide and then grouped them according to their STOPPIT placebo 
or progesterone category for descriptive purposes. The leucocytes were 
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identified using histological analysis in ten randomly selected high powered 
fields (x 400 objective magnification) and were counted by two independent 
observers who were blinded to the specimen details. The area for each high-
powered filed was 0.23mm2. The means for each observer were calculated and 
an unpaired t-test used to perform statistical analysis, a p value of <0.05 was 
considered significant. 
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RNA extraction for RT-PCR 
Total RNA was extracted and purified from the lower segment myometrial 
samples using the Tri-reagent method (Trizol, Invitrogen Ltd). This technique 
was employed for RNA isolation from both STOPPIT samples (kept in RNA later) 
and myometrial explants from cell culture experiments at the 24 hour timepoint. 
This was used for subsequent RT-PCR analysis using Taqman analysis. Tissues of 
known weight were ground and homogenized in Trizol (Invitrogen 15596-026) and 
1ml of Trizol added for each 50-100mg of sample. A short 5 minute incubation at 
room temperature then allowed dissociation of nucleoprotein complexes. 
Chloroform was added at a 1:5 concentration. This mixture was shaken and 
incubated at room temperature for as further 3 minutes. Samples were then 
centrifuged at 13,000 rpm for 15 minutes at 4◦C.  The upper aqueous phase 
containing the RNA was removed and the precipitated with isopropyl 1:2 
concentration of initial volume and incubated for 10 minutes at room 
temperature. After a further centrifuge at 10,000 for 5 minutes at 4◦C the 
isopropyl alcohol was decanted and 1ml of 75% ethanol added to the small white 
pellet at the bottom of the tube (containing total RNA). At this stage samples 
could all be stored at -80 ◦C prior to the next stage.  
Samples were centrifuged at 10,000 rpm for 5 minutes at 4◦C and then the 
ethanol was removed taking care not to dislodge the pellet. The pellet was 
allowed to dry at room temperature for 10 minutes before adding approximately 
20 µl of diethylprocarbonate treated water (DEPC). These were spun and 
incubated at 65◦C for 5 minutes on a heating block twice and then samples 
combined into one tube if duplicates were required due to an initial weight 
>100mg.  Quantification was carried out using a nanodrop to check RNA 
concentration ng/µl and ratio 260:280 for all samples which was used for 
subsequent step to DNase treat samples.  
DNase treatment of RNA sample 
After calculating the amount of RNA required (2.5µg) then making up each 
sample to total volume of 21.5µl with an individually calculated amount of DEPC 
water, we then added 2.5 µl of the 10X DNase buffer and 1 µl of DNase 1 ( DNA 
Free kit, Ambion cat no. 1906) to each sample. This was mixed at 37◦C for 30 
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minutes in the OMN-E thermacycler. The DNase inactivation reagent 
(microbeads) was resuspended and 2.5 µl added to each sample. This was 
incubated at room temperature for 2 minutes before centrifuging at 13,000 rpm 
for 1 minute. The supernatant containing the RNA was then transferred to a new 
microcentrifuge tube. Again, samples could be frozen at -80 ◦C at this point 
before the next stage of DNA preparation. After quantification (5 µl) was reverse 
transcribed using the High Capacity cDNA Reverse Transcriptase kit (ABI).This 
makes single stranded DNA.  By using the reverse transcription kit we prepared 
enough mastermix for the number of samples plus one. We also prepared a No 
RT control (Table 2). By adding 5 µl of 2 X RT mastermix to 5 µl of Dnase treated 
RNA ( up to 1µg) and then mixing and centrifuging, it is then incubated at 25◦C 
for 10 minutes followed by 37◦C for 120 minutes and finally 85◦C for 5 seconds on 
the PCR express. The resulting cDNA can be stored at -20◦C until further analysis. 
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Preparation  
Sample mix with 
RT(µl) No RT control(µl) 
10X RT buffer 1 1 
25 X dNTPs 0.4 0.4 
10 X random primers 1 1 
Mutiscribe reverse 
transcriptase 0.5 0 
Superasin ( 1U/µl) 0.5 0.5 
Nuclease free water 1.6 2.1 
Total per reaction 5 5 
 + 5µl RNA + 5µl RNA 
Total 10 µl 10 µl 
Table 2: DNase treatment of RNA sample 
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Quantitative RT-PCR 
Primers/Probes for pro labour genes, contraction associated proteins, 
endogenous uterine stimulants and endogenous inhibitors of uterine contractility 
were used from (ABI). cDNA was quantified using TaqMan technology on ABI 
Prism 7900HT ( Applied Biosystems).Briefly, 1.25 µl of 20 X target assay or 
control assay mix was added to 12.5 µl of 2X Mastermix ( Applied Biosystems), 
with 10.25 µl deionised distilled water and 1 µl cDNA. The thermal cycler 
conditions were 50◦C for 2 minutes; 95◦C for 10 minutes followed by the 40 
cycles of 95◦C 15 seconds and 60◦C for 1 minute. The cycle at which the 
fluorescence reached a preset threshold (cycle threshold) was used for 
quantitative analyses. Data was analysed using the sequence detection software 
which calculated the threshold cycle (CT) values .The cycle threshold in each 
assay was set at a level where the exponential increase in amplicon abundance 
was approximately parallel between all the samples. The expression target 
assays were normalised by subtracting the CT value of the 18S control or beta-
actin from the CT value of the relevant target assay. The fold increase relative 
to the control was obtained by using the formula 2-∆CT.TaqMan® gene expression 
assays are listed in Table 3.Progesterone Receptor A+B was supplied by Applied 
Biosystems and is detailed in Table 4. 
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Title 
TaqMan® Gene expression 
Assay  Assay ID Source 
Inos 
Nitric oxide synthase  
(inducible) Hs00167257_m1 Applied Biosystems 
Enos 
Nitric oxide synthase 
(endothelial) Hs00167166_m1 Applied Biosystems 
Bnos 
Nitric oxide synthase 
(neuronal) Hs00167223_m1 Applied Biosystems 
cGRP 
Calcitonin gene related 
peptide Hs00266142_m1 Applied Biosystems 
cGRP t 
Calcitonin gene related 
peptide receptor Hs00173787_m1 Applied Biosystems 
EP2 
Prostaglandin E receptor  
(subtype EP2) Hs00168754_m1 Applied Biosystems 
Cx 26 
Gap junction protein 
connexin 26 Hs0095589_m1 Applied Biosystems 
Cx 43 
Gap junction protein 
connexin 43 Hs00748445_s1 Applied Biosystems 
IL1-β Interleukin -1 Beta Hs00174097_m1 Applied Biosystems 
IL-6 Interleukin-6 Hs00174131_m1 Applied Biosystems 
IL-8 Interleukin-8 Hs00174103_m1 Applied Biosystems 
Cox-2 Cyclooxygenase-2 Hs00377721_m1 Applied Biosystems 
HPGD 
Hydroxyprostaglandin 
dehydrogenase 15-(NAD) Hs00168359_m1 Applied Biosystems 
18S Control 4310893E Applied Biosystems 
Β-actin Beta-actin control 4310881E Applied Biosystems 
Table 3: TaqMan® gene expression assays 
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Progesterone 
receptor Title Reference  Sequence 
PR-A+B F Forward primer 1817227 CAG TGG CGC TTC CAA ATG A 
PR-A+B R Reverse primer 1817228 GGT GGA ATC AAC TGT ATG TCT TGA 
PR-A+B probe Probe 1817229 AGC CAA GCC CTA AGC CAG AGA TTC ACT TT
Table 4 : Progesterone Receptor A+B gene expression assays 
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Cell lysis and Western Blot 
Cells were lysed for western blotting using the cell lytic method (Sigma) and 
complete mini protease inhibitor cocktail (Roche). Around 50 mg of weighed 
tissue was homogenised with 0.5 ml of the working cell lysis solution (1 tablet to 
10ml Cell lytic MT) and microcentrifuged at 6000 RPM for 10 minutes. The 
supernates were removed and microcentrifuged again at 13,000 RPM for a 
further 10 minutes. The final supernates were stored at -70◦C for subsequent 
analysis. After the protein concentration was determined in the supernatant by 
the Bradford technique (1976) all samples were diluted to 3 g/L with working 
cell lysis solution.  The samples were diluted 2:1 with sample loading buffer 
(SDS, 35 mM: glycerol, 1.4 mM; 2-mercaptoethanol, 0.3 mM; Bromophenol Blue, 
15 mM) and heat-treated at 90 ◦C for 5 min prior to electrophoresis. Gel 
electrophoresis was carried out using STOPPIT samples within a NuPAGE 4-12% 
Bis-Tris preset gel with NuPAGE  MES SDS running buffer containing 1mM 
dithiothreitol and set at 50mA for approximately 120 minutes. Following 
electrophoresis, the gel was washed in 25 mM phosphate buffer containing 
0.1%tween, pH 7.4 at room temperature, for 10 min before being transferred to 
nitrocellulose paper.  Bands were detected with the use of a marker (Biorad 
precision plus protein standard). Transfer was carried out with NuPage transfer 
and 10% methanol, using an X Cell Sure Lock ™ Mini-cell system (Invitrogen 
Laboratories Ltd).  The electrophoretic transfer of polypeptides to nitrocellulose 
paper was performed at 250mA for 90 minutes.   The membrane was blocked 
overnight with in PBS containing 5% dried milk, washed with PBS, 0.1% tween 
and incubated for 1 h with the polyclonal rabbit antibody raised against connexin 
43 (Sigma).  The primary antibody dilution was 1:16,000 in PBS and 0.1% tween, 
containing 5% dried milk.  Following sequential washing of the membrane with 
PBS plus 0.1% Tween 20 visualisation of the polypeptides which reacted with the 
primary antibody was achieved using a second (anti-rabbit IgG) antibody labelled 
with horseradish-peroxidase ( 1:20,000 dilution) followed by enhanced 
chemiluminescence (Supersignal Ultra, Pierce & Warriner, Chester, UK) 
according to the manufacturers instructions.  The bands illuminated were 
detected on X-ray film (Kodak) for visualization for 30 seconds to 1 minute. 
The nitrocellulose membrane was then stripped using a western blot stripping 
buffer (25mM glycine-HCL, pH2.5, 1% SDS in distilled water) and following 
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sequential washing was blocked overnight in a combination of 10% dried milk 
with 15% horse serum made up in PBS. This was incubated for 1 hour with the 
monoclonal mouse antibody raised against β-tubulin (Santa-Cruz) at a 1:1000 
dilution. After sequential washing of the membrane with PBS plus 0.1% Tween 20 
visualisation of the polypeptides which reacted with the primary antibody was 
achieved using a second (anti-mouse IgG) antibody labelled with horseradish-
peroxidase ( 1:20,000 dilution) followed by enhanced chemiluminescence as 
described before. 
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Analysis Western Blots 
Using Adobe Photoshop 7.0 we scanned our images with the EPSON Perfection 
3200 photo scanner. We then used an image analysis programme (Bio-Rad 
Quantity one) to assess the overall density ratio of the western blots. Bands of 
interest were highlighted and a global background subtraction was made for 
each film. We expressed the results as a ratio of density, measured in intensity 
units x mm2 (INTmm2) relative to the loading control gene β-tubulin. 
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CHAPTER 3 
The effects of progesterone, tocolytics and uterotonins on 
spontaneous myometrial contractility. 
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Contractility experiments 
Introduction 
Organ bath experiments are an effective tool for testing pharmacological agents. 
They allow for functional tests to be carried out on animal and human tissue 
which would not be possible in vivo. Muscles of all types are routinely excised 
and studied under isometric conditions using force transducers in standard organ 
baths. In such studies, the muscle is stretched or “preloaded,” as the 
magnitudes of the contractions evoked by various stimuli can vary markedly 
depending on this baseline parameter and many studies refer to an optimal 
preload tension (139). Organ bath studies have often been used to assess the 
functional properties of both animal and human myometrium under various 
conditions and under influence of various pharmacological agents to advance 
knowledge within this area (108, 126, 138). The tissue (human myometrium) can 
be divided evenly and treated with different drugs under highly controlled 
conditions and this can be repeated or carried out in using replicates to try and 
minimise intra-patient variation. This allows for a quality control step as certain 
tissues which failed to spontaneously contract can be eliminated from any 
further experiment. We obtained concentration-response curves for several 
different drugs to examine their effects on spontaneous myometrial 
contractions.  
Aim of chapter 
This chapter therefore discusses spontaneous myometrial contractility and its 
response to uterotonins, tocolytics and whether progesterone has any impact on 
myometrial contractility. 
Spontaneous myometrial Contractions 
We collected data from a select group of experiments, before undertaking 
experiments using specific drugs we were able to ascertain the spontaneous 
contractile response from a larger number of strips. Following equilibration for 2 
hours, myometrial strips contracted in a rhythmic manner (amplitude 46±1 mN, 
frequency 7.7±0.1 contractions h-1), data obtained from 64 strips from 15 
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patients. Contractions were sustained at a regular rate and rhythm after 
equilibration for in excess of 6 hours allowing completion of experiments in full 
(Figure 4).  
 
Oxytocin 
Oxytocin has an endogenous role in the induction of labour and is frequently 
used in the labour ward to both stimulate contractions and prevent post partum 
haemorrhage(71). The aim of this experiment was to determine the effects 
oxytocin, a potent uterotonins, has on spontaneous myometrial contractions and 
obtain the concentration-response relationship for this action. 
Oxytocin 10 pM-10 µM produced a concentration-dependent enhancement of 
spontaneous myometrial contractions. The maximum increase in amplitude was 
38 ± 17 %, the log EC50 oxytocin measured -9.9 (-10.2,-9.5 95% confidence 
intervals) on overall amplitude of contractions (Figure 5, Figure 6).The 
frequency of contractions were also enhanced by oxytocin by a maximum of 383 
±  243 % ,the log EC50 oxytocin measured -9.1 (-9.8,-8.4 95% confidence 
intervals). These data were obtained from 16 patients. 
Levcromakalim  
Levcromakalim is KATP channel opener which is able to hyperpolarise smooth 
muscle cells and prevents action potential generation. It was recognised as a 
potential tocolytic in 1993 by its effect on pregnant human myometrium before 
and after the onset of labour (64). The aim of this experiment was therefore to 
determine the effect that levcromakalim as on spontaneous myometrial 
contractions and determine the concentration-response relationship for this. 
Levcromakalim 100 pM -10 µM induced concentration-dependent inhibition of 
myometrial contraction amplitude and frequency. At concentrations of 100pM- 
0.01 µM it exerted no effects but higher concentrations (> 0.01 µM) led to a 
progressive fall in amplitude and frequency with the highest concentrations (>1 
µM) suppressing activity completely. Log EC 50 of the levcromakalim measured -
7.1 (-7.3,-6.9 95% confidence intervals) for amplitude of contractions. The 
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frequency of spontaneous contractions log EC 50 levcromakalim measured -7.2 (-
7.5,-6.9 95% confidence intervals) (Figure 7, Figure 8). These data were obtained 
from 12 strips from 12 patients. 
Laurie Anderson, 2009  93 
 
Figure 4 : Contractility trace showing the stability of rhythmic contractions of myometrial strip over 
time including the equilibration period for the first two hours. 
 
Figure 5 : Concentration-response curve showing the effect of oxytocin on the amplitude of 
spontaneous myometrial contractions. 
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Figure 6 : Concentration-response curve showing the effect of oxytocin on the frequency of 
spontaneous myometrial contractions.
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Figure 7 : Concentration-response curve showing the inhibitory effect of levcromakalim on the 
amplitude of spontaneous myometrial contractions. 
 
Figure 8 : Concentration-response curve showing the inhibitory effect of levcromakalim on the 
frequency of spontaneous myometrial contractions. 
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Nifedipine 
Nifedipine is a calcium channel blocker which although usually used in treatment 
of hypertension and angina (140) is used clinically as a tocolytic treatment for 
the preventions of preterm labour as recommended by RCOG guidelines (141). 
The aim of this experiment was therefore to determine the effects nifedipine 
has on spontaneous myometrial contractions and establish a concentration-
response relationship for this. 
 Nifedipine (100 pM-10 µM) produced concentration-dependent inhibition of 
spontaneous myometrial contractions amplitude and frequency (Figure 9, Figure 
10). At low concentrations of 100pM- 0.01 µM it showed little or no effect on 
amplitude or frequency but at higher concentrations >0.003 µM led to a 
progressive fall in the amplitude and frequency of contractions with the highest 
concentrations >0.3 µM suppressing activity completely. The log EC50 of 
nifedipine measured -8.0 (-8.1,-7.8 95% confidence intervals) for amplitude and 
log EC50 nifedipine -7.1 (-7.6,-6.6 95% confidence intervals) for frequency. 
Ritodrine 
Ritodrine has previously been a recommended tocolytic according to RCOG 
guidelines but has since been superseded by atosiban and nifedipine (141). It is a 
Beta 2 e -adrenergic agonist (142). The aim of this experiment was therefore to 
determine the effects ritodrine has on spontaneous myometrial contractions and 
establish the concentration-response relationship for this. 
 Ritodrine (β2-agonist, 0.01 µM-1 mM) produced a concentration–dependent 
inhibition on amplitude spontaneous myometrial concentrations (Figure 11). At 
concentrations of 0.3 mM it produced a tachyphylaxis and despite inhibiting 
amplitude of contractions in a concentration-dependent manner frequency 
increased by around 50% prior to complete inhibition at 1mM concentration 
within the organ bath (Figure 12). Lack of solubility prevented an examination at 
higher concentrations of ritodrine with any degree of accuracy. Log EC50 
[ritodrine] measured -3.9 (-3.9,-3.0 95% confidence intervals) for amplitude of 
spontaneous activity.  
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 Summary of tocolytic data  
When compared as a group (ANOVA) nifedipine was the most potent inhibitor of 
the amplitude of myometrial smooth muscle, levcromakalim was next and 
ritodrine was the least potent. 
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Figure 9 : Concentration-response curve showing the inhibitory effect of nifedipine on the amplitude 
of spontaneous myometrial contractions. 
 
Figure 10 : Concentration-response curve showing the inhibitory effect of nifedipine on the 
frequency of spontaneous myometrial contractions.
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Figure 11 : Concentration-response curve showing the inhibitory effect of ritodrine on the amplitude 
of spontaneous myometrial contractions. 
 
 
Figure 12: Concentration-response curve showing the inhibitory effect of ritodrine on the frequency 
of spontaneous myometrial contractions. 
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Figure 13 : Concentration-response curves showing the summary of tocolytic data. The amplitude 
of myometrial contractions and that both nifedipine and levcromakalim have an effect at lower 
concentrations than ritodrine. 
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Effects of progesterone and the synthetic progestin, 17α 
hydroxyprogesterone caproate  
Having established the effects of oxytocin and a range of tocolytics, we aimed to 
determine the in vitro effects that progesterone exerted on spontaneous 
myometrial contractions as well as the synthetic progestin 17α- 
hydroxyprogesterone caproate (17OHPC).  
Progesterone (10 nM- 30 µM) produced a concentration-dependent inhibitory 
effect on the amplitude of myometrial contractions (Figure 14, Figure 15). The 
vehicle, 70% ethanol, at appropriate dilutions, also exerted an inhibitory effect 
on the amplitude of contractions. Maximum inhibition of amplitude was 93±2% 
and 67±14% for progesterone 30 µM and vehicle respectively. 17OHPC also 
exerted an inhibitory effect on contraction amplitude but this was not 
significantly different from the vehicle (Figure 16). 
 Water Soluble Progesterone 
The aim of this experiment was to establish a concentration-response 
relationship to progesterone in vitro without the added inhibitory effects of 
ethanol seen at higher concentrations. Water soluble progesterone was 
encapsulated with a cylclodextrin compound. This enables hydrophobic 
molecules to be incorporated into the cavity of the cylclodextrin by displacing 
water, and when the water soluble complex is dissolved in a larger volume of 
aqueous solvent the process is reversed thereby releasing the molecule into the 
solvent. We subsequently tested the effects of the cyclodextrin compound which 
was used to make the progesterone water soluble on myometrial contractions. 
Water soluble progesterone also exerted a concentration-dependent inhibitory 
effect on amplitude (maximum inhibition of 82±10% at 100 µM, Figure 17). Time 
course experiments showed that this water soluble progesterone (100 µM) 
exerted a 42±5% inhibition of contractile amplitude 30 minutes after addition to 
the bath, and reached a maximal inhibition of 82±10% at 1 hour (Figure 18). We 
found an inconsistent effect of progesterone on the frequency of contractions 
(Figure 19); in some cases with higher frequency but low amplitude contractions 
prior to complete inhibition. The activity integral (area under the curve) showed 
an overall decrease with progesterone vs. control, p<0.05 (Figure 20). The 
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cylclodextrin compound exerted no effect on either the amplitude or frequency 
of myometrial contractions (Figure 21, Figure 22). 
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Figure 14 : Contractility trace showing the stability of rhythmic contraction of myometrial strips and 
inhibition of activity with progesterone 10-4M. 
Figure 15 : Concentration-response curve showing the effects of progesterone and vehicle (70% 
ethanol) on the amplitude of myometrial contractions. 
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Figure 16 : Concentration-response curve showing the effects of 17OHPC and vehicle (70% 
ethanol) on the amplitude of myometrial contractions. 
 
Figure 17 : Concentration-response curve for amplitude of contractions for water soluble 
progesterone 
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Figure 18 : Time course assessment of maximal concentration water soluble progesterone 10-4M 
over 4 hours on the amplitude of contractions. 
 
Figure 19 : Concentration-response curve for frequency of contractions with water soluble 
progesterone. 
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Figure 20 : Activity integral (area under the curve) assessment of control versus water soluble 
progesterone. 
 
Figure 21 : Cyclodextrin compound contractility results. Time course assessment of maximal 
concentration of cyclodextrin equivalent to the water soluble progesterone 10-4M concentration 
over 3 hours on the amplitude of contractions. 
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Figure 22 : Time course assessment of maximal concentration of cyclodextrin equivalent to the 
water soluble progesterone 10-4M concentration over 3 hours on the frequency of contractions. 
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Effects of potassium channel blockers on responses to 
progesterone 
It became evident with contractility experiments that progesterone exerted a 
rapid inhibitory effect on myometrial contractions. This apparent non genomic 
effect is still not fully understood although there are suggestions of progesterone 
membrane receptors regulating this function (48). These are still poorly 
understood and a rapidly developing area of research. I therefore hypothesised 
that this membranous effect acted via potassium channels. Potassium channels 
are present on myoctyes  and comprise a group of proteins that contribute 
significantly to uterine quiescence during pregnancy (128). 
In myometrium the potassium channels allow for adaptation of the gravid uterus 
to stretch and pressure akin to our simplified model using stretch to initiate 
myometrial contractions within the organ bath set up.    
As both progesterone (143) and potassium channels (128) are linked with 
maintaining uterine quiescence the aim of this experiment group was to 
determine if progesterone exerted its inhibitory effect on myometrial 
contractility via activation of  potassium channels. In order to determine this we 
adopted the approach of selectively blocking individual or groups of potassium 
channels using pharmacological inhibitors. 
Each of the potassium channel blocking agents, glibenclamide 1.5 µM (blocks 
KATP channels) (144), charybdotoxin 100 nM (blocks intermediate channels IKCa, 
BKCa, Kv) (144), iberiotoxin 100 nM (blocks large conductance BKCa channels) 
(145)  or apamin 100 nM (blocks small SKCa channels) (146) were added to 
myometrial strips at the end of the equilibration period. Concentration-response 
curves were then carried out adding water soluble progesterone as described 
above. Experiments were performed on separate strips with n> 6 for each agent.  
Table 1 details the demographics for the potassium channel series of 
experiments. Table 2 gives the new data for each potassium channel blocker 
with and without the presence of progesterone and the values for % inhibition of 
the amplitude of spontaneous contractions as well as the overall frequency in 
contractions per hour.   
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None of the selected potassium channel blockers had an independent effect on 
either the amplitude or frequency of spontaneous myometrial contractions prior 
to addition of progesterone. 
 Levcromakalim, a KATP channel opener, produced a concentration-dependent 
inhibition of the amplitude and frequency of spontaneous contractions. These 
effects were antagonised by the KATP channel blocker glibenclamide (1.5 µM) and 
a right shift in the curve is evident p<0.05 (Figure 23, Figure 24). In contrast, 
glibenclamide had no effect on the progesterone induced inhibition of 
myometrial contractility (Figure 25, Figure 26). 
 Charybdotoxin 10 nM (blocks IKCa, BKCa and Kv channels) also had no effect on 
the progesterone-induced inhibition of contractility. We observed with the 
addition of progesterone, a significant increase in frequency of contractions 
when in the presence of charybdotoxin. This was only observed at 10nM and not 
a sustained effect throughout the concentration-response regime (Figure 27, 
Figure 28).  
Iberiotoxin 100 nM (blocks BKCa channels) (Figure 29, Figure 30) and apamin 100 
nM (blocks SKCa channels) also failed to affect the ability of progesterone to 
inhibit myometrial contractility (Figure 31, Figure 32).  
Laurie Anderson, 2009  110 
 
Table 5 : Patient demographics .Details of patients, number of strips and demographics for each 
group of progesterone experiments. There was no detectable difference in age, BMI, gestation or 
baby weights from each subgroup of patients. 
 
  Glibenclamide Charybdotoxin Apamin Iberiotoxin 
Prog (+) 58.4±10.4 68.5±10.4 40.7±6.2 43.4±5.9 % Inhibition 
magnitude 
Prog (-) 74.9±6.9 74.3±8.2 54.8±7.6 54.8±7.6 
Prog (+) 4.9±1.5 9.5±2.4 10.7±3.4 18.3±2.9 Frequency of 
contractions per 
hour 
Prog (-) 6.6±2.3 9.5±3.6 13.8±2.2 13.8±2.2 
Table 6 : Potassium channel results. This shows the individual values of percentage inhibition (% ± 
SEM) of the amplitude of contractions and frequency per hour ± SEM. The selected potassium 
channel blocking agents as listed above are shown both in the presence of progesterone (prog+) 
and absence (prog-).   
 Progesterone & 
17OHPC 
Water soluble 
Progesterone 
Potassium 
channel 
Series 
Total 
Number women 26 8 21 55 
Total strips 90 27 184 301 
 Age (Years) 29.2 (±1.02) 33.4 (±1.4) 30.3(±1.4) 30.3(±0.7) 
BMI (kg/m2) 25.0 (±0.9) 27.6 (±2.2) 26.9 (±1.3) 26.1(±0.7) 
Gestation 
(days) 
274 (±0.9) 274 (±0.3) 274 (±0.8) 274(±0.3) 
Baby weight 
(Kg) 
3.47 (±0.1) 3.75 (±0.2) 3.48 (±0.1) 3.52(±0.1) 
Indication for 
LUSCS 
    
Previous LUSS 18 (69.2%) 8 (100%) 14 (66.7%) 40(72.7%) 
Other 8 (30.8 %) 0 (0%) 7 (23.3%) 15(27.3%) 
Parity     
0 4 (15.4%) 0(0%) 5 (23.8%) 9(16.4%) 
1 16 (61.5%) 7(87.5%) 13 (61.9%) 36(65.5%) 
2 3(11.5%) 1(12.5%) 3 (14.3%) 7(12.7%) 
≥3 3 (11.5%) 0(0.0%) 0 (0.0%) 3(5.4%) 
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Figure 23 : Concentration-response curve showing the effects on contraction amplitude of 
levcromakalim alone and in the presence of its antagonist, glibenclamide. The right shift of the 
curve is seen with glibenclamide p<0.05 ANOVA. 
 
Figure 24 : Concentration-response curve showing the effects on contraction frequency of 
levcromakalim alone and in the presence of its antagonist, glibenclamide. The right shift of the 
curve is seen with glibenclamide p<0.05 ANOVA. 
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Figure 25 : Concentration-response curve showing the effects on contraction amplitude of 
progesterone alone and in the presence of glibenclamide. No right shift of the curve is seen with 
glibenclamide. 
 
 
Figure 26 : Concentration-response curve showing the effects on contraction frequency of 
progesterone alone and in the presence of glibenclamide. No right shift of the curve is seen with 
glibenclamide. 
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Figure 27 : Concentration-response curve showing the effects on contraction amplitude of 
progesterone alone and in the presence of charybdotoxin. No right shift of the curve is seen with 
charybdotoxin. 
 
Figure 28 : Concentration-response curve showing the effects on contraction frequency of 
progesterone alone and in the presence of charybdotoxin. There is a significant increase in 
frequency of contractions when both progesterone and charybdotoxin are present at the lower 
concentration p<0.05 ANOVA. 
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Figure 29 : Concentration-response curve showing the effects on contraction amplitude of 
progesterone alone and in the presence of iberiotoxin. No right shift of the curve is seen with 
iberiotoxin. 
 
 
Figure 30 : Concentration-response curve showing the effects on contraction frequency of 
progesterone alone and in the presence of iberiotoxin. No right shift of the curve is seen with 
iberiotoxin. 
Laurie Anderson, 2009  115 
 
Figure 31 : Concentration-response curve showing the effects on contraction amplitude of 
progesterone alone and in the presence of apamin. No right shift of the curve is seen with apamin. 
 
Figure 32 : Concentration-response curve showing the effects on contraction frequency of 
progesterone alone and in the presence of apamin. No right shift of the curve is seen with apamin. 
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Effects of progesterone 1 µM incubation in vitro on oxytocin and 
tocolytics 
We added progesterone 1 µM, to the organ baths for 1 hour following the 
equilibration period, we then carried out the established concentration–response 
regimes for oxytocin and the three tocolytic drugs, levcromakalim, nifedipine 
and ritodrine. The aim was to establish if in vitro progesterone either enhanced 
the ability of tocolytics to function or inhibited the uterotonin, oxytocin.  
We performed this group of experiments following the initial established 
protocols for concentration–response curves and therefore used progesterone 
that was dissolved in ethanol rather than water soluble progesterone at this 
stage. We selected a 1 µM concentration of progesterone to be added to the 
baths based on data (figure 11) that indicated progesterone was starting to have 
an inhibitory effect on myometrial contractions at this concentration but there 
was no significant vehicle effect.  Oxytocin (10 pM-10 µM) produced a 
concentration-dependent increase in both amplitude and frequency of 
myometrial contractions. Levcromakalim (100 pM -10 µM), nifedipine (100 pM-10 
µM) and ritodrine (0.01 µM-1 mM) each produced a concentration-dependent 
inhibition of the amplitude and frequency of spontaneous contractions.  A 60 
minute progesterone (1 µM) incubation significantly reduced spontaneous 
amplitude of contractions compared with vehicle control p<0.01 ANOVA with 
Bonferoni correction (Figure 33). There was no significant difference in 
frequency of contractions with control, ethanol vehicle and 1 µM progesterone 
Figure 34. The vehicle control for the progesterone (0.07% ethanol) showed no 
effect on amplitude or frequency compared with the control. This 1 µM 
progesterone treatment however, failed to alter the concentration-dependent 
stimulatory effect of oxytocin (no shift seen in the concentration-response curve 
or inhibitory effects of levcromakalim, nifedipine or ritodrine, no shift seen in 
the concentration-response curves) n≥10 (Figure 35, Figure 36, Figure 37, Figure 
38, Figure 39, Figure 40, Figure 41, Figure 42).  
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Figure 33 : This graph shows the contraction amplitude after one hour incubation with nil (control), 
ethanol 0.07% (vehicle) or progesterone 10-6M. There was a significant reduction in contraction 
amplitude with the progesterone compared to vehicle control p<0.01 ANOVA. This dosage regime 
was chosen from previous progesterone data (Figure 15) as there appeared to be no vehicle effect 
at this concentration. 
 
Figure 34 : This graph shows the contraction frequency after one hour incubation with nil (control), 
ethanol 0.07% (vehicle) or progesterone 10-6M. There was no significant difference between the 
groups. 
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Figure 35 : Concentration-response curve showing the effects on contraction amplitude of oxytocin 
alone and in the presence of progesterone. No right shift of the curve is seen with progesterone. 
 
Figure 36 : Concentration-response curve showing the effects on contraction frequency of oxytocin 
alone and in the presence of progesterone. No right shift of the curve is seen with progesterone. 
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Figure 37 : Concentration-response curve showing the effects on contraction amplitude of 
nifedipine alone and in the presence of progesterone. No left shift of the curve is seen with 
progesterone. 
 
Figure 38 : Concentration-response curve showing the effects on contraction frequency of 
nifedipine alone and in the presence of progesterone. No left shift of the curve is seen with 
progesterone. 
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Figure 39 : Concentration-response curve showing the effects on contraction amplitude of 
levcromakalim alone and in the presence of progesterone. No left shift of the curve is seen with 
progesterone. 
 
Figure 40 : Concentration-response curve showing the effects on contraction frequency of 
levcromakalim alone and in the presence of progesterone. No left shift of the curve is seen with 
progesterone. 
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Figure 41 : Concentration-response curve showing the effects on contraction amplitude of ritodrine 
alone and in the presence of progesterone. No left shift of the curve is seen with progesterone. 
 
Figure 42: Concentration-response curve showing the effects on contraction frequency of ritodrine 
alone and in the presence of progesterone. No left shift of the curve is seen with progesterone. 
Ritodrine causes an increase in overall contraction frequency at higher doses 10-3M prior to 
inhibition. 
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Effects of in vivo progesterone and placebo 
We aimed to determine if prolonged maternal progesterone in vivo had any 
effects on spontaneous myometrial contractility when tested ex vivo and if again 
tocolytic effects were enhanced or oxytocic effects diminished by the 
progesterone used within the STOPPIT clinical trial. 
 We collected 18 samples in total from the STOPPIT trial patients undergoing 
caesarean section for clinical reasons. 16 were used for contractility studies 
within 12 hours of collection. At the time of sampling and the experiments we 
remained blinded to the placebo. Progesterone status was unblinded after all 
samples had been taken and the trial was completed (Spring 2008).Ten patients 
were within the placebo group and six patients were from the progesterone 
group, two of which were taken at emergency caesarean section, not pre-labour. 
Table 3 shows the patient demographics of the STOPPIT placebo and 
progesterone groups. There were no statistical differences between the groups 
in any category including age, BMI, gestation at delivery and baby weights of 
twin one and two (unpaired t-test). The majority of specimens, 12 of 18 in total, 
were collected at elective caesarean section, pre labour. In view of small 
numbers and difficulty obtaining these specimens we also collected some in 
labour samples at emergency caesarean section. Only two patients remained on 
trial treatment at the time of sampling, both within the placebo group, thus 
there were no patients actively receiving progesterone therapy at time of 
sampling. Mean pregnancy gestation (and gestation of sampling) was 252 days in 
the placebo group and 262 within the progesterone group (p, 0.075). Thus, the 
interval between sampling and last progesterone administration was 14 ±14 days 
(mean, SD) in the placebo group and 24 ± 6 in the progesterone group. We 
obtained contractility data from 16 of the 18 samples collected. In total, 30 
strips were examined from the placebo group versus 27 in the progesterone 
group.  
Contraction amplitude measured 55±4mN, frequency 8.1±0.7 h-1, for 
progesterone and 48±6 mN, 8.1±0.5 h-1, for placebo respectively p>0.05. . There 
was no significant difference between placebo and progesterone groups when 
spontaneous amplitude or frequency of contractions was measured over time 
(Figure 43, Figure 44). There was no statistical difference following activation 
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with to oxytocin, 1 pM-100 nM, (Figure 45, Figure 46) p>0.05, or inhibition with 
levcromakalim, 1 nM-100 µM, (Figure 47, Figure 48), nifedipine, 0.1 nM-10 µM, 
(Figure 49, Figure 50) p>0.05 or ritodrine, 10 nM-1 mM p>0.05, (Figure 51, Figure 
52) between the placebo and progesterone groups collected from STOPPIT 
patients (ANOVA).  
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 STOPPIT 
 Placebo 
 
STOPPIT 
Progesterone 
Number women 12 6 
Total strips 30 27 
Age (Years) 29.3(1.2) 31.8(1.1) 
BMI (kg/m2) 25.9(1.5) 25.0(3.1) 
Gestation (days) 252(4.6) 262(2.6) 
Baby weight (Kg) 
Twin 1 
Twin 2 
 
2.3(0.1) 
2.3(0.2) 
 
2.6(0.1) 
2.6(0.1) 
   
Previous LUSS 0 3 
ELLUCS 9 3 
Parity   
0 4 3 
1              6 3 
   
   
Table 7: STOPPIT patient demographics  
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Figure 43: Graph showing the percentage inhibition of spontaneous contraction amplitude over 
time. There is no evident difference between the placebo and progesterone samples.  
 
Figure 44: Graph displaying the baseline frequency data (contractions/hour) for both placebo and 
progesterone over time. There is no difference in frequency between placebo and progesterone.  
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Figure 45 : Concentration-response curve showing the effects on contraction amplitude of oxytocin 
in placebo and progesterone groups. No right shift of the curve is seen within the progesterone 
group. 
 
Figure 46: Concentration-response curve showing the effects on contraction frequency of oxytocin 
in placebo and progesterone groups. No right shift of the curve is seen within the progesterone 
group. 
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Figure 47 : Concentration-response curve showing the effects on contraction amplitude of 
levcromakalim in placebo and progesterone groups. No left shift of the curve is seen within the 
progesterone group. 
 
Figure 48 : Concentration-response curve showing the effects on contraction frequency of 
levcromakalim in placebo and progesterone groups. No left shift of the curve is seen within the 
progesterone group. 
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Figure 49 : Concentration-response curve showing the effects on contraction amplitude of 
nifedipine in placebo and progesterone groups. No left shift of the curve is seen within the 
progesterone group. 
 
Figure 50 : Concentration-response curve showing the effects on contraction frequency of 
nifedipine in placebo and progesterone groups. No left shift of the curve is seen within the 
progesterone group. 
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Figure 51: Concentration-response curve showing the effects on contraction amplitude of ritodrine 
in placebo and progesterone groups. No left shift of the curve is seen within the progesterone 
group. 
 
Figure 52 : Concentration-response curve showing the effects on contraction frequency of ritodrine 
in placebo and progesterone groups. No left shift of the curve is seen within the progesterone 
group. 
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Discussion  
Contractility Results 
We have examined human myometrial contractility both inherent and in 
response to several different drugs important to labour and contractions. This 
has also been done in the presence of progesterone which we hypothesised 
would have inhibitory effects on uterotonins and stimulatory effects on 
tocolytics. 
 In view of difficulties in obtaining upper segment myometrial biopsies from 
either classical caesarean section or performing a biopsy at extra risk to study 
patients we felt it appropriate to use lower segment for the purpose of our 
analyses. We have previously directly compared upper and lower segment and 
found qualitatively similar results (23, 25). Other groups (147) have also shown 
no difference between upper and lower segment biopsies in terms of myometrial 
contractility in vitro and concluded that the lower segment is appropriate for 
this purpose and for organ bath contractility analysis.  
Oxytocin is a nonapeptide hormone synthesised within the paraventricular nuclei 
of the hypothalamus and secreted by the posterior pituitary. It is linked to a G 
protein coupled receptor and its effects are mediated by tissue-specific oxytocin 
receptor expression which lead directly to contraction within the myometrium 
(73). The contraction is achieved by sarcoplasmic reticulum Ca2+ release and 
sensitisation of the contractile mechanisms to Ca2+  (148). Oxytocin also modifies 
the contraction threefold 1) increases the frequency of contractions, 2) 
Increases the basal tone i.e. not complete relaxation after a contraction and 3) 
Increases the amplitude and duration of overall contractions (71). We observed 
all of these findings in our own use of oxytocin on spontaneous myometrial 
contractions and at concentrations of greater than 10nM we observed a decrease 
in overall amplitude and observed a bell shaped curve evident with agonist 
activity. This was due to the incomplete relaxation and failure to return to the 
original baseline as is noted with oxytocin at high doses.  
Levcromakalim is an ATP- sensitive potassium channel opener (64) which allows 
an increase plasma membrane K+ permeability causing hyperpolarisation. The 
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membrane potential is therefore driven away from the action potential 
threshold. It is a potent smooth muscle relaxant and has been shown to have an 
inhibitory effect on human myometrial contractions in other groups and our own 
(64, 92). Levcromakalim has been used previously in the treatment of angina as 
a vascular smooth muscle relaxant (149). The sulfonylurea, glibenclamide, is an 
apparent competitive inhibitor of KATP channels (144).We demonstrated a 
concentration-response curve on spontaneous human myometrial contractions 
and also one that was antagonised by glibenclamide 1.5 µM. Levcromakalim is 
not used clinically as a tocolytic within labour ward settings but this could 
represent a potential new approach for tocolysis via potassium channels as 
suggested by Morrison et al (64). 
Calcium channel blockers are highly specific inhibitors of L-type voltage 
operated calcium channels and are smooth muscle relaxants that act by 
inhibiting the intracellular influx of calcium ions (150). Nifedipine is the most 
commonly used calcium channel blocker for tocolysis (151). It is still used 
clinically within the UK as a short term treatment for preterm labour, as 
recommended by the Royal college of Obstetricians and Gynaecologists (141). 
The use of nifedipine as a tocolytic for 48 hours may enable administration of a 
short course of corticosteroids. These has been shown to help mature the fetus’ 
lungs and reduce the risk of neonatal respiratory distress syndrome (152). The 
use of tocolytics such as nifedipine, may also allow transfer of the fetus in utero 
to a tertiary referral unit with adequate neonatal facilities if threatened 
preterm labour is diagnosed. Nifedipine, however, is not licensed for tocolytic 
use in the UK. Our group has also shown previously that nifedipine produced a 
concentration-dependent inhibitory effect on both amplitude and frequency of 
spontaneous human myometrial contractions (92). 
Ritodrine, a β2-adrenergic agonist has, in the past has been used as a tocolytic 
clinically (153). We found that it produced a concentration-dependent inhibition 
of the amplitude of contractions. The frequency of contractions showed, at 
doses greater than 100µM, a transient excitatory effect prior to inhibition of the 
contractions overall. This is thought to occur due to a transient excitement of 
contractile alpha-adrenoreceptors (154). There is also evidence to support a 
structural and functional link between the β2-adrenergic receptor and BKCa in 
maintaining uterine quiescence with levels of both decreasing in labour (155) 
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(156). Nifedipine and atosiban( an oxytocin receptor antagonist) are now 
recommended prior to consideration of ritodrine as a tocolytic in the prevention 
of preterm labour (141).  
Our study has shown that in vitro progesterone, albeit at high concentrations, 
exerts consistent, rapid and sustained inhibition of the amplitude of spontaneous 
myometrial contractions. The rapidity of action of progesterone implies a non-
genomic effect. Although the effects on the frequency of contractions were less 
consistent than that of amplitude the net effect was one of overall inhibition of 
contractile activity, as measured by activity integral. This unexpected effect on 
frequency has been noted before in vitro (101, 102).   
The concentrations of progesterone required to inhibit contractions in vitro are 
unlikely to be achieved with therapeutic doses of progesterone in vivo.  
However, it may not be the absolute concentration of progesterone that is 
important in vivo, given that it has been suggested that patterns of change as 
opposed to absolute concentrations of progesterone and other steroid hormones 
may be the important factor in affecting myometrial contractility  (157).  
Unlike natural progesterone, however ,17OHPC did not exert any inhibitory 
effect on myometrial activity over and above that see with its vehicle (70% 
ethanol), thus confirming the work of another group (158). Despite this, a 
number of clinical trials administering intramuscular injections of 17OHPC have 
been successful in preventing preterm delivery in high risk women. Sexton et al 
suggests that this positive clinical outcome may well be mediated through long-
term genomic pathways which cannot be reproduced under organ bath 
conditions (158); we were only able to conduct experiment for 8 hours in vitro 
before myometrial contractility began to decline. It is possible therefore that 
17OHPC requires in vivo conditions to exert an effect. A contractility study 
investigating progesterone and 17OHPC carried out by Ruddock et al showed that 
17OHPC levels, when incubated with myometrial tissues were reduced by 
between 90- 98%. Progesterone was less effected with a loss of 29-50% detected 
(100).They used ethanol as opposed to DMSO as a solvent and showed less 
vehicle effects. 17OHPC however did not appear to present within the organ 
baths at the end of the experiments.  It also remains unclear as to whether 
17OHPC is active itself or requires metabolic activation. One suggested pathway 
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is hydrolysis by plasma and tissue esterases, but a recent study showed that 
17OHPC was not hydrolysed to by esterases  in vitro suggesting again either in 
vivo requirements or alternative mechanisms of metabolism (159). Progesterone 
may also differ from 17OHPC in vitro as they potentially act upon different 
receptors. 17OHPC has recently been found to have lower affinity than 
progesterone for the progesterone PR receptor (160).  The non-genomic 
pathways by which progesterone itself  inhibits myometrial contractility in vitro 
may operate through the cell membrane progesterone receptors α, β and γ, 
which are similar to G-protein coupled receptors (109) . Their role in the process 
of labour is, however, not yet understood and progesterone’s main action in 
maintaining uterine quiescence is generally accepted to result via the PR-B 
receptor (48, 77). An alternative non-genomic pathway of progesterone action is 
interaction with gamma amino butyric acid A (GABAA) receptors. These receptors 
appear to be important in the emerging effects that progesterone has on the 
brain (reference). Additionally, initial studies of rat myometrium GABAA 
antagonists prevented progesterone induced inhibition of contractions, 
suggesting that progesterone might mediate its action via the GABA receptor 
(107). A prior study found that relaxation produced by the above steroids was 
not blocked by the GABAA receptor antagonists, picrotoxin or bicuculline, but 
was reversed by calcium, they suggest that blockade of calcium influx appeared 
to be responsible this relaxation (108).  
These results could not be replicated in more recent studies of human 
myometrium, with the authors concluding that blockade of calcium influx 
appears to be responsible (108).  
In this study, which made use of selective inhibitors, we clearly demonstrate 
that progesterone does not exert its inhibition of myometrial contraction via a 
range of potassium channels, including KATP, BKCa, IKCa and SKCa. Progesterone 
treated strips showed no significant difference in either contraction amplitude 
or frequency after addition of each potassium channel blocker. Apamin did not 
alter the spontaneous myometrial contractility and as a selective blocker of SKCa 
channels demonstrated no role for this potassium channel in regulating 
spontaneous contractions (161). Recent mice studies however, examining small 
conductance Ca2+-activated potassium  (SK) channel, SK3  suggest that this 
channel plays an important role in regulating uterine function by limiting influx 
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through L-type Ca2+ channels and disrupting the development of phasic 
contractile events (162). We observed normal phasic contractions prior and post 
addition of apamin which disrupts these channels. The lack of effect of 
glibenclamide which selectively blocks KATP channels (163) also suggests it has 
little or no role in this regulation.  Iberiotoxin and charybdotoxin are both able 
to block BKCa channels, charybdotoxin however, is less selective and also blocks 
intermediate IKCa  and voltage operated Kv channels (164) .These BKCa  are large 
conductance and calcium sensitive potassium channels. Iberiotoxin had no 
independent effects on myometrial contractility indicating they have little or no 
role in regulating spontaneous contractility .Charybdotoxin had no independent 
effect on myometrial contractility but in combination with progesterone it 
appeared to increase the frequency of contractions (10nM progesterone).This 
effect was not maintained after the initial addition of progesterone and 
therefore does not give a clear indication of an intermediate IKCa  or BKCa role 
within this mechanism of action. Other studies have shown evidence which 
conflicts with this. In human non -labouring myometrium others have observed 
increased levels of BKCa channels but decreased BKCa channel expression was 
seen in preterm and term labouring myometrium. Consequently, these channels 
may be a part of the mechanism to induce spontaneous labour contractions (156, 
165) . 
Other groups have studied vascular smooth muscle and progesterone, which 
causes a relaxation of rat mesentery They demonstrated a lack of effect of 
potassium channel blockers on progesterone-induced relaxation suggesting that 
these K channels play little or no role within vascular smooth muscle 
(166).Similarly ,we have been unable to demonstrate any effect of potassium 
channel blockers on progesterone-induced relaxation of myometrial smooth 
muscle.   
Alternative pathways by which progesterone may exert its inhibitory effect could 
be via sodium or chloride channels. There is some evidence to suggest that 
sodium channels may be up regulated in myometrium at  late gestation (167) but 
the distinct roles of specific sodium channels is not clearly understood. Ion 
channels may well have regulatory pathways related to myometrial function but 
whether progesterone utilises them in its mechanism to prevent preterm labour 
remains unclear.  
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The other major finding of the study is that in vivo progesterone therapy to 
prevent pre-term labour does not appear to modify contractility ex vivo. This 
may, however, be due to study design limitations. Our sample group from the 
progesterone-treated arm of the clinical trial discontinued their administration 
of progesterone at 34 weeks (238 days). The mean sample gestation within the 
progesterone group was 262 days, therefore providing a significant period (24 
±6, mean days ±SD) in which patients were no longer actively receiving 
progesterone. Whether progesterone treatment in vivo, would manifest changes 
in myometrial contractility ex vivo if examined during the treatment window, 
remains to be determined. Small sample numbers from this STOPPIT substudy 
may also contribute to lack of evidence of functional effect by progesterone. 
Due to initial study design we were unable to collect the proposed number >40 
in order to have an adequately powered study therefore these results must be 
interpreted with caution. 
The progesterone metabolite 5 β-dihydroprogesterone is thought to reduce 
oxytocin binding to it’s receptor in cultured cells (168).There is evidence to 
suggest that progesterone interacts with the rodent oxytocin receptor but not 
the human receptor(168) Thornton et al also demonstrated a right-shift in the 
activity integral of the oxytocin concentration-response curve with 100µM of the 
metabolite (126).With progesterone we were unable to demonstrate any change 
in the oxytocin concentration-response. Other groups have reported a small 
inhibitory response with progesterone and even less with 5 α-reduced 
metabolites of progesterone suggesting significant differences between 
progesterone and its many metabolites (169). 
 A previous study has reported enhanced responses to β-sympathomimetics 
following both in vivo and in vitro treatment with progesterone (104). However, 
we did not see an enhanced effect of any tocolytic, including levcromakalim (a 
KATP channel opener), nifedipine (a calcium channel blocker) and ritodrine (a β-2 
agonist) in either our in vitro or in vivo progesterone groups. This is in contrast 
to previous work carried out by Chanrachakul et al, where they demonstrated an 
enhancement of the tocolytic effect of ritodrine using a lower concentration of 
progesterone (0.01 µM)  in vitro (99). Their experimental design involved using 
oxytocin-induced contractions as opposed to spontaneous contractions in our 
study. It is possible that different progesterone preparations and regimes may 
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underlie experimental outcome differences however both clearly show a rapid 
non-genomic effect of progesterone alone. Additionally, they used progesterone 
dissolved in ethanol (against appropriate ethanol controls) in contrast to our own 
study where we used progesterone in cyclodextrin. The differences between the 
Chanrachakul study and are own are hard to explain unless progesterone’s effect 
in enhancing the tocolytic effects of ritodrine require either ethanol or 
stimulation with oxytocin to become apparent. Their experimental design 
involved using oxytocin-induced contractions as opposed to spontaneous 
contractions in our study.  Lastly although a potential weakness of our study may 
be the use of lower segment myometrial biopsies, others have previously shown 
no difference between upper and lower segment biopsies in terms of myometrial 
contractility in vitro  (147) . 
If active progesterone administration directly alters myometrial contractility in 
vivo as well as indirectly enhancing tocolytic activity, it is possible our in vivo 
progesterone samples are out with this window of “active progesterone therapy” 
to show clear evidence to support this theory. One previous clinical trial found 
that administration of a large bolus of progesterone into the amniotic fluid of 
women at term in labour decreased spontaneous contraction frequency and 
intensity within minutes, but study numbers were small (127). Alternatively, 
progesterone administration may not alter fundamental tissue contractility and 
such evidence to support progesterone’s inhibitory effect on myometrial 
contractility may be due to high pharmacological doses in organ bath conditions 
as well as in vivo. Our group would suggest that to inhibit myometrial 
contractility ex vivo that active progesterone treatment is required, as this is 
likely to act via short term non genomic pathways. 
In conclusion we have demonstrated that progesterone can inhibit myometrial 
contractility in vitro however its mechanism of action both in vitro and in vivo 
warrants further investigation. 
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CHAPTER 4 
The effects of progesterone and 17 α hydroxyprogesterone 
caproate on cytokine release, uterine relaxants and contraction 
associated proteins within myometrium in vitro 
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Introduction 
A wide variety of mediators have been implicated in the control of labour and 
the initiation of preterm labour including pro-inflammatory cytokines (170) and 
contraction associated proteins (171). We hypothesised that progesterone may 
have an impact on these mediators and that this might contribute to the 
mechanism of action of progesterone in preventing preterm birth. We looked at 
a several groups of labour and inflammatory associated genes as well as known 
smooth muscle relaxants and promoters of uterine quiescence.  
As well as progesterone itself, 17OHPC has been demonstrated to prevent  
preterm labour (111) particularly in high risk groups. Again, by looking at various 
different genes as above we compared 17OHPC with progesterone. 
Aim of Chapter 
The aims of the following experiments were to determine cytokine release into 
its surrounding cell culture medium from myometrial tissue in vitro in the 
presence of various concentrations of progesterone over a 24 hour period. 
Myometrial tissue samples were incubated with nil (control), progesterone 
(water soluble) or 17OHPC at 10-6M, 10-5M and 10-4 M concentrations. DMSO 
controls were carried out for 17OHPC. By weighing three small myometrial 
explants from each patient’s biopsy we were able to standardise the amount of 
tissue being used per gram wet weight .Each set of experiments was performed 
in duplicate and with myometrial biopsies obtained from 7 separate patients for 
every cytokine measured. We then measured the final mRNA density levels 
within the myometrial explants of various uterine relaxants, stimulants and 
contraction associated proteins at the final 24 hour time-point. We used the Bio-
Plex® suspension array technology and were able to quantitate seven pro-
inflammatory cytokines from the supernatants of the myometrial tissues. Our 
assay was customised by the manufacturer to measure cytokines: IL1β, IL6, IL8, 
IL10, IFN γ, MCP and TNF α. The suspension array is composed of colour-coded 
bead sets, each of which may be conjugated with a unique reactant specific to a 
given target, listed above, creating an immunoassay. We performed an 
operational-validation kit with the system in order to validate the performance 
of the system. The kit included a series of standards to generate a standard 
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curve for each antibody. This technique can be likened to ELISA (enzyme linked 
immunoassay) in which we detected the presence of an antibody or antigen 
within a sample that is linked to a detected enzyme such as peroxidise. Although 
not an identical system the background theory is comparable and this flow-
cytometric technology assay uses monoclonal antibodies linked to fluorescent 
beads. We also elected not to stimulate cytokine release as a marker of 
inflammation or labour rather we measured the basal levels over time produced 
from myometrium within culture medium only. An example of this is by using 
lipopolysacharide (LPS) to stimulate an inflammatory response (172). 
Inflammation is certainly one cause of preterm labour however in twin 
pregnancy (as recruited in STOPPIT) stretch and other mechanisms are 
implicated as underlying mechanisms relating to the higher rates of preterm 
labour. We felt it therefore more appropriate to make any comparison with our 
STOPPIT data that the myometrium should not be stimulated by an inflammatory 
mediator. 
We also carried out an assessment of lactate dehydrogenase (LDH) release as a 
marker of cell death. LDH is released from cells as cell membrane integrity is 
lost. By measuring LDH release prior to the commencement of a cell culture and 
again measuring LDH release over time up to and beyond our selected 24 hour 
time-points we were able to rule out loss of tissue viability within our 
myometrial explants and during the allocated time-points selected for our cell 
culture. 
We then measured expression of mRNA for a number of pro labour substances, 
contraction associated proteins, endogenous uterine stimulants and endogenous 
inhibitors of uterine contractility using RT-PCR. We were only able to carry this 
out at the final 24 hour time-point, at the end of the cell culture experiment. 
We selected primer probe sets for IL1β, IL6, IL8, COX-2, INOS, bNOS, eNOS, 
cGRP, cGRPR, ep2, Cx-26, Cx-43 and Progesterone receptor A+B. A table of 
these genes is listed within materials and methods (Table 3, Table 4) .DMSO 
affected mRNA expression and cytokine release on its own therefore in view of 
the impact that the vehicle control DMSO had on both BioPlex results and RT-
PCR the results for 17OHPC are difficult to interpret, we planned to use a water 
soluble version of 17OHP but were unable to source one.  
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Statistical testing and graph display as carried out using GraphPad Prism, this 
calculates a p value of greater or less than 0.05 as shown. This indicates 
significance but does not give an exact p value number. 
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Results  
Release of Cytokines from myometrial explants in the presence of 
progesterone and 17 OHPC 
IL1β 
This pro-inflammatory cytokine was released into the supernatant in increasing 
amounts over time but was produced in low levels relative to other cytokines. 
Using time and the progesterone treatment as independent variables, time had a 
significant effect on the levels (all expressed as pgml-1/g wet weight, mean ± 
SEM) detected with 24 hours showing the highest levels n=8, p<0.001 compared 
with baseline. Cytokine production (without additional progesterone) measured 
0.8 ± 0.3 pgml-1/g wet weight after 1 hour and reached 12.6 ± 1.8 at 24 hours . 
Treatment with 17 OHPC did not alter IL1 β levels at low concentration, 10-6M. 
However, at higher concentrations of 10-4 M there was a significant vehicle 
effect compared to control, p<0.05, therefore at high levels 17OHPC had no 
effect different from that of its vehicle dimethyl sulfoxide (DMSO) .Treatment 
with progesterone 10-6M, 10-5M and 10-4M did not alter the amount of IL1β 
released into the supernatant when compared with control, (two-way ANOVA, 
GraphPad Prism, Figure 53, Figure 54). 
 
IL6 
IL6 was more readily released into the supernatants than IL1β without any 
inflammatory stimulation. Again, using time and progesterone treatment as the 
sources of variation we found that time had a significant effect on the release of 
IL6 p<0.001 (e.g.1 hour control levels measured 177 ± 55, 24 hours levels 3003 ± 
475) but progesterone concentrations 10-6M, 10-5M, 10-4M had no impact on IL-6 
levels (all expressed as pgml-1/g wet weight, mean ± SEM) (Figure 55).Treatment 
with 17OHPC had no effect on IL6 different from that of its vehicle control 
(Figure 56). 
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Figure 53 : Levels of IL1β detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with progesterone 1µM, 10 µM and 100 µM. Over 
time there was a significant increase in levels of IL1β + p<0.001 (ANOVA) but progesterone did not 
have any effect when compared with control. 
 
Figure 54 : Levels of IL1β detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with 17OHPC 1µM, 10 µM and 100 µM. and the 
equivalent DMSO control. Over time there was a significant increase in levels of IL1β + p<0.001 
(ANOVA). The DMSO vehicle significantly reduced levels of IL1β at 100 µM * p<0.05. The 
17OHPC results do not differ from its vehicle at this concentration. 
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Figure 55 : Levels of IL6 detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with progesterone 1µM, 10 µM and 100 µM. Over 
time there was a significant increase in levels of IL6 +p<0.001 (ANOVA) but progesterone did not 
have any effect when compared with control. 
 
Figure 56 : Levels of IL6 detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with 17OHPC 1µM, 10 µM and 100 µM. and the 
equivalent DMSO control. Over time there was a significant increase in levels of IL6 +p<0.001 
(ANOVA). 17OHPC had no effect on IL6. 
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IL8 
This pro- inflammatory cytokine similarly to IL6 was readily released into the 
supernatants from non-stimulated myometrial explants. Low levels were 
detectable at 1 hour compared with 4 hours and 24 hours p<0.001. Progesterone 
had no effect at any of the concentrations on the overall levels of IL8 detected 
p>0.05 and time again was the only source of variation (two-way ANOVA, 
GraphPad Prism) (Figure 57). Levels of the control at time 1 hour measured 42 ± 
23 (all expressed as pgml-1/g wet weight, mean ± SEM). Treatment with 17 
OHPC did not alter IL8 levels at low concentration, 10-6M. However, at higher 
concentrations of 10-4 M there was a significant vehicle effect compared to 
control, p<0.05, therefore at high levels 17OHPC had no effect different from 
that of its vehicle (DMSO) (Figure 58). 
IL10 
This cytokine is an anti-inflammatory cytokine, our hypothesis that progesterone 
may increase levels of IL10 rather than decrease (as with pro-inflammatory 
cytokines) in order to maintain uterine quiescence. Low levels of IL10 were 
detected using this Bio-Plex® array. Time again, was the significant variation 
factor with an increase in release over the time-points, p<0.001(Figure 59) 
(ANOVA). Progesterone at 10-6M, 10-5 and 10-4M showed no change in the 
amount of IL10 released compared with control p>0.05  (two-way ANOVA, 
GraphPad Prism). Levels of the control at time 1 hour measured 9.8 ± 4.4 (all 
expressed as pgml-1/g wet weight, mean ± SEM).Treatment with 17OHPC had no 
effect on IL10 different from that of its vehicle control at 10-4 M there was a 
significant vehicle effect compared to control, p<0.05 (Figure 60).Progesterone 
at these concentrations does not appear to increase the amount of IL10 released 
compared with a control. 
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Figure 57 : Levels of IL8 detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with progesterone 1µM, 10 µM and 100 µM. Very 
low levels were seen at 1 hour in comparison with 24 hours. Over time there was a significant 
increase in levels of IL8 + p<0.001 (ANOVA) but progesterone did not have any effect when 
compared with control. 
 
Figure 58 : Levels of IL8 detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with 17OHPC 1µM, 10 µM and 100 µM. and the 
equivalent DMSO control. Over time there was a significant increase in levels of IL8 + p<0.001 
(ANOVA). The DMSO vehicle significantly reduced levels of IL8 at 10 µM and 100 µM * p<0.05.  
The 17OHPC results do not differ from its vehicle at this concentration. 
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Figure 59 : Levels of IL10 detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with progesterone 1µM, 10 µM and 100 µM. Very 
low levels were seen at 1 hour in comparison with 24 hours. Over time there was a significant 
increase in levels of IL10 + p<0.001 (ANOVA) but progesterone did not have any effect when 
compared with control. 
 
 
Figure 60 : Levels of IL10 detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with 17OHPC 1µM, 10 µM and 100 µM. and the 
equivalent DMSO control. Over time there was a significant increase in levels of IL10 + p<0.001 
(ANOVA). The DMSO vehicle significantly reduced levels of IL10 at 100 µM * p<0.05.  The 
17OHPC results do not differ from its vehicle at this concentration. 
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IFNγ 
Moderate levels of IFNγ were detected with this assay from cell culture. 
Progesterone had no effect at any of the concentrations on the overall levels of 
IFNγ detected p>0.05 and time again was the only source of variation p<0.001 
(two-way ANOVA, GraphPad Prism). Levels of the control well at 1 hour 
measured 34 ± 18 (all expressed as pgml-1/g wet weight, mean ± SEM) (Figure 
61). Treatment with 17 OHPC did not alter IL8 levels at low concentration, 10-
6M. However, at higher concentrations of 10-5 M and 10-4 M there was a 
significant vehicle effect compared to control, p<0.05, therefore at high levels 
17OHPC had no effect different from that of its vehicle (DMSO) (Figure 62). We 
also detected significantly lower levels overall of IFNγ released into the 
supernatants with 17OHPC. Progesterone at these concentrations does not 
appear to reduce the amount of IFNγ released into the supernatants compared 
with control in vitro. 
MCP-1 
Moderate levels of MCP-1 again, were detected with this assay from cell culture. 
Progesterone had no inhibitory effect at any concentration on the overall levels 
of MCP-1 detected p>0.05.Time again was the only source of variation (two-way 
ANOVA, GraphPad Prism) p<0.001. Levels of the control well at 1 hour measured 
114 ± 42 (all expressed as pgml-1/g wet weight, mean ± SEM) (Figure 63). 
Treatment with 17 OHPC did not alter MCP-1 levels at low concentration, 10-6M. 
However, at higher concentrations of 10-4 M there was a significant vehicle 
effect compared to control, p<0.05, therefore at high levels 17OHPC had no 
effect different from that of its vehicle (DMSO) (Figure 64).Progesterone at 
these concentrations does not appear to reduce the amount of MCP-1 released 
into the supernatants compared with control in vitro. 
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Figure 61 : Levels of IFNγ detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with progesterone 1µM, 10 µM and 100 µM. Over 
time there was a significant increase in levels of IFNγ + p<0.001 (ANOVA) but progesterone did not 
have any effect when compared with control. 
 
Figure 62 : Levels of IFNγ detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with 17OHPC 1µM, 10 µM and 100 µM. and the 
equivalent DMSO control. Over time there was a significant increase in levels of IFNγ + p<0.001 
(ANOVA). The DMSO vehicle significantly reduced levels of IFNγ at 100 µM * p<0.05.  The 
17OHPC results do not differ from its vehicle at this concentration.  
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Figure 63 : Levels of MCP-1 detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with progesterone 1µM, 10 µM and 100 µM. Over 
time there was a significant increase in levels of MCP-1, + p<0.001 (ANOVA) but progesterone did 
not have any effect when compared with control. 
 
Figure 64 : Levels of MCP-1 detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with 17OHPC 1µM, 10 µM and 100 µM. and the 
equivalent DMSO control. Over time there was a significant increase in levels of MCP-1 + p<0.001 
(ANOVA). The DMSO vehicle significantly reduced levels of MCP-1 at 100 µM, * p<0.05.  The 
17OHPC results do not differ from its vehicle at this concentration.  
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TNF-α 
Low levels of TNF-α were detected with this assay from cell culture. 
Progesterone had no inhibitory effect at any concentration on the overall levels 
of TNF-α detected, p>0.05.Time again was the only source of variation (two-way 
ANOVA, GraphPad Prism) p<0.001. Levels of the control well at 1 hour measured 
5.2 ± 1.5 (all expressed as pgml-1/g wet weight, mean ± SEM) (Figure 65). 
Treatment with 17OHPC had no effect on MCP different from that of its vehicle 
control (Figure 66). Progesterone at these concentrations does not appear to 
reduce the amount of TNF-α released into the supernatants compared with a 
control in vitro. 
Tissue Viability 
We evaluated our own LDH assay kit by performing a standard curve in order to 
ascertain that it was detecting correctly. Measurements were detected 
spectrophotometrically using optical density (OD) at 490-690 nanometer (nm) 
wavelength .We then carried out an assessment of LDH release from a control 
well at 24 hour intervals up to 96 hours (Figure 67); however this did not give us 
an accurate time zero assay of LDH release. Because the tissue is removed from 
the patient using dissection and placed in medium we required an assessment of 
the basal LDH levels due to initial tissue trauma from dissection, removal from 
patient and transport to the laboratory. We therefore compared a control tissue 
specimen with an identical specimen treated with a lysis buffer. The lysis 
treated sample was used as an indicator of maximum superficial cell death for 
the purposes of this experiment. The results showed that there was little change 
over the 24 hour period and therefore the overall percentage cytotoxicity was 
within an acceptable range (Figure 68). Although there is a degree of LDH 
release within our experiment, as an overall estimate of tissue viability there 
appears to be some initial cell damage at time zero likely caused by initial 
removal from the patient and sampling. The overall estimate of tissue viability 
calculated as a percentage of the maximum LDH released is approximately 80% 
at 1 hour (estimate of % viability= 100-% of overall maximum LDH release). This 
estimate of tissue viability falls to 60% at the 24 hour time point (Figure 69).  
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Figure 65 : Levels of TNF-α detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with progesterone 1µM, 10 µM and 100 µM. Over 
time there was a significant increase in levels of TNF-α, + p<0.001 (ANOVA) but progesterone did 
not have any effect when compared with control. 
 
Figure 66 : Levels of TNF-α detected n=7 (pgml-1/g wet weight, mean ± SEM) at 1, 4 and 24 hour 
time-points within the supernatant after treatment with 17OHPC 1µM, 10 µM and 100 µM. and the 
equivalent DMSO control. Over time there was a significant increase in levels of TNF-α + p<0.001 
(ANOVA). The DMSO vehicle significantly reduced levels of TNF- α at 100 µM, * p<0.05.  The 
17OHPC results do not differ from its vehicle at this concentration. 
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Figure 67 : LDH levels from the supernatants gathered over a 5 day period at 1, 4, 24, 48, 72, 96 
and 120 hours. We used 24 hours as our final time-point. This gives an indicator of cell membrane 
integrity over time. 
 
Figure 68 : LDH levels at our selected time-points for cell culture including a zero time-point. There 
were also samples treated with a lysis buffer to induce cell death as a comparison.  Relative levels 
at time zero indicate an acceptable amount of cell death within the accepted 24 hour time period. 
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Figure 69 : This figure shows calculated mU/ml LDH released from the control preparation as well 
as LDH released from tissue incubated with a lysis buffer. The tissue with lysis buffer is a marker of 
maximum superficial cell death. Although there is a degree of LDH release, as an overall estimate 
of tissue viability there appears to be some initial cell damage at time zero. The overall estimate of 
tissue viability is 80% at 1 hour and falls to 60% at the 24 hour time point. 
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Results RT-PCR 
After assessing the cytokine release into the surrounding supernatants we 
measured the relative tissue mRNA expression of various labour and uterine 
related genes relative to a control gene within myometrial tissue. Real time RT-
PCR (Abi, Taqman) was used to quantitate endogenous inhibitors of uterine 
contractility (cGRPt, ep2), promoters of uterine relaxation ( NOS, pgdh) 
cytokines (IL6, IL8, IL1β), prostaglandin production enzyme ( COX-2) and gap 
junction components (connexin 26 and connexin 43). We also measured 
progesterone receptor A+B in combination. All results were expressed relative to 
18s and β-actin. For continuity we have expressed our results in this chapter 
relative to housekeeping gene 18S as our later analysis of STOPPIT samples using 
RT-PCR this housekeeping gene was also used. This housekeeping gene has been 
widely used within myometrial and parturition studies as a suitable control 
(173). The synthetic progestin, 17 OHPC had significant vehicle effects (DMSO) 
therefore we analysed only the tissues from our control versus progesterone 
groups at each concentration. 
Nitric-oxide synthase 
We looked at three separate isoforms of NOS, iNOS (inducible), eNOS 
(endothelial) and bNOS (neuronal).They produce NO which activates guanylate 
cyclise and promotes smooth muscle relaxation. The 24 hour progesterone 
incubation at 10-6M, 10-5 and 10-4M did not modify any iNOS, eNOS or bNOS levels 
detectable within the myometrium when compared to the control sample 
(ANOVA with Bonferoni comparison test). Although it did not reach statistical 
significance inos does show a trend with a reduction with each concentration of 
progesterone. As the uterus is non-neuronal it expresses very little bNOS (Figure 
70, Figure 71, Figure 72). 
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Figure 70 : This graph shows inos gene mRNA expression levels, relative to 18S.The density ratio 
for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression after the 
24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control myometrium 
(ANOVA). Low levels were of inos were detected overall. 
 
Figure 71 : This graph shows enos gene mRNA expression levels, relative to 18S. The density ratio 
for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression after the 
24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control myometrium 
(ANOVA). Higher levels of enos were detected compared with inos and bnos. 
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Figure 72 : This graph shows bnos gene mRNA expression levels, relative to 18S. The density ratio 
for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression after the 
24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control myometrium 
(ANOVA). Low levels were of bnos were detected overall. 
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Calcitonin gene related peptide and receptor 
CGRP inhibits myometrial contractile activity. We measured mRNA for both the 
peptide and its receptor. There was no detectable difference of CGRP or CGRPR 
after 24 hour incubation with 10-6M, 10-5 and 10-4M progesterone when compared 
with control (ANOVA with Bonferoni comparison test). Expression of the receptor 
relative to control gene was higher than the peptide expression itself in human 
non labour myometrium at term (Figure 73, Figure 74). 
Endothelial phosphate receptor EP2 
This is a subgroup of receptor for prostaglandin E2  and  is G protein coupled. Its 
activation leads to a rise in cAMP and myometrial relaxation. There was no 
detectable difference in mRNA of EP2 relative to 18S in the progesterone 
treated groups with any concentration of progesterone compared with control 
(ANOVA with Bonferoni comparison test) (Figure 75). 
15-hydroxyprostaglandin dehydrogenase PGDH 
This enzyme is associated with the catabolism of prostaglandins, which are 
strongly implicated in the onset and maintenance of parturition. Again, 24 hour 
incubation with 10-6M, 10-5 and 10-4M progesterone did not modify levels of PGDH 
detectable against the control (ANOVA with Bonferoni comparison test) ( Figure 
76).Although graphically it may appear that progesterone reduced expression at 
concentrations of 10-5 and 10-4M this does not reach statistical significance. 
Pro-inflammatory cytokines 
We measured IL1β, IL6 and IL8 all of which are generated in the uterus and 
cervix and implicated in labour and preterm labour. In a similar pattern to the 
BioPlex supernatant results we demonstrated no difference in the levels of IL1β, 
IL6 and IL8 following 24 hour incubation with 10-6M, 10-5 and 10-4M progesterone 
compared to control (ANOVA with Bonferoni comparison test) (Figure 77, Figure 
78 and Figure 79). Low levels of IL1β compared to IL6 and Il8 were detected with 
this analysis which is in agreement with the Bio-Plex assay results. 
 
Laurie Anderson, 2009  158 
 
Figure 73 : This graph shows cGRP gene mRNA expression levels; relative to 18S. The density 
ratio for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression 
after the 24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control 
myometrium (ANOVA). Low levels were of cGRP were detected overall. 
 
Figure 74 : This graph shows cGRP receptor gene mRNA expression levels; relative to 18S. The 
density ratio for mRNA n=6 expressed as mean ± SEM.There was no significant change in 
expression after the 24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with 
control myometrium (ANOVA). Higher levels were of cGRP receptor were detected relative to its 
peptide. 
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Figure 75 : This graph shows EP2 gene mRNA expression levels, relative to 18S. The density ratio 
for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression after the 
24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control myometrium 
(ANOVA). 
 
Figure 76 : This graph shows PGDH gene mRNA expression levels; relative to 18S. The density 
ratio for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression 
after the 24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control 
myometrium (ANOVA). 
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Figure 77 : This graph shows IL1β gene mRNA expression levels; relative to 18S. The density ratio 
for mRNA n=6 expressed as mean ± SEM.There was no  significant change in expression after the 
24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control myometrium 
(ANOVA). Low levels of this pro-inflammatory cytokine were detected overall. 
 
 
Figure 78 : This graph shows IL6 gene mRNA expression levels; relative to 18S. The density ratio 
for mRNA n=6 expressed as mean ± SEM.The density ratio for mRNA n=6 expressed as mean ± 
SEM.There was no significant change in expression after the 24 hour incubation with progesterone 
1µM, 10 µM and 100 µM compared with control myometrium (ANOVA). 
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Figure 79 : This graph shows IL8 gene mRNA expression levels; relative to 18S. The density ratio 
for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression after the 
24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control myometrium 
(ANOVA). 
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COX-2 
COX-2 is a contractile agent which promotes prostaglandin synthesis. Again, 24 
hour incubation with 10-6M, 10-5 and 10-4M progesterone did not modify levels of 
COX-2 detectable against the control (ANOVA with Bonferoni comparison test, 
GraphPad prism). 
Gap junction proteins 
We measured contraction associated proteins connexin 26 and 43. These form 
components of gap junction transmembrane proteins which aid to formulate 
synchronous contractile activity. Again, 24 hour incubation with 10-6M, 10-5 and 
10-4M progesterone did not modify levels of connexin 26 detectable against the 
control. In contrast we did observe an inhibition in connexin 43 levels in the 
progesterone 10-6M and 10-4M incubations with progesterone incubation 
compared to control p<0.05 (ANOVA with Bonferoni comparison test, GraphPad 
prism). 
Progesterone receptor A+B 
We measured the progesterone receptor A+B together. PRB is the full length 
gene and also encodes for PRA (truncated form by 164 N-terminal amino acids). 
The incubation with 10-6M, 10-5 and 10-4M progesterone did not modify levels of 
PRA+B together, detectable against the control. 
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Figure 80 : This graph shows COX-2 gene mRNA expression levels, relative to 18S. The density 
ratio for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression 
after the 24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control 
myometrium (ANOVA). 
 
Figure 81 : This graph shows Cx26 gene mRNA expression levels, relative to 18S. The density 
ratio for mRNA n=6 expressed as mean ± SEM.There was no significant change in expression 
after the 24 hour incubation with progesterone 1µM, 10 µM and 100 µM compared with control 
myometrium (ANOVA). 
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Figure 82 : This graph shows Cx43 gene mRNA expression levels, relative to 18S. The density 
ratio for mRNA n=6 expressed as mean ± SEM.There was a  significant change in expression after 
the 24 hour incubation with progesterone 1µM  and 100 µM compared with control myometrium 
(ANOVA) p<0.05. 
 
 
Figure 83 : This graph shows progesterone receptor A and B gene mRNA expression levels, 
relative to 18S. The density ratio for mRNA n=6 expressed as mean ± SEM.There was no 
significant change in expression after the 24 hour incubation with progesterone 1µM, 10 µM and 
100 µM compared with control myometrium (ANOVA). We measured the progesterone receptor A 
and B together.  
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Discussion 
The effects of progesterone and 17 α hydroxyprogesterone 
caproate on cytokine release, uterine relaxants and contraction 
associated proteins within myometrium in vitro 
In this chapter we aimed to look specifically at progestogenic effects in vitro. A 
wide variety of mediators have been implicated in the control of labour and 
preterm labour, including pro-inflammatory cytokines and contraction associated 
proteins. The aims of the following experiments were to determine cytokine 
release into the surrounding cell culture medium from myometrial tissue in vitro 
with three concentrations of progesterone over a 24 hour period. We aimed to 
determine the myometrial effects of progesterone and 17-α 
hydroxyprogesterone caproate (17OHPC) after tissue culture over a 24 hour 
period.  
We again used lower uterine segment myometrium sampled at prelabour 
elective caesarean section which we have previously discussed in chapter 3.  
As we were investigating the effects of progesterone on several markers we 
wanted to make a comparison between our in vitro and in vivo (chapter 5) 
experimental models. Within STOPPIT, patients received vaginal progesterone, 
90mg daily. Progesterone can be administered orally, vaginally or 
intramuscularly. Oral preparations show a wide variation in levels due to 
individual’s gastric filling and enterohepatic circulation. The vaginal route 
provides higher uterine circulating levels but this is not consistently reflected in 
serum levels (174). There is also evidence to support the uterine first pass effect 
with vaginal progesterone preparations giving targeted higher uterine 
concentrations of the vaginally delivered drug (175). The half-life of vaginal 
progesterone 100mg is approximately 13 hours (176) and within STOPPIT (123) 
trial this vaginal tablet was replenished at the same time every 24 hours. 
Therefore for the in vitro comparison we selected shorter times 1 and 4 hours in 
addition to 24 hours. The shorter time-points were selected after the 
contractility studies carried out had shown maximal effects of progesterone at 1 
hour on myometrial contractility which was maintained for over 4 hours. We also 
selected three concentrations of progesterone and 17OHPC. In view of difficulty 
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determining exact myometrial progesterone concentrations we extracted 
information from our previous contractility data that had shown significant 
inhibitory effects at high doses of 100µM. 
17OHPC does not appear to modify any of the cytokines released, however we 
did not continue our analysis with this progestin as there were significant vehicle 
effects detected. As mentioned in chapter 3, a contractility study investigating 
progesterone and 17OHPC and the effects on human myometrial contractions 
carried out by Ruddock et al showed that 17OHPC levels, when incubated with 
myometrial tissues were reduced by between 90- 98%. Progesterone was less 
effected with a loss of 29-50% detected (100).They used ethanol as opposed to 
DMSO as a solvent and showed less vehicle effects. 17OHPC however did not 
appear to present within the organ baths at the end of the experiments. As it is 
strongly lipophilic and difficult to dissolve, preparations that have been used in 
clinical trials are dissolved in castor oil (119). Its half life is unclear in women 
and its maternal metabolic pathway unclear as well as its target organ site. With 
significant vehicle effects our results are difficult to interpret and indeed show 
no discernible difference in any inhibition towards cytokines without similar 
vehicle effects. It is also possible as in the paper published by Rudduck et al that 
the 17OHPC is not reaching the myometrial tissue and is therefore not able to 
actively modify it in vitro.Our further analysis of myometrial mRNA expression of 
various contraction associated proteins and inflammatory markers therefore only 
takes into account the progesterone treated and control samples. 
The pathophysiology of labour both term and preterm is poorly understood. It is 
likely a complex culmination in a series of events and therefore to halt this 
process at one single step such as with tocolysis to stop contractions has not 
been successful in either prolonging the pregnancy or improving the neonatal 
outcome. Progesterone and synthetic progestin, 17OHPC, have been shown to 
reduce the incidence of preterm delivery in high risk groups (114). We examined 
both natural progesterone, which was used in the STOPPIT (123) study and we 
also looked at this synthetic progestin in view of ongoing clinical trials 
investigating progestins for the prevention of preterm labour. Smith et al 
recently investigated the plasma levels of progesterone amongst other 
hormones. They suggest that it is the patterns of change as opposed to absolute 
concentrations of progesterone, oestriadiol, oestriol and corticotrophin releasing 
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hormone that are common to most pregnancies. They noted declining 
progesterone to oestriol ratio that occurs later in gestation as labour approaches 
and this theory would support the basis of supplementary progesterone to 
prevent preterm delivery.  
If these pro-inflammatory cytokines are implicated in labour and preterm labour 
this offers one possible target site for treatment or prevention of preterm 
labour. Our focus in particular, relates to steroid control with progesterone and 
was one potential mechanism of action for progesterone in the prevention of 
preterm labour. 
 We detected levels of several pro and one anti inflammatory cytokine from our 
assays, measured from the surrounding cell culture fluid (supernatants) and 
released into the medium by the myometrial tissue. The cytokine IL8 followed by 
IL6 was most abundant within our assays and IL1β was least detected. The 
review from Keelen et al in 2002 examines cytokines, prostaglandins in the 
context of term and preterm delivery. They looked at amnion and choriodecidual 
membranes at term not in labour and in spontaneous labour as well as preterm 
labour with and without intrauterine infection present. They were able to 
demonstrate relative expression of cytokines and chemokines cDNA analysis 
within the four sub-groups. They showed dramatically increased levels in a 
number of chemokines within membranes of preterm deliveries complicated by 
chorioamnionitis. Many cytokines and chemokines were also evident in tissues 
prior to labour but with a modest expression increase in normal term labour. For 
example IL8 levels within amniotic fluid increased in pregnancy towards term 
with further elevation after the onset of labour (177). Levels of IL8 were also 
increased within myometrium from lower uterine segment with the onset of 
labour (178). With our in vitro model we are able to show that each 
cytokine/chemokine measured was released from myometrium which had not 
been stimulated to simulate labour by any inflammatory agent. An inflammatory 
stimulus, such as LPS (lipopolysacharide) has been shown to stimulate production 
of cytokines in particular with IL1β and IL6 expressed in preterm and term 
myometrium prior to onset of labour. Other groups have shown IL8 and TNF α 
were only expressed in myometrium in active labour (172). Although our in vitro 
model does not replicate their method we found a similar pattern in cytokine 
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levels with lower segment myometrium that had not been stimulated with the 
inflammatory agent LPS, and was left in cell culture for 24 hours. 
Gustafsson et al found no difference in the secretion of IFN-γ, IL-4, IL-10, TGF-β 
or TNF α when comparing decidual tissues before and after the onset of labour 
(179) but there are limited data on cytokine levels from human myometrial 
tissues. TNF α has a stimulatory role with prostaglandin synthesis and therefore 
a rise may have been expected with labouring samples. Young et al identified 
small amounts of TNF α in myometrium of labouring women (25) and other 
studies have also only detected low levels (172). We demonstrated low levels of 
TNF-α within the Bio-Plex ® assay but this increased at each time-point with the 
most abundant levels being measured from the supernatant after 24 hours in cell 
culture. 
MCP-1,monocyte chemoattractant protein ,also known as C-C chemokine motif 
ligand 2, CCL-2 is up-regulated in both term and preterm labour (180).Its main 
role is to recruit monocytes and leucocytes to sources of inflammation and can 
be up-regulated by other inflammatory mediators such as cytokines IL1β and 
interferon γ.We observed no difference in expression of MCP-1 following the 
progesterone incubation. 
Our progesterone incubations at 1, 10 and 100µM had no direct inhibitory effect 
on cytokine release into the surrounding cell culture medium under in vitro 
conditions tested. We hypothesised that the mechanism of action of 
progesterone in preventing preterm delivery may occur via suppression of 
endogenous myometrial prostaglandin and cytokine production. This hypothesis 
was supported by non pregnant human studies with up-regulation of IL8 and 
COX-2 in response to progesterone withdrawal (181). This may indicate that our 
study is underpowered to detect a significant difference within the cytokines. It 
is also possible that our in vitro model fails to adequately replicate the 
physiology. We cannot be certain that progesterone was penetrating further 
than the outer cell layers within our cell culture model and therefore it is 
possible that the concentrations affecting the myometrium were indeed much 
lower than in the cell culture well. 
There is good evidence to show that following a traumatic brain injury the 
excessive release of IL1β and TNF-α is a major cause of cerebral oedema and 
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progesterone has been shown to attenuate the production of these pro-
inflammatory cytokines (182).This may however not be replicated within 
myometrial systems. Our data shows no attenuation in the production of pro-
inflammatory cytokines with progesterone. In his review of the preterm 
parturition syndrome, Romero suggests that in infection-related preterm birth, 
the increased concentration of IL1β in gestational tissue could stimulate nuclear 
factor-kappa B (NF-κB) .This activation of NF-κB can increase COX-2 (mRNA and 
protein expression) and prostaglandin production and also could repress 
progesterone activity resulting in a functional progesterone withdrawal and, 
thus, preterm parturition (12). It may therefore indicate that once the 
inflammatory cascade has been activated that supplementary progesterone will 
have little anti-inflammatory effect in myometrium.  
Although we did not see an effect with our in vitro model there is evidence to 
support this theory from the functional progesterone withdrawal which we have 
discussed previously. It remains unclear how supplementary progesterone would 
have any effect during pregnancy when endogenous levels are already very high 
and progesterone as a prevention for preterm labour has only been shown to be 
effective in a small subgroup of high risk women with a history of preterm birth 
and not in multiple pregnancy (114). If levels of progesterone are already high 
then the progesterone receptor ratio change towards term or labour and 
development of the contractile phenotype may be central to the parturition 
pathway. This may also be linked into the inflammatory cascade which is being 
linked very closely with the process of normal and abnormal labour. 
Inflammatory cytokines, in particular prostaglandins (PGE2 and PGF2α) may be 
involved in both term and infection-associated birth. In many animal species 
prostaglandins are able to trigger parturition by inducing the progesterone 
withdrawal (77, 183). Humans differ with no detectable fall in progesterone to 
trigger parturition. It is now thought to be a functional withdrawal in response 
to progesterone receptor ratios that is responsible for the loss of progesterone 
quiescence. Progesterone’s main action in maintaining uterine quiescence is 
generally accepted to result via the PR-B receptor (48, 77).  Prostaglandins are 
also used for the induction of labour in women and can trigger parturition at all 
stages of pregnancy. For induction of labour however, this can take over 12 
hours suggesting that a latency period is required for contractile phenotype to 
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take over. Madsen et al demonstrated that prostaglandin PGF2α increased the 
PRA/PRB ratio by increasing PRA but not PRB in a human myometrial cell line 
suggesting that PGF2α, either by local production or presence within the 
myometrium could initiate labour by modulating the nPR expression to induce 
functional progesterone withdrawal (184). The NF-κB transcription factor is a 
key mediator in inflammatory response (27) and has also been shown to 
stimulate expression of PRA, PRB and PRC in myometrial cells indicating an up-
regulation of the inhibitory PR isoforms and a mechanism for the loss of uterine 
quiescence (79). 
We may therefore have looked too far along the pathway within the 
inflammatory cascade to show a change in pro-inflammatory cytokines. It may 
be a response to the withdrawal of the progesterone levels and their PR isoforms 
receptors that causes a reduction in vivo and our model has over simplified what 
may actually be occurring in vivo. We also did not measure samples from amnion 
or choriodecidua but focused on myometrium itself and release of cytokines into 
the surrounding cell culture medium. Within our subsequent analysis of 
myometrial tissue using RT-PCR we selected to look again at IL1β, IL6 and IL8 to 
determine the expression of cytokines within the myometrium. There was no 
significant reduction following the progesterone incubations in the expression of 
these cytokines, supporting the data obtained from the Bio-Plex array.  
Our analysis of the mRNA relative expression in myometrial explants at the 24 
hour time shows no change in the nitric oxide synthase isoforms (NOS), 
calcitonin gene related peptide and receptor (CGRP), endothelial phosphate 
receptor EP2, 15-hydroxyprostaglandin dehydrogenase (PGDH),  26 (Cx-26), COX-
2 and progesterone receptor A+B ( PR A+B) or interleukins (IL1β, IL6 and IL8) . 
There was however a significant reduction in expression of the contraction 
associated protein, connexin 43 with progesterone compared to control.  
We did not see an up-regulation in any isoforms of mRNA NOS although there was 
an inhibitory trend with iNOS which did not reach statistical significance 
following progesterone incubation. It is possible however, that our study is 
underpowered to detect a difference as trends were apparent within some 
graphical data that may indicate a progestogenic effect. Norman et al showed 
using Western blotting that pregnancy was associated with an up-regulation of 
Laurie Anderson, 2009  171 
both endothelial and nitric oxide synthase expression and neuronal nitric oxide 
synthase expression within human myometrium (185).The isoforms of nitric oxide 
synthase have been identified within human myometrium but do not appear to 
be modified with the onset of labour (186, 187).Other groups were able to 
demonstrate all three isoforms within human myometrium but iNOS and nNOS 
were only detectable in small amounts as seen with our results (188). They also 
showed that eNOS was not correlated with gestational age suggesting it was 
unlikely to have a role in modulating myometrial tone throughout pregnancy. 
NOS have been implicated in cervical remodelling and as a smooth muscle and 
potential uterine relaxant. Within a rat model, Bulbul et al demonstrated 
increased iNOS expression and nNOS expression with 17-β estradiol and 
progesterone in combination. They were unable to demonstrate a change in 
eNOS expression with steroid hormones (189). Our hypothesis that progesterone 
may upregulate these endogenous inhibitors of uterine contractility like 
potential tocolytics as with the nitric oxide donors, glyceryl trinitrate and 
sodium nitroprusside which can inhibit myometrial contractions (92) was not 
reflected in the results from the in vitro cell culture.  
In rat uterine myometrial smooth muscle cell lines, progesterone has been 
shown to up regulate calcitonin-gene related peptide receptor components, 
calcitonin-gene related peptide being a potent smooth muscle relaxant (134). 
Dong et al report that CGRP induced a concentration-dependent relaxation in 
spontaneously contracting myometrium from pregnant women. This relaxatory 
effect however, was reduced in myometrium obtained from patients during 
labour and in the non-pregnant state (91) .CGRP-receptors are abundant in the 
myometrial cells of pregnant women who are not in labour, and are minimal in 
uterine specimens from women in labour and in the non-pregnant state. Another 
endogenous inhibitor of uterine contractility, the relaxant prostaglandin E 
receptor subtype two (EP2) is regulated by steroid hormones within the rat 
uterus and progesterone lead to an increase in expression (133). Evidence 
showing that treatment with progesterone enhanced myometrial calcitonin 
gene-related peptide B receptor protein expression in  cultured pregnant 
myometrial explants were elevated further when combined incubation with 17β-
estradiol plus progesterone was carried out (190) .We were unable to replicate 
this effect within human myometrial explants with similar dose regimes and time 
courses for progesterone alone. This may be related to our original experimental 
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design as monolayer of cells may allow a greater degree of penetration of a drug 
than explants of myometrium and a longer genomic effect may have been seen 
beyond 24 hours. There are several EP receptor isoforms within human 
myometrium and some are expressed higher in the lower than upper segment, 
such as EP2, they also demonstrated that within the upper segment, EP2 was 
higher in term labour samples and lower in preterm labour samples compared to 
term non-labour. This expression profile is difficult to explain, as it does not 
correspond with the current theory supporting a contractile upper segment 
during labour (191). 
Prostaglandins are inactivated by an NAD +(nicotinamide-adenine dinucleotide ) 
dependent 15-hydroxyprostaglandin dehydrogenase (PGDH), which catalyzes the 
initial conversion of PGE2 and PGF2α to their biologically inactive 15-keto 
derivatives and although the amnion and chorion are major sites of prostaglandin 
synthesis and metabolism (192), this enzyme has been located to myocytes 
within myometrium (131). They also showed a decrease in PGDH activity in 
preterm and term labour, hypothesising that this would lead to a decreased 
metabolism of prostaglandins within the myometrium and subsequently an 
overall increase in prostaglandin levels. Greenland et al examined the PGDH 
promoter gene and suggested that progesterone was an important stimulus for 
PGDH expression in the utero-placental unit. This may be a mechanism for 
maintenance of uterine quiescence during pregnancy. In myometrial smooth 
muscle cells, both isoforms of the progesterone receptor, PR-B and PR-A, caused 
a ligand-dependent activation of PGDH-2368/luc3 but suggested that there were 
multiple and complex crosstalk pathways for regulation of PGDH (193). Our in 
vitro model, again, showed no up-regulation with PGDH following progesterone 
incubation. Other groups have looked directly at prostaglandins and their ability 
to stimulate labour in women by inducing the functional progesterone 
withdrawal (change in PR-A: PR-B ratio). Madsen et al concluded that 
prostaglandins acting via the protein kinase-C pathway facilitate functional 
progesterone withdrawal by increasing the myometrial PR-A:PR-B expression 
ratio (184). 
Prostaglandins are formed from the precursor arachidonic acid which itself is a 
substrate for at least three enzyme groups. The cyclo-oxygenase (COX) or 
prostaglandin endoperoxide synthase pathway produces prostaglandin 
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endoperoxides, which are then synthesized to prostaglandins by specific 
synthase enzymes.COX-2 mRNA and protein expression, has been shown to 
increase at term with significant up-regulation occurring prior to the onset of 
labour (130). Slater et al suggest that this up-regulation mediates an increase in 
prostaglandin synthesis in human myometrium at term, and may well have a role 
in the parturition process rather than as a consequence of labour. We postulated 
that within non labouring myometrium that progesterone could inhibit COX-2 
expression. We showed no difference, however in COX-2 expression following the 
progesterone incubation. Others have tested a similar hypothesis that 
progesterone inhibits uterine contractility by blocking nuclear factor kappaB 
(NF-kappaB) activation and induction of COX-2.Immortalized human fundal 
myometrial cells were treated with IL1β with and without progesterone. IL1β 
alone caused a marked up-regulation of COX-2 mRNA, but treatment with 
progesterone suppressed this induction (194). The fundal myometrial cell line 
differs from lower segment myometrial explants and they stimulated an 
inflammatory response within the cells using IL1β, these methodological 
differences could allow for the inherent differences seen in COX-2 mRNA 
expression with progesterone in our results.  
In labour, synchronous contractions of the uterus depend on electrical coupling 
of myometrial smooth muscle cells by gap junctions (87). Normal labour is 
hypothesised to occur after the functional progesterone withdrawal allowing a 
contractile phenotype to dominate via activation of contraction associated 
proteins. Some of the important contraction associated proteins are the oxytocin 
receptor, PGDH and gap-junction protein connexin 43 (48). In the human 
myometrium, gap junctions are scarce in the non-pregnant uterus, but become 
abundant at term in preparation for labour. Connexin 26 and 43 are major 
components of these gap junctions and allow the uterus to function as a 
syncitium. Both have been identified within rat myometrium(195). Increased 
levels of connexin 43 mRNA have been detected in later gestation of pregnancy 
with further elevation of levels in labouring women(171). In human myometrial 
cell cultures expression of connexin 43 is up-regulated with oestriol and 
inhibited by progestin (4, 88). This suggested that progesterone could decrease 
the contraction capacity of myometrium by reducing connexin 43 expression and 
therefore gap junction formation. Although we demonstrated no difference with 
connexin 26 mRNA expression, there was a significant reduction in connexin 43 
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expression with both the lowest and highest progesterone incubation 
concentrations. This supports other data regarding these contraction associated 
proteins and is one potential mechanism of action that progesterone may 
prevent uterine contractions.  
We finally looked at the progesterone receptor A and B but due to commercial 
availability we were unable to look at the receptor expressions separately.  
There was no change in expression of the receptors following progesterone 
incubation however this may be explained by the PRA: PRB ratio. The functional 
progesterone withdrawal suggests that genomic actions of progesterone are 
mediated by their nuclear receptors. The full length PRB and truncated PRA are 
controlled by separate promoters but studies suggest that PRB is the principal 
mediator. PRA is also thought to have an inhibitory effect on PRB and the extent 
of this will depend on its amount relative to PRB. It is therefore thought that the 
ratio or PRA:PRB is inversely related to the progesterone response(48, 77, 78). 
Measuring both in combination with progesterone may well show no change in 
expression as it is the overall ratio that can determine an effect. 
In summary we were able to show cytokine release from myometrial explants 
that was not inhibited by progesterone over a 24 hour time period. We 
demonstrated a reduction in gap junction component connexin 43 with 
progesterone in agreement with other literature. We speculate that this may 
well be an important mechanism of action of progesterone for the prevention of 
preterm birth and warrants further investigation.  
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CHAPTER 5 
The impact of prolonged maternal progesterone on human myometrium: The 
myometrial effects of prolonged in vivo treatment with progesterone  
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Introduction 
We elected again to look at the group of mediators that have been implicated in 
the control of labour and preterm labour: such as the pro-inflammatory 
cytokines and contraction associated proteins mentioned in chapter 4. We 
hypothesised that progesterone would alter expression of these agents in vivo. 
We anticipated this would enable us to compare the effects of progesterone on 
myometrium both in vivo and in vitro. 
Aim of Chapter 
Using RT-PCR we quantified pro-labour genes, contraction associated proteins, 
endogenous uterine stimulants and endogenous inhibitors of uterine 
contractility. We selected probes for IL1β, IL6, IL8, iNOS, bNOS, eNOS, cGRP, 
cGRPR, ep2, Cx-26, Cx-43 as we have previously looked at the in vitro effects of 
progesterone on the expression of these genes in myometrium in chapter 4.  
We localised expression of inflammatory mediators IL1β, IL6, IL8 and TNFα to 
examine using immunohistochemistry techniques established and published from 
our laboratory. We also used the leucocyte cell marker CD 45 to calculate the 
density of inflammatory cells and compare the placebo to progesterone groups 
as had been done before with labouring versus non labouring myometrium. 
Young et al showed that parturition was associated with a significant increase in 
IL1β, IL6 and IL8 expression in leucocytes in labouring cervix and myometrium 
and we have also previously shown that leucocytes (predominantly neutrophils 
and macrophages) infiltrated the cervix coinciding with the onset of labour (25). 
We aimed to observe if there were any differences in these events in the  
placebo and progesterone groups.  
Our final aim within this chapter was to determine if changes in gene expression 
were accompanied by changes in protein expression. Hence we investigated the 
latter using Western blotting on proteins extracted from STOPPIT samples. We 
investigated the contraction associated protein, connexin 43.  
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STOPPIT samples 
The molecular effects of progesterone in vivo on human myometrium are largely 
unknown and with our unique access to this cohort of women participating we 
were able, with appropriate consent and ethics to carry out this substudy. 
Although we have previously mentioned the STOPPIT trial and samples collected 
from this cohort in chapter 2 and 3, the focus in this previous chapter was on 
contractility studies. As previously explained the 10 x10 x 30 mm lower uterine 
segment sample was divided to allow separate analyses. The myometrium used 
for contractility studies had to be freshly transported in Krebs-Henseleit solution 
and experiments carried out within 12 hours as discussed in chapter 3. The other 
samples were stored in either mRNA later for subsequent molecular studies or in 
formalin for subsequent paraffin embedding and immunohistochemistry studies. 
It is these molecular and immunohistochemistry studies that we will discuss in 
this chapter. 
In total, we collected 18 samples over the 17 month period. Samples collected 
at elective lower uterine segment caesarean section were nine from the placebo 
group and only three from the progesterone group. Patients were consented 
within the antenatal clinic and therefore prior to labour or their planned 
caesarean delivery. The total number of samples including some from labouring 
patients reached twelve in the placebo group and six within the progesterone 
group. After consenting, only a single specimen was not obtained; this patient 
required an emergency caesarean for the second twin, and it was therefore not 
deemed appropriate to collect the myometrium at this time. Three other 
consented STOPPIT patients went on to have a successful vaginal delivery of 
their twins. We were therefore confident that we had obtained as many samples 
as was practically possible within the limits of obstetric care for multiple 
pregnancies. The demographic data is shown again in this chapter (also in 
chapter 3) showing there was no detectable significant difference in either 
groups for age, BMI, gestation or baby weight for twin one and two (unpaired t-
test).  
The majority of specimens were collected at pre –labour elective caesarean 
section however three patients from placebo and three from progesterone were 
sampled at emergency caesarean section (Table 8). The reasons for emergency 
caesarean section varied and were failure to progress in the 1st stage of labour, 
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spontaneous rupture of membranes with twin one breech presentation and failed 
induction of labour with prostaglandins.  
The time between sampling and completion of the placebo or progesterone also 
varied and we were only able to collect a total of three biopsies that were on 
treatment or within 2 weeks of completion of treatment. All three of these were 
within the placebo group. The mean gestation of delivery in the STOPPIT group 
was 36+4 weeks, the median gestation was 37+1 weeks.  
The clinical trial finished recruiting in 2007 therefore there were no additional 
samples after summer 2008 once all patients within the trial had delivered. Over 
500 patients were recruited in this multicentre trial. The results of the STOPPIT 
study were published in June 2009: there were no differences in the primary 
outcome (preterm delivery) between the progesterone and the placebo group. 
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 STOPPIT 
 Placebo 
 
STOPPIT 
Progesterone 
Number women 12 6 
Age (Years) 29.3(1.2) 31.8(1.1) 
BMI (kg/m2) 25.9(1.5) 25.0(3.1) 
Gestation (days) 252(4.6) 262(2.6) 
Baby weight (Kg) 
Twin 1 
Twin 2 
 
2.3(0.1) 
2.3(0.2) 
 
2.6(0.1) 
2.6(0.1) 
Previous LUSS 0 3 
ELLUCS 9 3 
Parity   
0 4 3 
1               6 3 
   
   
   
   
Table 8 : The STOPPIT sample patient demographic data (mean ± SEM) showing there was no 
detectable significant difference in either groups for age, BMI, gestation or baby weight for twin one 
and two (unpaired t-test). The majority of specimens were collected at prelabour elective 
caesarean section however three patients from placebo and three from progesterone were 
sampled at emergency caesarean section. 
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 Results RT-PCR 
We examined the inherent mRNA expression of various labour and uterine 
related genes within the myometrial tissue. Real time RT-PCR (Abi,Taqman) was 
used to quantitate endogenous inhibitors of uterine contractility (cGRP, cGRPR, 
EP2), promoters of uterine relaxation (NOS,PGDH) cytokines (IL1β, IL6, IL8) and 
gap junction components (connexin 26 and 43 ). For continuity we have 
expressed our results in this chapter relative to housekeeping gene 18S as in our 
previous analysis of in vitro progesterone samples this housekeeping gene was 
also used. 
For analysis purposes we looked at the total group of STOPPIT patients, placebo 
versus progesterone. The initial proposal was only to collect samples from 
uncomplicated patients undergoing routine caesarean deliver not in labour 
“uncomplicated not in labour participants”. However, in view of the limited 
numbers all suitable STOPPIT patients, including labouring ones that required 
caesarean delivery were included within our sample cohort.  Some additional 
samples were therefore collected from women who did not fulfil our initial entry 
criteria. These women were either in labour or had required some form of 
medical intervention either due to labour, induction of labour or rupture of 
membranes prior to caesarean section. In view therefore that these were not a 
“clean” cohort of not in labour samples we carried out two separate analyses. 
The first included all STOPPIT samples, the “total STOPPIT cohort” group and 
the second included only uncomplicated not in labour samples, the 
“standardised STOPPIT cohort”. The latter consists of patients within the 
STOPPIT trial, not in labour with no complications. As we know from previous 
data, many of the inflammatory markers can be up regulated within human 
myometrium in labour. We therefore felt it necessary to look at both the “Total” 
cohort and “standardised” cohort prior to analysis of the data.  
We analysed our data by log transforming our results and confirmed a normal 
distribution with Kolmogorov-Smirnova test. We then performed unpaired t-test 
and equal variances were not assumed. Data within the graphs was presented in 
an untransformed format and levels were expressed as mean ± SEM for box plot 
graphs and individual levels obtained for each sample in the scatter plot graphs.  
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We plotted all of our data on a scatter plot to assess overall distribution. 
Although women at the extremes of low gestation were in the placebo group, 
there were no significant differences in mean gestation in the progesterone and 
placebo group. We have shown one example of a scatter plot graph.  
On plotting individual values against gestation, the question of an effect with 
some of our measured genes arose. Although there was no statistically 
significant difference in gestation between the groups we wanted to make a full 
comparison of our data. We have therefore performed scatter plot graphs for all 
individual values against gestation. This shows that there were no samples from 
within the progesterone group taken under 250 days gestation. The other scatter 
plot graphs are presented within the appendix of this thesis. 
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Nitric-oxide synthase 
We looked at three separate isoforms of NOS, iNOS (inducible), eNOS 
(endothelial) and bNOS (neuronal). 
Inos 
Levels of inos detected were relatively low with similar expression as seen with 
our in vitro myometrial model. There was no difference in expression between 
placebo and progesterone groups for both the total STOPPIT cohort and the 
standardised STOPPIT cohort (unpaired t-test, log transformed data, Figure 84, 
Figure 85). In view of small numbers, we also plotted the individual values 
obtained for both groups against the pregnancy gestation (Figure 86, Figure 87). 
We were able to see therefore that the majority of progesterone treated 
samples were within the latter gestations obtained and that any early ones had 
been within the placebo group. 
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Figure 84: This graph shows inos gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM). There was no significant difference between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 85 : This graph shows inos gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data,  expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups within the standardised STOPPIT cohort of patients, p>0.05 
(unpaired t-test log transformed data). Patients within placebo group n=9, progesterone n=3. 
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Figure 86 : Scatter plot graph showing inos gene mRNA expression levels, relative to 18S.Total 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
 
Figure 87 : Scatter plot graph showing inos gene mRNA expression levels, relative to 18S. 
Standardised STOPPIT cohort values have been plotted with gestation in order to ascertain if 
gestation may have had an overall effect. All progesterone samples were sampled at a gestation 
>250 days (35+5). 
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Enos 
Enos expression again, showed similar values as seen in with our in vitro 
myometrial model. Enos showed higher levels of expression than both inos and 
bnos. There was no difference in expression between placebo and progesterone 
groups for both the total STOPPIT cohort, p>0.05 (Figure 88). There was a 
significant difference however when analysis was restricted to the standardised 
STOPPIT cohort, p <0.05 (unpaired t-test log transformed data, Figure 89). We 
also plotted the individual values against gestation (appendix). All samples 
within the progesterone group were obtained at a gestation of greater than 250 
(35+5) days. All samples from earlier gestations were within the placebo group. 
Bnos 
Levels of bnos detected showed low expression in human myometrium, similar to 
our in vitro myometrial model. There was no difference in expression between 
placebo and progesterone groups for the total STOPPIT cohort and standardised 
STOPPIT cohort, p>0.05 (unpaired t-test, log transformed data, Figure 90, Figure 
91). We also plotted the individual values obtained for both groups against the 
pregnancy gestation (appendix).  
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Figure 88 : This graph shows enos gene mRNA expression levels, relative to 18S. Data display is 
of untransformed data, expressed as mean ± (SEM). There was no significant difference between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 89 : This graph shows enos gene mRNA expression levels, relative to 18S. Data display is 
of untransformed data, expressed as mean ± (SEM). There was a significant difference between 
placebo and progesterone groups when analysis was restricted to the standardised STOPPIT 
cohort of patients, p<0.05 (unpaired t-test log transformed data). Patients within placebo group 
n=9, progesterone n=3. 
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Figure 90 : This graph shows bnos gene mRNA expression levels, relative to 18S. Data display is 
of untransformed data, expressed as mean ± (SEM). There was no detectable significant difference 
between placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 
(unpaired t-test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 91 : This graph shows bnos gene mRNA expression levels, relative to 18S. Data display is 
of untransformed data, expressed as mean ± (SEM). There was no detectable significant difference 
between placebo and progesterone groups within the standardised STOPPIT cohort of patients, 
p>0.05 (unpaired t-test log transformed data). Patients within placebo group n=9, progesterone 
n=3. 
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cGRP, cGRPR 
CGRP inhibits myometrial contractile activity. We measured both the peptide 
and its receptor. Levels again, were comparable to our in vitro model of 
expression of both cGRP and its receptor within human myometrium. Levels of 
the receptor were higher than the peptide expression itself in human 
myometrium. There was no difference in cGRP or its receptor expression 
between placebo and progesterone groups for both the total STOPPIT cohort and 
standardised STOPPIT cohort only , p>0.05 (unpaired t-test, log transformed data 
Figure 92, Figure 93, Figure 94, Figure 95).We also plotted the individual values 
obtained for both groups against the pregnancy gestation (appendix) . 
EP2 
This is a subgroup of receptor for prostaglandin E2  and  is G protein coupled. . Its 
activation leads to a rise in cAMP and myometrial relaxation. Levels of 
expression were again comparable to levels within our in vitro model looking at 
EP2 within human myometrium. There was no statistically significant difference 
between the placebo and progesterone groups in the total STOPPIT cohort , p > 
0.05, however when analysis was restricted to standardised STOPPIT cohort 
there was a lower expression of EP2 in the placebo group, p <0.05 (unpaired t-
test log transformed data, Figure 96, Figure 97). We also plotted the individual 
values obtained for both groups against the pregnancy gestation (appendix). 
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Figure 92 : This graph shows cGRP gene mRNA expression levels, relative to 18S. Data display is 
of untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 93 : This graph shows cGRP gene mRNA expression levels, relative to 18S. Data display is 
of untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups within the standardised STOPPIT cohort of patients, p>0.05 
(unpaired t-test log transformed data). Patients within placebo group n=9, progesterone n=3. 
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Figure 94 : This graph shows cGRPR gene mRNA expression levels, relative to 18S. Data display 
is of untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 95 : This graph shows cGRPR gene mRNA expression levels, relative to 18S. Data display 
is of untransformed data, expressed as mean ± (SEM).There was no detectable significant 
difference between placebo and progesterone groups with the ELLUCS STOPPIT cohort of 
patients, p>0.05 (unpaired t-test log transformed data). Patients within placebo group n=9, 
progesterone n=3. 
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Figure 96 : This graph shows EP2 gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
 
Figure 97 : This graph shows EP2 gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM).There was a significant difference between 
placebo and progesterone groups when analysis was restricted to the ELLUCS STOPPIT cohort of 
patients, p<0.05 (unpaired t-test log transformed data). Patients within placebo group n=9, 
progesterone n=3. 
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Pro-inflammatory cytokines 
We selected IL1β, IL6 and IL8 all of which are generated in the uterus and cervix 
and implicated in labour and preterm labour. There was no difference in 
expression between placebo and progesterone groups for both the total STOPPIT 
cohort and standardised STOPPIT cohort with all three pro-inflammatory 
cytokines,  IL1β (Figure 98, Figure 99), IL6 (Figure 100,  
Figure 101,) and IL8 (Figure 102, Figure 103), p>0.05 (unpaired t-test log 
transformed data).  
Contraction associated proteins connexin 26 and 43 
Within our group we observed a lower expression of the contraction associated 
protein connexin 26 within the standardised STOPPIT cohort and the total 
STOPPIT cohort (Figure 104, Figure 105) , p>0.05 (unpaired t-test log 
transformed data). We observed no statistical difference in connexin 43 between 
placebo and progesterone within the total STOPPIT cohort however; when 
analysis was restricted to the standardised STOPPIT cohort there was a lower 
expression within the progesterone group (Figure 106, Figure 107).  
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Figure 98 : This graph shows IL1β gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
 
Figure 99 : This graph shows IL1β gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups within the standardised STOPPIT cohort of patients, p>0.05 
(unpaired t-test log transformed data). Patients within placebo group n=9, progesterone n=3. 
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Figure 100 : This graph shows IL6 gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 101 : This graph shows IL6 gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups within the standardised STOPPIT cohort of patients, p>0.05 
(unpaired t-test log transformed data). Patients within placebo group n=9, progesterone n=3. 
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Figure 102 : This graph shows IL8 gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 103 : This graph shows IL8 gene mRNA expression levels, relative to 18S. Data display is of 
untransformed data, expressed as mean ± (SEM).There was no significant difference between 
placebo and progesterone groups within the standardised STOPPIT cohort of patients, p>0.05 
(unpaired t-test log transformed data). Patients within placebo group n=9, progesterone n=3. 
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Figure 104 : This graph shows Cx 26 gene mRNA expression levels, relative to 18S. Data display 
is of untransformed data, expressed as mean ± (SEM).There was a relative reduction between 
placebo and progesterone groups with the total STOPPIT cohort of patients, p<0.05 (unpaired t-
test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 105 : This graph shows Cx 26   gene mRNA expression levels, relative to 18S. Data display 
is of untransformed data, expressed as mean ± (SEM).There was a relative reduction between 
placebo and progesterone groups within the standardised STOPPIT cohort of patients, p<0.05 
(unpaired t-test log transformed data). Patients within placebo group n=9, progesterone n=3. 
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Figure 106 : This graph shows Cx 43 gene mRNA expression levels, relative to 18S. Data display 
is of untransformed data, expressed as mean ± (SEM). There was no significant difference 
between placebo and progesterone groups with the total STOPPIT cohort of patients, p>0.05 
(unpaired t-test log transformed data). Patients within placebo group n=12, progesterone n=6. 
 
Figure 107 : This graph shows Cx 43 gene mRNA expression levels, relative to 18S. Data display 
is of untransformed data, expressed as mean ± (SEM). There was a significant difference between 
placebo and progesterone groups when analysis was restricted to the standardised STOPPIT 
cohort of patients, p<0.05 (unpaired t-test log transformed data). Patients within placebo group 
n=9, progesterone n=3. 
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Immunohistochemistry Results 
We examined all 18 samples stained for each pro-inflammatory cytokine and the 
CD 45 leucocyte marker. At the time of analysis we remained blinded to the 
STOPPIT group and made our comparison with the evidence gathered at this 
stage. We stained the tissue for cytokine localisations however we did not 
attempt to analyse staining intensity semi-quantitatively. The leucocytes were 
identified using histological analysis in ten randomly selected high powered 
fields (x 400 objective magnification) and were counted by two independent 
observers who were blinded to the specimen details. We were then able to 
comment if any difference existed between the placebo and progesterone 
groups for CD45 only. We looked at the total STOPPIT cohort as a group. We did 
not have adequate numbers of samples to look at in labour versus not in labour 
where previous studies have shown differences. All magnifications are shown at 
x20 unless stated. 
 
IL1β 
The positive control using tonsil showed clear staining and the negative control 
showed blue staining only. There was strong staining evident within the 
myocytes for IL1β (Figure 108). A gradient of staining was sometimes evident 
however, myocytes generally stained brown with their darker nuclei evident 
within the cell. The surrounding stroma and showed little evidence of staining. 
There was strong staining within the endothelial lining of blood vessels. There 
was also darker staining in areas within blood vessels or adjacent to the blood 
vessel.  
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Figure 108 : IL1β staining at (x 20) for A) Tonsil positive control, B) Myometrium negative control, C) A placebo group example from STOPPIT samples and D) A 
progesterone group example from STOPPIT tissue.  
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IL6 
The positive control using tonsil showed pale staining and the negative control 
showed blue staining only. There was faint staining of myocytes with IL6 and a 
gradient of staining was evident within the myometrial sections (Figure 109). 
Myocytes were generally stained brown with their darker nuclei present within 
the cell. The surrounding stroma again, stained blue with little expression. 
There was also staining in areas within blood vessels or adjacent to the blood 
vessel.  
IL8 
The positive control using tonsil showed dark staining and the negative control 
showed blue staining only. For the myometrial samples there was a gradient of 
tissue staining evident within some of the sections. Myocytes showed expression 
of IL8 with darker brown nuclei evident within the cells (Figure 110). Some 
myocytes showed expression which was less uniform in appearance but this may 
have been due to the gradient of staining present throughout. Generally, blood 
vessels and the endothelial lining stained brown giving evidence of expression. 
The surrounding connective tissue and stroma was blue with less expression 
evident however, there were a population of cells staining within the stroma. 
This may well have been a white cell population of cells but further confirmation 
of this would be required. Some of the progesterone samples showed very pale 
staining or non stained samples (one in labour sample, one not in labour).  
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Figure 109 : IL6 staining at (x 20) A) Tonsil positive control, B) Myometrium negative control, C) A placebo group example from STOPPIT samples and D) A progesterone 
group example from STOPPIT tissue.  
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Figure 110 : IL8 staining (x 10) for A) Tonsil positive control and (x 20) for B) Myometrium negative control, C) A placebo group example from STOPPIT samples and D) A 
progesterone group example from STOPPIT tissue.  
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TNF-α 
The positive control showed clear evidence of staining and the negative control 
stained blue only. Staining throughout was generally moderate however there 
was a gradient of staining evident and some non- uniform patterns. Myocytes 
generally stained brown with varying degrees of expression throughout the 
section and there were darker nuclei evident within the cell structure (Figure 
111). The stroma tissue showed little expression with evidence of brown cells 
stained within indicating a possible white cell population.  
CD 45 
This is also known as the common leucocyte antigen and is present in all 
hematopoietic cells except erythrocytes and platelets. There was generally 
uniform staining however there was no expression around or within myocytes 
(Figure 112). There was some expression within the stroma and near blood 
vessels. No obvious difference was noted between the groups of placebo and 
progesterone and there was no statistical difference in the CD45 count p>0.05 
(unpaired t-test). 
Table 9 : CD 45 cell count with mean data from two independent observers shown. There was no 
statistical difference between the placebo and progesterone groups p>0.05 (unpaired t-test).
Group Mean Count SEM Number of fields observed 
Placebo 3.00 0.22 240 
Progesterone 2.86 0.40         120 
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Figure 111 : TNF-α staining (x 20) for A) Tonsil positive control B) Myometrium negative control, C) A placebo group example from STOPPIT samples and D) A 
progesterone group example from STOPPIT tissue
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Figure 112 : CD45 (x 20) A) Tonsil positive control B) Myometrium negative control, C) A placebo group example from STOPPIT samples and D) A progesterone group 
example from STOPPIT tissue. Arrows indicate CD45 positive cells. There is no detectable difference between the placebo and progesterone staining for CD45
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Western Blot 
Connexin 43 
Having identified no changes in the pro-inflammatory cytokines we selected to 
further investigate the contraction associated proteins. Time constraints 
prohibited an extensive investigation of the proteins from the STOPPIT samples 
and therefore we selected to look at connexin 43. The mRNA data had shown 
less expression within the progesterone treatment group both in vitro and in 
vivo and when compared to the control or placebo. We developed and optimised 
the antibody concentrations and protocol as discussed in chapter 2. Connexin 43 
has a molecular weight of around 43 kilo Daltons. The intended loading control 
β-actin has an identical molecular weight and therefore prior to protocol 
optimisation we elected to use a different loading control β-tubulin which has a 
higher molecular weight of 55 kilo Daltons. This was in order to identify bands at 
the separate molecular weights. Our protocol however required that our initial 
blot was stripped and then probed again, for the loading control antibody. 
Tubulin is present in almost all eukaryotic cells and is used commonly as a 
housekeeping gene. 
We were able to show an even distribution of protein on the initial gel 
electrophoresis (stained with Coomassie blue) and there was little difference 
between the extracted proteins from the myometrial samples (Figure 113). We 
were then able to clearly demonstrate the presence of connexin 43 with clear 
bands evident at around 43 KDa, (between the 37kDa and 50kDa molecular 
weight marker indicator). We also showed the presence of β-tubulin clearly at 55 
kDa however, samples one and three lacked expression of this. Although there 
was a clear difference in mRNA expression, less expression within the 
progesterone group compared to placebo, this did not translate into a protein 
effect. We detected no difference statistically between the density ratio for 
placebo versus progesterone p>0.05 t-test (Figure 115, Figure 116). Connexin 43 
mRNA expression did not correlate with its protein expression when analysed 
with respect to the clinical grouping. 
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Figure 113 : Protein gel showing the spread for each protein extracted from the 18 STOPPIT samples. The molecular weight marker is indicated (M) and (PL) placebo, 
(PR) progesterone for each. This shows generally an even distribution amongst the specimens. 
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Figure 114 : Western Blot of connexin 43 and the loading control gene β-tubulin for all 18 STOPPIT myometrial samples. Samples 1 and 3 showed no expression of the 
housekeeping gene. Sample 15 showed no expression of connexin 43. The STOPPIT group and number given to each sample are indicated below.  
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Figure 115 : Western analysis of connexin 43, indicating each STOPPIT myometrial sample 
relative to the control β-tubulin. 
 
Figure 116 : Western analysis of connexin 43, indicating each STOPPIT myometrial sample and 
divided into STOPPIT groups. There was no difference in protein analysis between the placebo 
and progesterone group, p>0.05 (t-test). 
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Discussion 
The impact of prolonged maternal progesterone on human 
myometrium: The myometrial effects of prolonged in vivo 
treatment with progesterone. 
In this chapter we aimed to look at the myometrial effects of progesterone 
versus placebo in vivo. In addition to our in vitro data (chapter 4) our cohort of 
STOPPIT patients allowed us to examine possible in vivo effects.  
New evidence published after this study was commenced suggests that the 
evidence to support the prevention of preterm delivery in twins is not as robust 
as in high risk singleton pregnancies (114). Our study however, enabled a 
valuable opportunity to obtain myometrial tissue from participating patients on 
either a progesterone treatment and with placebo controls, all randomised and 
blinded. We hoped to use this as a marker of progesterone treatment on 
myometrium in vivo. 
Within the clinical trial, participants were randomised either to daily 
progesterone gel (90mg) (Crinone®) or placebo gel both administered vaginally 
by the participant and starting at 24 weeks + 0 days gestation. Patients were 
required to administer the gel at the same time each day and also asked to keep 
a diary of any symptoms or added information. They generally attended the 
antenatal clinic between every two to four weeks and were seen by a designated 
STOPPIT midwife. They were also contacted by telephone at regular intervals to 
ensure compliance and general wellbeing.    
The mode of delivery in women participating in STOPPIT was left to the pregnant 
woman and her obstetrician providing her care. There is however a higher rate 
of caesarean section in twins, largely due to malpresentations or intrapartum 
complications (196). Within the STOPPIT cohort the caesarean section rate was 
approximately 67% at the start of substudy recruitment and of these sections 
around 70% were semi-elective and pre-labour. Within the study centres an 
average of 4 participants per month were randomised in Glasgow and 3 in 
Edinburgh. We calculated a loss rate of around 15 % (patients unwilling to 
donate a biopsy, having a vaginal delivery), but overall thought we would be 
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able to obtain fresh biopsies from around 45 women over the 17 month 
recruitment period. We also hoped that around 50% of these women would be on 
placebo/progesterone or within 2 weeks of stopping. We therefore assumed a 
sample size of approximately 20 in placebo and progesterone groups, the study 
therefore had a 95% power to show a difference in 1.2 standard deviations 
between the groups. 
Unfortunately, we were unable to achieve this number of patients within our 
cohort, initially due to the practical difficulties of transporting samples in an 
adequate time frame from Edinburgh, to the place of all experimental 
equipment in Glasgow.  There was also a higher loss rate and reduction in the 
recruitment numbers within Glasgow itself. As we were blinded at the time of 
sampling we were unable to determine the amount within each group we had 
obtained. We therefore elected to collect all consented patients within STOPPIT 
substudy whether they had an elective or emergency intrapartum caesarean 
section.  
The gestational stage at which the myometrial biopsies were collected was 
generally at an interval greater than two weeks after finishing participating 
within the clinical trial i.e. a break of 14 days or more from the additional 
placebo or progesterone. As an unpredictable variable within this cohort it is 
possible therefore that some myometrial effects of supplementary progesterone 
have been lost. Any non-genomic action of progesterone would take minutes as 
opposed to hours (48) and therefore these effects are unlikely to have persisted. 
Genomic actions may well persist longer and therefore changes hypothesised in 
gene expression may still be evident within the samples. This time delay may 
well have implications for our data interpretation comparing the placebo and 
progesterone group.    
Progesterone levels at term are already high, with higher levels detectable 
within the myometrium than maternal plasma (197). Early studies by Csapo 
indicated a potential progesterone deficiency in preterm labour (198) but these 
findings have not been reproduced and the mechanism of action for 
progesterone to prevent preterm labour remains unknown. It is not fully 
understood either how a supplementary dose of progesterone may prevent 
preterm labour when placenta and myometrial progesterone levels are already 
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high. Levels within the myometrium on supplementary progesterone may well be 
higher than serum levels due to uterine first pass metabolism and studies have 
shown after vaginal administration of progesterone, uterine tissue concentration 
has been found to exceed by more than 10-fold the levels achieved by systemic 
administration (199). This uterine first-pass effect may lead to myometrial 
changes if prolonged as in the STOPPIT cohort. 
The numbers achieved within this study are small. This therefore, may 
underpower our study and we should interpret our results with caution. To carry 
out human in vivo studies is a difficult undertaking and therefore important to 
carry out when appropriate. Many in vivo studies prior to this have supported the 
idea that progesterone can influence the myometrium. Pinto et al found that 
large doses of progesterone (100- 200 mg bolus IV, almost twice as much as the 
placenta produces in 24 hours at term) given to women in labour at term was 
able to inhibit the frequency and intensity of uterine contractions. There cohort 
was also small but they were able to clearly demonstrate a non-genomic effect 
of progesterone in vivo. Our cohort of women is also small, but we have been 
able to demonstrate some changes within our myometrium between placebo and 
progesterone groups. We will discuss these in the following section. 
This study demonstrated that the predominant isoform of NOS within our human 
myometrial samples was eNOS. This is consistent with other data which localised 
eNOS to myometrial smooth muscle cells (185) . Norman et al also demonstrated 
an up regulation of eNOS in pregnant myometrium versus non pregnant 
suggesting that this may play a role in myometrial quiescence. There was 
however, no change in NOS activity or expression comparing uterine tissues 
taken immediately before and after the onset of labour suggesting no regulatory 
involvement in the acute onset of parturition (200). Bartlett et al again showed 
the detection of mRNA for all three NOS isoforms however a high cycle number 
implied a low copy number. They went on to demonstrate that eNOS, iNOS and 
bNOS proteins were not expressed at detectable levels in myocytes of human 
myometrium throughout pregnancy (201). They concluded therefore that NO 
produced by the myometrium played an insignificant role in the regulation of 
uterine smooth muscle tone during pregnancy. This opposes data that 
endogenous nitric oxide plays a role in the control of myometrial contractility 
during pregnancy.   
Laurie Anderson, 2009  213 
In rat uterine tissue, cells obtained from progesterone-primed uterine tissue 
presented an increase in the nitrite concentration concomitant with a decrease 
in the PGE production (202). NO production was compared in the rat uterus and 
cervix in another group and they observed that treatment with the antiprogestin 
onapristone suppressed uterine NO production while continuous administration 
of progesterone from day 19 of pregnancy increased NO production. We 
demonstrated no difference in MRNA expression for all iNOS and bNOS isoforms 
within the placebo versus progesterone groups. We observed within the elective 
caesarean group that there was less eNOS mRNA expression in the progesterone 
versus placebo group. Norman et al previously demonstrated that there was an 
elevated level of eNOS protein in preterm non-labouring samples compared with 
term non-labouring and non-pregnant tissue. Our cohort of women within the 
placebo group has a wider range of gestational ages and a greater proportion of 
this group were sampled from women at a more preterm gestation <250 days, 
suggesting this higher eNOS expression within the placebo group could be simply 
a gestational effect. If progesterone promoted myometrial relaxation by 
inducing eNOS production then an up regulation would have been predicted 
rather than our observation of the opposite. Within the myometrium treated 
with progesterone and as we have observed down regulation of eNOS a potential 
uterine relaxant we also see down regulation of mRNA expression for contraction 
associated proteins, connexin 26 and 43. We propose that a compensatory 
mechanism may well occur in myometrial tissue with supplementary 
progesterone reducing expression of contraction associated proteins 
fundamental to the mechanism of labour.  
We observed no changes in CGRP or its receptor within the two groups. Dong et 
al concluded from their work that increased CGRP-receptors in myometrium, and 
resulting enhanced myometrial sensitivity to CGRP, may play a role in 
maintaining human myometrium in a quiescent state during pregnancy. Both 
Western blotting and mRNA analysis showed that CGRP-receptors are present in 
human myometrium, and that the expression of these receptors is increased 
during pregnancy and decreased during term labour (91). They also 
demonstrated that in vitro progesterone increased CGRP receptor expression in 
myometrial explants. Other groups have studied animal models with 
ovariectomised mice. They showed that levels of inhibition exerted by CGRP 
during the various stages of the estrous cycle and in response to steroid hormone 
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treatment correlated with the protein levels of CGRP-Receptor. The myometrial 
mRNA levels did not change significantly during the mouse estrous cycle or in 
response to hormone (progesterone) treatment, indicating that the regulation of 
CGRP-Receptor protein does not occur at the transcriptional level (203). In 
relation to labour itself another group demonstrated that parturition had no 
impact on maternal serum CGRP levels, and no significant correlation existed 
between plasma CGRP levels and cervical dilatation during labour (204). If levels 
of CGRP therefore are not implicated in the parturition process then this may 
explain why we observed no difference between our groups within both 
emergency and elective caesarean section cohort. This indicates that CGRP may 
not play a central role in either labour itself or the prevention of preterm 
labour.  
We observed no difference within the groups for prostaglandin receptor subtype 
EP2. When analysis was restricted to non labouring samples there was a lower 
mRNA density within the progesterone group compared to placebo. Previously in 
animal models progesterone has been shown to increase   EP2 mRNA expression. 
They concluded that the expression of relaxant EP2 receptors in the rat uterus 
increases with pregnancy and decreases with labour, and appeared to be 
progesterone dependent (133).  Other data has shown that in humans within the 
upper uterine segment, EP2 was higher in term labour samples and lower  in 
preterm labour samples compared to term non-labour (191). They suggest this 
does not fit with the theory of a contractile phenotype within the upper segment 
at term. These observations may indicate that the EP2 perhaps plays a role in 
controlling the timing of labour-onset possibly by maintaining quiescence until 
the excitatory influences become more dominant allowing a shift to a contractile 
phenotype. Again, our data also suggest a compensatory mechanism may exist or 
indeed a balance between uterine contractions promoters and uterine relaxants 
is present and in which progesterone may have a central role .Our data used 
lower segment samples and is not a comparison of labouring versus non-
labouring however as a uterine relaxant the decrease within the progesterone 
group does not reflect an expected progesterone enhanced EP2 presence within 
myometrium. Again, this may be due to small sample numbers or indeed a 
gestational effect with a larger number of preterm samples within the placebo 
cohort.  
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Within our results targeting the pro-inflammatory cytokines we observed no 
differences within our mRNA gene data for IL1β, IL6 and IL8. Our 
immunohistochemistry data supports this and although we observed expression 
of pro- inflammatory cytokines within our myometrial samples both placebo and 
progesterone groups were stained in a similar manner. The CD45, common 
leucocyte antigen demonstrated that again, there were little differences within 
the two groups. The inflammatory process involved in parturition appears to 
involve complex signalling pathways and interactions between cervix and 
myometrium and there is gathering evidence to suggest that labour itself is an 
inflammatory process. Osman et al showed that parturition was associated with 
a significant increase in IL-1β, IL-6 and IL-8 mRNA expression in cervix and 
myometrium and their histological analysis demonstrated that leukocytes 
(predominantly neutrophils and macrophages) infiltrated the uterine cervix 
coincident with the onset of labour (24). There is also debate suggesting that 
term labour and preterm labour are not identical processes and may be triggered 
following different pathways or mechanisms. Such studies have shown within 
lower segment myometrium , the levels of IL-1β, IL-6 and IL-8 mRNA expression 
were significantly higher in term labour samples compared with preterm labour 
samples (205). Our data focuses on myometrium and then in addition the effect 
of progesterone. Progesterone has been demonstrated to suppress the immune 
response in early pregnancy (181). Progesterone has also been shown to 
decrease the production of IL-6 after LPS stimulation without altering the 
production of TNF-α or IL-10 in fetoplacental arteries using a placental explant 
model (206). We observed no such change or difference in our groups using 
progesterone specifically.  Elovitz et al demonstrated that the progestogenic 
agent, medroxyprogesterone acetate, reduced COX-2, IL-1β and TNF-α mRNA 
expression in the myometrium of pregnant mice pretreated with LPS. These 
studies demonstrated that progestational agents decreased the incidence of 
inflammation-induced preterm parturition and medroxyprogesterone completely 
prevented preterm birth compared to progesterone which decreased the overall 
rate of preterm birth (207). They suggest that medroxyprogesterone may well 
have this additional immunosuppressive action due to its glucocorticoid receptor 
binding ability as well as progesterone receptor (208). 
 It is also difficult to determine within human studies antenatally which patients 
with preterm labour have pregnancies which are complicated by intrauterine 
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inflammation. Our cohort specifically has less patients that were preterm 
(before 250 days gestation) within the progesterone group and very few in labour 
making it difficult to make conclusions due to small numbers. Our decision to 
study the effects of progesterone in vivo and in vitro, rather than 
medroxyprogesterone acetate, was to specifically evaluate an agent that is 
currently used in clinical practice for the prevention of preterm birth. The type 
of progesterone may well have a specific interaction with the inflammatory 
cascade and this may explain why we observe little difference with progesterone 
compared with groups showing reduction in pro-inflammatory cytokines with 
other progestins. 
We observed a lower expression in the progesterone treated group with the 
contraction associated proteins mRNA for both connexin 26 and 43 within the 
elective caesarean section cohort and connexin 26 within the total STOPPIT 
group. This is mirrored within our myometrial cell culture work where we also 
observed a lower expression of connexin 43 within our in vitro data when treated 
with progesterone (chapter 4). One suggestion is that this principal genomic 
mechanism by which progesterone represses myometrial contractility is by 
modulating the expression of genes encoding contraction associated proteins 
such as connexin 43 (48).  Within animal models using rats, Lye et al 
demonstrated that connexin 43 levels were at there highest during delivery and 
were closely associated with the protein levels and appearance of gap junctions. 
The  connexin 43 levels were positively regulated by oestrogen and negatively by 
progesterone during pregnancy (209, 210). There is evidence to support that in 
humans there is a  correlation between increased cervical dilation or increased 
frequency of uterine contractions and increased area of gap junctions within the 
myometrium (86). The progesterone agonist, medroxyprogesterone acetate to 
treat causes a marked decrease in the levels of connexin 43 mRNA in uterine 
smooth muscle cultures (211). It is thought that connexin 43 is synthesised days 
prior to parturition but accumulates within the cytoplasm until labour when it is 
transported to the plasma membrane and forms part of the gap junction plaques 
present at the cell surface (89).  
The assembly of gap junction protein into functional gap junction plaques is the 
last point in a stepwise process that begins with oestrogen-dependent expression 
of the connexin 43 gene and continues with synthesis of connexin 43 in the rough 
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endoplasmic reticulum and transport to the Golgi, followed by its trafficking to 
the plasma membrane and its assembly into functional gap junctions. Hendrix et 
al found that the trafficking of myometrial connexin 43 from the Golgi and 
assembly into gap junctions at the plasma membrane was suppressed in 
progesterone treated rats but suggested that it may be the trafficking that of  to 
the plasma membrane which is important rather than its synthesis (90).It may 
well be the ratio of oestrogen to progesterone that plays a central role 
regulating gap junction formation rather than progesterone levels alone in 
human myometrium (212). Within our samples, although we demonstrate a lower 
expression of connexin 43 in the progesterone group we observed no detectable 
difference in the protein levels. If myometrial samples had been collected a 
later time point this may have shown a reduction in connexin 43 protein 
synthesis. The samples however were all collected at caesarean section and 
therefore at one single time point, which may not have allowed for the 
reduction in protein synthesis within the endoplasmic reticulum.   
Although we see a lower expression of the connexins, contraction associated 
protein mRNA there is also lower expression of EP2 and eNOS mRNA. This 
potentially reflects a gestational effect however could suggest some 
compensatory recovery after progesterone administration. We saw no functional 
changes with the contractility data (chapter 2) and hypothesised that this may 
indicate loss of instant non-genomic effects of progesterone after withdrawal of 
administration. The longer genomic effects which may be sustained with loss of s 
could explain one mechanism of action of progesterone in the prevention of 
preterm labour. It is also possible that this does not demonstrate a long-term 
detrimental impact on myometrial function with down regulation of these 
endogenous inhibitors alongside the down regulation of contraction associated 
proteins, s. This may suggest a functional and compensatory recovery occurs 
after progesterone administration.  
The samples importantly were all obtained from twin pregnancies and uterine 
stretch is thought to have a key role in the onset of preterm labour. Mechanical 
stretch of the myometrium has biological consequences and may alter gap 
junction expression and responsiveness to inflammatory stimuli. Multiple 
pregnancy compared to singleton pregnancies however showed no difference in 
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expression of prostaglandin E2 receptors, or gap junction proteins within 
myometrium (213). 
Events that take place prior to and that are involved in parturition will interact 
with steroid hormones. If the functional progesterone withdrawal is central to a 
normal labour process then it may well play a part in preterm labour. The causes 
of preterm labour, whether inflammatory or idiopathic, may not have identical 
processes or sequence of events triggering parturition. In multiple pregnancies 
the mechanism may differ due to stretch mechanisms. Parturition will therefore 
occur when all the stimulatory influences reach a threshold which can overcome 
the uterine quiescence maintained by progesterone. It is likely therefore that 
contraction associated proteins are one such mechanism necessary for labour. 
There is good evidence to show that progesterone has an inhibitory effect on 
connexin 43, a major component of myometrial gap junctions. Gap junction 
formation is essential for developing and maintaining synchronous contractions 
within the uterus, a fundamental process within parturition. 
The STOPPIT trial showed that progesterone, administered vaginally, does not 
prevent preterm birth in women with twin pregnancy. However, different 
pathophysiological mechanisms may account for the apparent difference in 
efficacy of progesterone in high risk singleton and twin pregnancy. The aetiology 
of preterm labour in twin pregnancy and spontaneous preterm birth is highly 
unlikely to have identical mechanisms of action. Although risk factors such as 
inflammatory processes, uterine overdistension or cervical disorders may have 
different pathological initiating factors, it is possible that a degree of overlap 
occurs once parturition processes have commenced. Factors such as increase in 
pro-inflammatory cytokines or gap junction proteins may be common to all 
parturition processes despite their initiating triggers. This may therefore explain 
why, although progesterone appears not to prevent preterm labour in twins we 
can still identify modifying mechanisms of action such as a reduction in the 
expression of connexin 43. Additional information on whether these changes are 
reproducible within singleton pregnancies and patients on 17OHPC as opposed to 
vaginal progesterone will confirm or refute this hypothesis.  
Progesterone clearly has both non-genomic and genomic properties and 
maintains pregnancy and promotes relaxation through a combination of these. 
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More evidence is required to confirm our findings and further sampling of 
patients participating in clinical trials of progesterone to prevent preterm labour 
would be of extreme benefit. We would urge research groups carrying out trials 
of progesterone to prevent preterm labour to further investigate their study 
population’s myometrium, membranes and placenta where possible. As evidence 
builds around progesterone and its mechanism of action, our understanding of 
appropriate clinical regimes will be maximised.   
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CHAPTER 6 
Final discussion and future work 
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Conclusions 
There are evidently myometrial effects of progesterone and these appear to be 
both non genomic and genomic. The purpose of this thesis was to investigate the 
role of progesterone on human myometrium both in vitro and in vivo. 
In selecting pregnant patients both undergoing routine elective caesarean 
section and then within the STOPPIT study on progesterone or placebo treatment 
we had a significant number of myometrial biopsies on which to test our 
hypotheses. In view of the limitations within animal studies due to fundamental 
differences in our reproductive pathways our focus on human myometrium is an 
important one.  
We hypothesised that progesterone has a direct inhibitory effect on spontaneous 
myometrial contractility, induces increased sensitivity to tocolytic agents and 
decreases sensitivity to contractile agonists such as oxytocin. These data were 
presented in chapter 3 of this thesis. 
We found that progesterone albeit at high concentrations, exerted consistent, 
rapid and sustained inhibition of the amplitude of spontaneous myometrial 
contractions in vitro however, this affect was not achieved through the principal 
potassium channels. In contrast, 17OHPC did not exert any inhibitory effect on 
myometrial activity in vitro. We found, at the selected pharmacological doses 
used in vitro that progesterone did not increase sensitivity to tocolytic agent’s 
nifedipine, ritodrine or levcromakalim with respect to spontaneous contractions. 
There was no decrease in sensitivity to the uterotonins oxytocin. Lastly, from 
our STOPPIT patient cohort we demonstrated no difference between the 
progesterone and placebo groups in either spontaneous contractility, response to 
tocolytics as above or response to oxytocin. One main conclusion of this arm of 
the study is that in vivo progesterone therapy to prevent pre-term labour does 
not appear to modify contractility ex vivo. 
 We have suggested that these differences between our in vivo and in vitro data 
may be due to the non genomic actions of progesterone requiring active 
progesterone therapy. This was lacking within the STOPPIT progesterone cohort. 
Whether progesterone treatment in vivo would manifest changed in contractility 
ex vivo if examined during the treatment remains to be determined.  
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The mechanism of action of progesterone both in inhibiting myometrial 
contractility and in preventing preterm birth therefore continues to warrant 
further investigation. 
We then hypothesised that progesterone has inhibitory effects on endogenous 
uterine stimulants, stimulatory effects on endogenous uterine relaxants, induces 
upregulation of endogenous receptors that inhibit uterine contractions and 
inhibits contraction associated proteins. These data regarding the myometrial 
effects of progesterone in vitro were presented in chapter 4. 
We demonstrated that administration of progesterone but not 17OHPC for up to 
24 hours in vitro does not appear to modify uterine stimulants such as cytokines, 
COX-2  or endogenous uterine relaxants such as nitric oxide synthetases and 
prostaglandin dehydrogenase. Progesterone but not 17OHPC inhibited production 
of gap junction component connexin 43, an important contraction associated 
protein that is widely implicated in the parturition process. This modification of 
contraction associated protein is in agreement with other literature presented 
on human myometrial data in vitro (4) .  
Lastly we hypothesised that progesterone in vivo has inhibitory effects on 
endogenous uterine stimulants, stimulatory effects on endogenous uterine 
relaxants, induces upregulation of endogenous receptors that inhibit uterine 
contractions and inhibits contraction associated proteins. These data are 
presented in chapter 5.  
The STOPPIT trial concluded that progesterone, administered vaginally, does not 
prevent preterm birth in women with twin pregnancy. The STOPPIT cohort of 
patients we identified however, were actively receiving either progesterone or 
placebo between 24 and 34 weeks gestation on a daily basis. We used these 
patients as a potential example of the myometrial effects of progesterone in 
vivo with a placebo treated control group. Despite the negative findings of the 
trial with respect to preterm labour, these patients still may have displayed 
changes of the myometrium with progesterone administration. Since data are 
extremely limited on the in vivo effects of progesterone in humans we feel our 
data are an important addition. Although there are limitations within our data 
such as time delay between last progesterone dose and delivery and small 
numbers we acknowledge this. Nevertheless, this was a valid way of attempting 
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to further understand and ascertain myometrial differences from in vivo 
progesterone therapy. The data in chapter 5 highlights some important areas 
which are mirrored within the in vitro data. Prolonged maternal administration 
of progesterone appears to inhibit expression of gap junction components 26 and 
connexin 43 in myometrium.  Connexin 43 importantly, was also modified in 
vitro within the progesterone treated arm. Uterine contractile inhibitors eNOS 
and EP2 were also unexpectedly, down regulated within the progesterone group. 
The s, as we have previously stated play an essential role in regulating 
synchronous myometrial contractions. If progesterone has been of benefit in 
those at risk of preterm labour with a history of spontaneous preterm birth, it is 
possible therefore that this is by stopping the development of these synchronous 
contractions whilst on progesterone therapy. The mechanism of preterm birth in 
twin pregnancy may be more related to stretch and pressure mechanisms which 
potentially modify prostaglandin synthesis via COX-2 (214) or inflammatory 
mediators such as IL8 (44). However, ex-vivo assessment of the functional 
impact of this does not demonstrate a long-term inhibitory impact on 
myometrial function with down regulation of endogenous inhibitors such as eNOS 
and EP2. This suggests a functional and compensatory recovery occurs after 
progesterone administration.  
It is also important to understand the background to the functional progesterone 
withdrawal whereby the relaxatory actions mediated through PR-B are inhibited 
via a change in the PR-A to PR-B ratio. If normal myometrium can change and 
develop into a contractile phenotype towards term mediated via the loss of 
progesterone quiescence then early inappropriate progesterone withdrawal may 
also be important in the pathogenesis of preterm labour. This was out with the 
aims and hypotheses of this thesis however many groups such as Mesiano et al 
are researching this area in greater detail. 
Progesterone clearly has both non-genomic and genomic properties as 
demonstrated in this thesis and throughout the literature. Progesterone 
maintains pregnancy and promotes relaxation through a combination of these 
however its mechanism of action in the prevention of preterm labour is still 
unclear. We would suggest that modification of gap junction components such as 
connexin 43 may be one of the main myometrial effects of progesterone in 
humans.  
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As evidence builds around progesterone and its mechanism of action, our 
understanding of appropriate clinical regimes in the prevention of preterm 
labour will be maximised.  Clinical trials so far have shown that progesterone 
may be of benefit in women with a history of spontaneous preterm birth and, or 
a short cervix. It does not appear to be of benefit in twins (3) . This highlights 
that the underlying mechanisms of preterm birth have a multifactorial aetiology 
and the mechanism of preterm birth in twins is unlikely to be identical to the 
mechanism in women with a history of spontaneous preterm birth. The role of 
progesterone therefore may be limited to a subpopulation within those classified 
“at risk” of preterm birth.   
In summary, this thesis has highlighted that although our understanding of the 
myometrial effects of progesterone is advancing there is still a lack of data from 
in vivo studies. Progesterone is potentially the most important reproductive 
hormone, involved at every stage from conceptus to birth. Its effects on the 
myometrium are only one aspect of the whole parturition process but critical to 
the timing, co-ordination and physiology of birth. 
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Future Research 
This work represents further insights into the myometrial effects of 
progesterone. However there are clearly further avenues for future research 
based upon these findings.  
Due to time limitations within this study we were unable to carry out full 
Western blot protocols to determine the protein analysis of the remaining 
connexin 26, as well as the other endogenous uterine stimulants and endogenous 
uterine relaxants. Further immunohistochemistry of the connexin 26 and 43 
within the STOPPIT cohort would also be of benefit, providing a more complete 
analysis of the samples and therefore a more complete analysis of the data.  
If progesterone withdrawal and oestrogen activation initiate parturition then it 
may also be of benefit to examine myometrium in vitro cell culture in a 
concentration-response manner with combinations of these steroid hormones at 
different ratios.  
One of the main findings of our study was the reduction in mRNA expression of 
gap junction components connexin 26 and 43. Father assessment of these 
contraction associated proteins within the human myometrium in non-labouring 
and labouring as well as preterm non-labouring and preterm labouring would be 
a useful avenue to pursue. There is some evidence that expression of connexin 
43 in the human pregnancy myometrium increases with the onset of labour (86). 
Evidence of this within preterm samples may support the theory that 
spontaneous preterm labour is related to an early upregulation of myometrial 
gap junctions. Cells within the vast majority of human tissues communicate 
directly through these clustered arrays of gap junctions and there is an apparent 
genetic component with autosomal dominant or recessive mutations of the genes 
linked to other medical conditions such as hearing loss and a skin diseases (215). 
There a proposed genetic component of preterm labour and this raises the 
possibility of one such possible genetic abnormality.  
If the connexins are implicated in preterm labour then this raises the possibility 
of gap junctions and connexins as pharmacological targets. They allowing rapid 
intercellular communication and synchronisation of coupled cell activities, 
playing a critical role in many signalling processes, including co-ordinated 
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cardiac and smooth muscle contractions, neuronal excitability, neurotransmitter 
release, insulin secretion and epithelial electrolyte transport, No natural toxin 
or specific inhibitor of the connexins has been identified yet and most agents 
also affect other ionic channels and receptors. Future research, may further 
clarify gap junction physiology and the role of myometrial gap junctions as a 
potential pharmacological target in the prevention of preterm labour. 
It is evident that research surrounding progesterone to prevent preterm labour is 
ongoing and evolving every year. Current trials such as the OPPTMUM study 
“Does progesterone prophylaxis to prevent preterm labour improve outcome?” 
which is a UK-based randomised trial to determine if progesterone prophylaxis to 
prevent preterm labour improves outcome has started recruiting in 2009. It is 
aimed at women at high risk of preterm labour and uses natural progesterone, 
200mg daily from 22 – 34 weeks gestation, compared to placebo as its regime. 
The question posed is does progesterone improve obstetric outcome by 
lengthening pregnancy and thus reducing the incidence of preterm delivery 
before 34 weeks gestation. It also focuses on neonatal morbidity and mortality 
as well as longer term childhood cognitive function. These research aims are 
worthy and necessary in building a clearer picture as suggested by Tita et al on 
progesterone regimes, categories of women who will benefit from progesterone 
and longer term child outcomes (3). We would also suggest that in addition to 
our study that all preterm labour progesterone clinical trials consider obtaining 
funding and ethical approval to look at the myometrial effects of progesterone. 
National rates of caesarean section are now over 20 % in England and Wales 
(216). All studies of progesterone in vivo are likely to have a number of patients 
that require caesarean section for clinical reasons and we have shown that 
sampling the myometrium is relatively simple and easy. With the appropriate 
consent further examples of this may provide advances in our understanding of 
the mechanisms of action of progesterone. It would be of benefit to see more 
conclusive evidence that progesterone modifies the myometrium in vivo and not 
only myometrium but also the placental tissues. It is also possible that as 
progesterone has been shown to be of benefit in high risk patients with previous 
preterm labour, changes seen within myometrial gap junction components may 
be more evident in myometrium from patients in which there is a clinical benefit 
from progesterone.    
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The nature of the cascade of events culminating in labour and preterm labour is 
a complex subject. Therapeutic advances and greater understanding of the 
mechanism of preterm birth may be possible through human myometrial studies 
and in particular progesterone and its mechanism of action.
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Contents 
This appendix contains figures referenced in chapter 5. These are scatter plot 
graphs of STOPPIT data containing gene mRNA expression results against 
gestational age in pregnancy. 
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Figure 117: This graph shows enos gene mRNA expression levels, relative to 18S.Total STOPPIT 
cohort values have been plotted with gestation in order to ascertain if gestation may have had an 
overall effect.  All progesterone samples were sampled at a gestation >250 days (35+5). 
 
Figure 118 : This graph shows enos gene mRNA expression levels, relative to 18S.Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
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Figure 119 : This graph shows bnos gene mRNA expression levels, relative to 18S.Total STOPPIT 
cohort values have been plotted with gestation in order to ascertain if gestation may have had an 
overall effect.  All progesterone samples were sampled at a gestation >250 days (35+5). 
 
Figure 120 : This graph shows bnos gene mRNA expression levels, relative to 18S.Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
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Figure 121 : This graph shows cGRP gene mRNA expression levels, relative to 18S.Total 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
 
Figure 122 : This graph shows cGRP gene mRNA expression levels, relative to 18S.Satndardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
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Figure 123 : This graph shows cGRPR gene mRNA expression levels, relative to 18S.Total 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
 
Figure 124 : This graph shows cGRPR gene mRNA expression levels, relative to 18S.Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
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Figure 125 : This graph shows EP2 gene mRNA expression levels, relative to 18S.Total STOPPIT 
cohort values have been plotted with gestation in order to ascertain if gestation may have had an 
overall effect.  All progesterone samples were sampled at a gestation >250 days (35+5). 
 
Figure 126 : This graph shows EP2 gene mRNA expression levels, relative to 18S.Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
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Figure 127 : This graph shows IL1β gene mRNA expression levels, relative to 18S.Total STOPPIT 
cohort values have been plotted with gestation in order to ascertain if gestation may have had an 
overall effect.  All progesterone samples were sampled at a gestation >250 days (35+5).  
 
Figure 128 : This graph shows IL1β gene mRNA expression levels, relative to 18S. Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5).  
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Figure 129 : This graph shows IL6 gene mRNA expression levels, relative to 18S.Total STOPPIT 
cohort values have been plotted with gestation in order to ascertain if gestation may have had an 
overall effect.  All progesterone samples were sampled at a gestation >250 days (35+5).  
 
Figure 130 : This graph shows IL6 gene mRNA expression levels, relative to18S.Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.  All progesterone samples were sampled at a gestation >250 days 
(35+5). 
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Figure 131 : This graph shows IL8 gene mRNA expression levels, relative to 18S.Total STOPPIT 
cohort values have been plotted with gestation in order to ascertain if gestation may have had an 
overall effect.   
 
Figure 132 : This graph shows IL8 gene mRNA expression levels, relative to 18S.Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.   
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Figure 133 : This graph shows Cx 26 gene mRNA expression levels, relative to 18S.Total 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect 
 
Figure 134 : This graph shows Cx 26 gene mRNA expression levels, relative to 18S.Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.   
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Figure 135 : This graph shows Cx 43 gene mRNA expression levels, relative to 18S.Total 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect 
 
Figure 136 : This graph shows Cx 43 gene mRNA expression levels, relative to 18S.Standardised 
STOPPIT cohort values have been plotted with gestation in order to ascertain if gestation may 
have had an overall effect.   
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Short title: Myometrial contractility and progesterone. 
Précis: Progesterone but not 17α-hydroxyprogesterone caproate inhibits spontaneous 
myometrial contractions in vitro and not via specific potassium channels. 
Laurie Anderson, 2009  267 
ABSTRACT 
 
Objectives: Recent clinical trials have demonstrated a beneficial effect of supplementation 
with progesterone to prevent preterm labor. We aimed to determine the effects of 
progesterone treatment in vitro and in vivo and 17α-hydroxyprogesterone caproate 
(17OHPC) in vitro on myometrial contractions. 
Methods: Myometrial strips were taken from women undergoing cesarean delivery at 
term. We also obtained myometrial biopsies from women participating in a clinical trial of 
progesterone to prevent preterm labor in twins (STOPPIT). After establishment of 
spontaneous contractions, strips were exposed to progesterone or 17OHPC. Separate strips 
were exposed to oxytocin and tocolytics alone and in combination with progesterone. 
Potassium channel blockers were added in conjunction with progesterone. STOPPIT 
samples were used to compare the effects of in vivo progesterone and placebo. We 
measured amplitude, frequency and activity integral of contractions. 
Results: Maximum inhibition of contraction amplitude was 93±2% and 67±14% for 
progesterone at 30 µM and vehicle (70% ethanol), respectively, p<0.05. 17OHPC did not 
exert an inhibitory effect. Water soluble progesterone exerted a maximal inhibitory effect 
on amplitude of contractions of 82±10% at 100 µM, p<0.05. The inhibitory effect of 
progesterone was unaffected by potassium channel blockers. There was no difference 
between in vivo placebo and progesterone-treated groups in either amplitude or frequency 
of contractions, nor was there any difference in the response to oxytocin or the tocolytic 
drugs. 
Conclusions: Progesterone exerts rapid inhibition of the amplitude of myometrial 
contractions in vitro but 17OHPC does not.  The action of progesterone does not appear to 
operate via potassium
 
channels nor does it lead to enhancement of the activity of certain 
tocolytic drugs.  
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INTRODUCTION 
Preterm birth is the single biggest cause of perinatal morbidity and mortality with rates of 
preterm birth rising worldwide. The UK now has the highest rate of premature birth in 
Europe (2) with 5.3% of overall births in Scotland  occurring spontaneously before 37 
weeks gestation (1). It has long been established that progesterone is a pre-requisite for a 
successful pregnancy outcome, with functional withdrawal of progesterone now thought to 
underlie human labor. Consistent with this theory, recent clinical trials have demonstrated 
a beneficial effect of supplementation with either progesterone or the synthetic progestin, 
17 α-hydroxyprogesterone caproate (17OHPC), in the prevention of preterm labor (104, 
111). However, progesterone is not uniformly effective in preventing preterm labor and at 
present its principal mode of action on myometrium is unknown (48).  
 
Progesterone and its related progestins have both an indirect and direct, concentration-
dependent relaxant effect on spontaneous myometrial contractile activity (98, 105, 106).  
Progesterone is thought to modulate potassium channel activity. Potassium channels are 
widely expressed on the myocyte membrane surface (129); specifically adenosine 
triphosphate sensitive-potassium channels (KATP), BKCa (large conductance channel), IKCa 
(intermediate conductance channel), KV (voltage-operated channel) and SKCa (small 
conductance channel) are all present in pregnant myometrium (128).  Additionally, 
levcromakalim, a KATP opener, has been shown to exert a concentration-dependent 
inhibition of spontaneous myometrial activity in vitro (64, 92).Calcium channel blockers 
such as nifedipine have also been used widely as tocolytic agents to eliminate myometrial 
contractions in vivo (55). The opening of potassium channels or closure of calcium 
channels by progesterone could either hyperpolarise or prevent depolarisation of the cell 
respectively and would thereby potentially directly inhibit contractile activity.  In addition 
to these immediate effects on the myometrium, progesterone may also sensitise the uterus 
to tocolytics.  A clinical trial using vaginal progesterone  reported that patients responded 
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more favourably to β-mimetics tocolysis when pretreated with progesterone compared to 
placebo (104), despite no difference in the incidence of threatened preterm labor in the two 
groups. In vitro progesterone has been shown to sensitise myometrium to the relaxant 
effects of the β2-agonist, ritodrine (99).  
 
The purpose of this study was therefore to determine: 1) the effects of in vitro progesterone 
and its synthetic analogue, 17OHPC, on spontaneous myometrial contractility in vitro 2) 
whether in vitro progesterone exerts its myometrial effects via specific potassium channels, 
and 3) whether in vitro progesterone enhances activity of other tocolytic drugs.  
 
 
 MATERIALS AND METHODS  
Subjects and Preparation of tissues 
We recruited 84 women undergoing elective prelabor cesarean section between 37 and 41 
weeks gestation from three maternity hospitals within Scotland. The project was approved 
by North Glasgow University Hospitals Research Ethics Committee reference number 
05/S0705/18. All patients gave written informed consent to participate. At operation, a 
myometrial biopsy 2cm long, 1cm wide and 1cm thick was taken from the mid-upper lip of 
the lower segment cesarean section incision into the myometrium. This was done 
following delivery of the baby and prior to routine clinical administration of Syntocinon 5 
IU. Myometrial biopsies were immediately placed in a buffered Krebs solution (NaCl 133 
mM, KCl 4.7 mM, glucose 11.1 mM, MgS04 1.2 mM, KH2PO4 1.2 mM, CaCl2 1.2 mM, 
TES 10 mM), stored at 4°C and used within 12 hours of collection.  
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In the laboratory, strips of myometrium 15mm long, 2mm wide and 2mm deep were cut, 
secured with silk and placed under isometric conditions with a 20 milliNewton (mN) 
resting tension.  When suspended in this manner strips developed rhythmic activity which 
stabilised within 90 minutes to 3 hours. Once stable activity had developed with the 
amplitude and frequency having less than 5% variation between contractions then we were 
added drugs as relevant for each experiment. Each biopsy from a participant was divided 
into identical strips. One a strip from each participant was used to test each drug and a 
further strip was used as a control strip. Additionally multiple drugs were tested in parallel 
from each participant.  No participant provided more than one strip for each drug (or 
control). Contractility was recorded via a tension transducer (FT03, Grass Technologies, 
Slough, UK) attached to one end of the strip which was connected to a data acquisition 
system (PowerLab ML870/P, Chart, version 3.6, all AD Instruments). Each tissue strip was 
suspended in a separate 10ml organ bath filled with Krebs-Henseleit solution, gassed with 
95% O2/5% CO2, and maintained at 37 oC.  
Contractile analysis 
The amplitude of spontaneous contraction was taken as the mean amplitude of 3 
consecutive contractions recorded prior to the addition of drug. Stable activity was defined 
as a series of at least 3 contractions reaching the same amplitude and frequency after the 2-
hour equilibration period. The response to drug was defined as the effect on contraction at 
the time point of interest and recorded in milliNewtons (mN).  Frequency was recorded in 
contractions h-1 by measuring the interval between the peaks of two consecutive 
contractions occurring at the time point of interest. For time point analysis, contraction 
amplitude and frequency were recorded following the development of stable rhythmic 
activity, immediately prior to addition of drug (time 0) and at 30 minute periods thereafter 
for 4 hours. An integral measure of contractile activity was determined by the area under 
the tension curve for each contraction.  
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Progesterone, 17OHPC experiments and water soluble progesterone 
Progesterone (10 nM-100 µM final bath concentrations) was added at 20-minute intervals 
to reach cumulative concentrations of 10 nM, 100 nM, 1 µM etc. Amplitude and frequency 
of contractions were recorded at the end of each time period. Similar experiments were 
then carried out with 17OHPC.  Both progesterone and 17OHPC were dissolved in a 70% 
ethanol vehicle with subsequent dilutions in Krebs. For progesterone and 17OHPC a 
parallel series of time matched experiments were carried out using ethanol (70%) vehicle 
control diluted in Krebs as appropriate. As will be seen from the results, the ethanol 
vehicle inhibited myometrial contraction, thus interfering with the actions of progesterone 
itself. Accordingly, a water soluble progesterone contained within a cyclodextrin was also 
examined which required no vehicle control as it was dissolved in Krebs solution. We 
subsequently tested the effects of the cyclodextrin compound which was used to make the 
progesterone water soluble on myometrial contractions. 
 
In order to assess the effects of progesterone for periods greater than 20 minutes, time 
course experiments were carried out. A single dose of water soluble progesterone, to reach 
a bath concentration of 100 µM, was added after the equilibration period. Thereafter the 
amplitude and frequency were recorded at 30 minute intervals over a period of 4 hours.  
 
Potassium channel experiments 
In view of the inhibitory effect of ethanol at high concentrations, these experiments were 
conducted with only water soluble progesterone. Each of the potassium channel blocking 
agents, glibenclamide 1.5 µM (blocks KATP channels), charybdotoxin 100 nM (blocks  
IKCa, BKCa and Kv channels), iberiotoxin 100 nM (blocks BKCa channels)  and apamin 100 
nM (blocks SKCa channels) were added to myometrial strips when spontaneous rhythmic 
activity had stabilised and progesterone was added after  20 minutes. Concentration-
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response curves were then carried out adding water soluble progesterone as described 
above.  Time matched controls were included for all agents and a DMSO vehicle control 
was also included for glibenclamide. Time course experiments were also repeated with 
progesterone 100 µM after treatment with each potassium channel blocking agent. 
 
In vitro progesterone incubation with oxytocin, levcromakalim, nifedipine and ritodrine 
We performed concentration-response curves to examine the effects on myometrial activity 
of oxytocin (which stimulates myometrial contractions in concentrations of 10 pM-10 
µM), levcromakalim (a KATP channel opener, 100 pM -10 µM), nifedipine (a calcium 
channel blocker, 100 pM-10 µM) and ritodrine (a β2-agonist, 0.01 µM-1 mM) all added to 
cumulatively to achieve final bath concentrations at these ranges, on separate strips from 
patients, n≥6. We also constructed parallel concentration-response curves on tissues 
incubated for 60 min with progesterone 1 µM . 
 
Drugs and solutions 
All concentrations stated are final bath concentrations. All drugs were obtained from 
Sigma (Poole) except for iberiotoxin and charybdotoxin which were obtained from 
Latoxan (France). All drugs were dissolved in saline except levcromakalim ( DMSO 
solvent), oxytocin ( acetic acid), nifedipine ( ethanol), progesterone ( 70% ethanol), 
17OHPC ( 70% ethanol) and  glibenclamide ( DMSO).The maximum concentration 
reached with ethanol was 0.2% of the total organ bath volume for all experiments except 
the progesterone (70% ethanol). This reached higher ethanol concentrations and 
consequentially we used alternative progesterone. Water soluble progesterone, Sigma 
(Poole) is contained within a cylclodextrin (Sigma) compound. This enables hydrophobic 
molecules to be incorporated into the cavity of the cylclodextrin by displacing water, and 
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when the water soluble complex is dissolved in a larger volume of aqueous solvent the 
process is reversed thereby releasing the molecule into the solvent. 
 
Statistical analysis 
A reduction in the magnitude of the amplitude contractions was expressed as a percentage 
inhibition (mean ± SEM) of the contraction obtained immediately before the first addition 
of the drug. Statistical analysis was carried out using one-way analysis of variance with 
either Bonferroni correction or Kruskal-Wallis test for non parametric data or unpaired t 
test, for parametric data (Graph Pad Prism, Minitab). N is defined as the number of patients 
and myometrial strip number is stated separately. A value of p< 0.05 was considered to 
indicate statistical significance. 
 
RESULTS 
Effects of progesterone, 17OHPC and water soluble progesterone 
Following equilibration for 2 hours, myometrial strips contracted in a rhythmic manner 
(amplitude 46±1 mN, frequency 7.7±0.1 contractions h-1) for >4hours (figures 1a,1d), data 
obtained from 64 strips from 15 patients. Progesterone dissolved in ethanol (10 nM- 30 
µM) produced a concentration-dependent inhibitory effect on the amplitude of myometrial 
contractions (figure 1a, b). The vehicle 70% ethanol, at appropriate dilutions, also exerted 
an inhibitory effect on the amplitude of contractions. Maximum inhibition of amplitude 
was 93±2% and 67±14% for 30 µM progesterone and appropriate vehicle. 17OHPC also 
exerted an inhibitory effect on contraction amplitude but this was not significantly different 
from the vehicle (figure 1c). 
Given the demonstrable inhibitory effect of the ethanol vehicle at high concentrations on 
myometrial contractions, we used water soluble progesterone (which does not contain 
ethanol) for all subsequent experiments. The cyclodextrin compound encapsulating the 
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progesterone was tested alone, with 6 myometrial biopsies and had no effect on either the 
amplitude or frequency of myometrial contractions (data not shown). Time course 
experiments showed that water soluble progesterone (100 µM) exerted a 42±5% inhibition 
of contractile amplitude 30 minutes after addition to the bath, and reached a maximal 
inhibition of 82±10% at 1 hour (figure 1d). Water soluble progesterone also exerted a 
concentration-dependent inhibitory effect on amplitude (max of 82±10% at 100 µM (figure 
1e). Water soluble progesterone generally had no effect on the frequency of contractions 
(figure 1f); but in some cases a small rise was seen. Overall the activity integral (area 
under the curve) showed a clear decrease with progesterone compared with control (figure 
1g).  
Effects of potassium channel blockers on responses to progesterone 
Levcromakalim, a KATP channel opener, produced a concentration-dependent inhibition of 
the amplitude and frequency of spontaneous contractions. These effects were antagonised 
by the KATP channel blocker, glibenclamide (1.5 µM) (figure 2a, b). In contrast, 
glibenclamide had no effect on the progesterone-induced inhibition of myometrial 
contractility (figure 2c, d). Charybdotoxin 10 nM (which blocks IKCa, BKCa and Kv 
channels), iberiotoxin 100 nM (which blocks BKCa channels) and apamin 100 nM (which 
blocks SKCa channels) failed to affect the ability of progesterone to inhibit myometrial 
contractility (figure 3 a-f).  
 
Effects of progesterone 1 µM incubation in vitro on oxytocin and tocolytics 
Previous work has suggested sensitisation to tocolytics by progesterone (0.01 µM) in vitro 
(99). As expected, oxytocin (10 pM-10 µM) produced a concentration-dependent increase 
in both amplitude and frequency of myometrial contractions. Levcromakalim (100 pM -10 
µM), nifedipine (100 pM-10 µM) and ritodrine (0.01 µM-1 mM) each produced a 
concentration-dependent inhibition of the amplitude and frequency of spontaneous 
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contractions.  A short 60 minute water soluble progesterone (1 µM) incubation did not alter 
spontaneous amplitude or frequency of myometrial contractions. This progesterone 
incubation also failed to alter the concentration-dependent stimulatory effect of oxytocin or 
concentration-dependent inhibitory effects of levcromakalim, nifedipine or ritodrine n≥10 
(figure 4 a-d).  
 
DISCUSSION 
Our study clearly demonstrates that progesterone, albeit at high concentrations, exerts 
consistent, rapid and sustained inhibition of the amplitude of spontaneous myometrial 
contractions in vitro - consistent with effects observed in clinical studies of acute 
administration of progesterone at term (127). In contrast, 17OHPC did not exert any 
inhibitory effect on myometrial activity over and above that seen with its vehicle (70% 
ethanol). However, the concentrations of progesterone required to inhibit contractions in 
vitro (100 µM) are unlikely to be achieved with therapeutic doses of progesterone in vivo. 
However, it may not be the absolute concentration of progesterone that is important in 
vivo, given that it has been suggested that patterns of change as opposed to absolute 
concentrations of progesterone and other steroid hormones may be the important factor in 
affecting myometrial contractility  (157).  
Our observation that 17OHPC had no independent inhibitory effect confirms previous 
work from other groups(158). Despite this, a number of clinical trials administering 
intramuscular injections of 17OHPC have been successful in preventing preterm delivery 
in high risk women. Sexton et al suggests that this positive clinical outcome may well be 
mediated through long-term genomic pathways which cannot be reproduced under organ 
bath conditions (158). We were unable to test this as we were only able to conduct 
experiments for 8 hours in vitro before myometrial contractility began to decline 
(presumably due to cell death and lack of energy substrates in the tissue). It is possible 
therefore that 17OHPC requires either prolonged incubation (which cannot be tested in 
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vitro) or the contribution of other tissues or molecules that are present in vivo to exert an 
effect.  It also remains unclear as to whether 17OHPC is active itself or requires metabolic 
activation. One suggested pathway of activation is hydrolysis of 17 OHP by plasma and 
tissue esterases, but a recent study showed that this does not occur in vitro, suggesting 
again either different effects in vivo or alternative mechanisms of metabolism (159). 
Progesterone and 17OHPC may potentially act upon different receptors in vitro and in 
vivo. For example, 17OHPC has recently been found to have lower affinity than 
progesterone for the progesterone PR receptor (160).  These differences may account for 
the greater efficacy of progesterone compared with 17OHPC on contractility in vitro. 
In this study, the speed of the progesterone response suggests a non-genomic effect.  
However by use of selective inhibitors, we clearly demonstrate that progesterone does not 
exert its inhibition of myometrial contraction via a range of potassium channels, including 
KATP, BKCa, IKCa and SKCa, despite a key role for them in contractile responses. 
Alternative pathways in which progesterone may exert an effect could be via sodium or 
chloride channels. There is some evidence to suggest that sodium channels may be up 
regulated in myometrium at  late gestation (167) but the distinct roles of specific sodium 
channels is not clearly understood. Ion channels may well have regulatory pathways 
related to myometrial function but whether progesterone utilises them in its mechanism to 
prevent preterm labor remains unclear. 
There are several non-genomic pathways by which progesterone may inhibit myometrial 
contractility in vitro. We consider the most likely to be those operating through the cell 
membrane progesterone receptors α, β and γ, which themselves are similar to G-protein 
coupled receptors (109) . An alternative non-genomic pathway of progesterone action is 
interaction with gamma amino butyric acid A (GABAA) receptors. These receptors appear 
to be important in the emerging effects that progesterone has on the brain (97, 217). 
Additionally, initial studies of rat myometrium GABAA antagonists prevented progesterone 
induced inhibition of contractions, suggesting that progesterone might mediate its action 
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via the GABA receptor (107). These results could not be replicated in more recent studies 
of human myometrium. A prior study found that relaxation produced by the above steroids 
was not blocked by the GABAA receptor antagonists, picrotoxin or bicuculline, but was 
reversed by calcium, they suggest that blockade of calcium influx appeared to be 
responsible this relaxation (108).  
Thus the potential role of GABA receptors in the mechanism of action of progesterone in 
inhibiting myometrial contractions remains controversial, with progesterone’s main 
genomic action in maintaining uterine quiescence is considered to result via the PR-B 
receptor (48, 77).  
A previous study has reported enhanced responses to β-sympathomimetics following both 
in vivo and in vitro treatment with progesterone (104). However, we did not see an 
enhanced effect of any tocolytic, including levcromakalim (a KATP channel opener), 
nifedipine (a calcium channel blocker) and ritodrine (a β2- agonist) in our in vitro 
progesterone groups. This is in contrast to previous work carried out by Chanrachakul et al, 
where they demonstrated an enhancement of the tocolytic effect of ritodrine using a lower 
concentration of progesterone (0.01 µM)  in vitro (99). Their experimental design involved 
using oxytocin-induced contractions as opposed to spontaneous contractions in our study. 
Additionally, they used progesterone dissolved in ethanol (against appropriate ethanol 
controls) in contrast to our own study where we used progesterone in cyclodextrin. The 
differences between the Chanrachakul study and our own are hard to explain unless 
progesterone’s effect in enhancing the tocolytic effects of ritodrine require either ethanol or 
stimulation with oxytocin to become apparent. Their experimental design involved using 
oxytocin-induced contractions as opposed to spontaneous contractions in our study.  Lastly 
although a potential weakness of our study may be the use of lower segment myometrial 
biopsies, others have previously shown no difference between upper and lower segment 
biopsies in terms of myometrial contractility in vitro  (147) . 
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Progesterone has been demonstrated to suppress the immune response in early pregnancy 
(181). Elovitz et al demonstrated that the progestational agent, medroxyprogesterone 
acetate, reduced COX-2, IL-1β and TNF-α mRNA expression in the myometrium of 
pregnant mice pretreated with LPS. These studies demonstrated that progestational agents 
decreased the incidence of inflammation-induced preterm parturition and 
medroxyprogesterone completely prevented preterm birth compared to progesterone which 
decreased the overall rate of preterm birth (207).Although it is tempting to speculate that 
this inhibition of production of inflammatory genes may be part of the mechanism of 
action by which progesterone affects myometrial contractility, again this would be a 
genomic effect that would take longer than the rapid effects on contractility that we 
observed with progesterone. 
In conclusion we have clearly demonstrated that progesterone but not 17OHPC inhibits 
myometrial contractility in vitro, however, this affect is not achieved through the principal 
potassium channels.  Further we show that progesterone does not enhance the inhibitory 
response of tocolytics with respect to spontaneous contractions.  The mechanism of action 
of progesterone both in inhibiting myometrial contractility and in preventing preterm birth 
therefore continues to warrant further investigation. 
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Figure 1(a) Contractility trace showing the stability of rhythmic contraction of myometrial strips and 
inhibition of activity by progesterone (100µM). Concentration-response curves showing the effects 
of progesterone and the appropriate dilution of vehicle (70% ethanol) n≥9 (b) and 17OHPC n≥6(c). 
Time course assessment (d) of a maximal concentration water soluble progesterone,100µM over 4 
hours on the amplitude of contractions. Concentration-response curves for amplitude of 
contractions (e) and frequency of contractions (f) both for water soluble progesterone n≥5. Activity 
integral assessment of control versus water soluble progesterone (g) *p<0.05 n≥6.  
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Figure 2. Concentration-response curves showing the effects of levcromakalim and progesterone 
on amplitude (a and c) and frequency (b and d) of myometrial contractions. The effects of 
glibenclamide (1.5 µM) on the actions of levcromakalim and progesterone are also shown n≥7.The 
right shift in the curve is evident, * p<0.05 indicates a difference between the response of 
contractile amplitude and frequency levcromakalim , and in the presence of its antagonist 
glibenclamide ( ANOVA). 
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Figure 3. Concentration-response curves showing how changes in amplitude and frequent of 
myometrial contractions induced by progesterone are influenced by the presence of charybdotoxin 
n≥6 (a, b), iberiotoxin n≥6 (c, d) and apamin n≥6 (e, f). There was no significant difference in the 
response of contractions to progesterone in the presence of any of the potassium channel agents 
tested (ANOVA). 
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Figure 4. Concentration-response curves showing the effects of oxytocin (a), levcromakalim (b), 
nifedipine (c) and ritodrine (d) on the amplitude of myometrial contractility in  vitro following 
incubation with progesterone 1 µM n≥6 . There was no significant difference in any of the drugs 
tested after the incubation with progesterone (ANOVA). 
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ABSTRACT 
 
Objectives: Recent clinical trials have demonstrated a beneficial effect of supplementation 
with progesterone to prevent preterm labor. We aimed to determine the effects of 
progesterone treatment in vitro and in vivo and 17α-hydroxyprogesterone caproate 
(17OHPC) in vitro on myometrial contractions. 
Methods: Myometrial strips were taken from women undergoing cesarean delivery at 
term. We also obtained myometrial biopsies from women participating in a clinical trial of 
progesterone to prevent preterm labor in twins (STOPPIT). After establishment of 
spontaneous contractions, strips were exposed to progesterone or 17OHPC. Separate strips 
were exposed to oxytocin and tocolytics alone and in combination with progesterone. 
Potassium channel blockers were added in conjunction with progesterone. STOPPIT 
samples were used to compare the effects of in vivo progesterone and placebo. We 
measured amplitude, frequency and activity integral of contractions. 
Results: Maximum inhibition of contraction amplitude was 93±2% and 67±14% for 
progesterone at 30 µM and vehicle (70% ethanol), respectively, p<0.05. 17OHPC did not 
exert an inhibitory effect. Water soluble progesterone exerted a maximal inhibitory effect 
on amplitude of contractions of 82±10% at 100 µM, p<0.05. The inhibitory effect of 
progesterone was unaffected by potassium channel blockers. There was no difference 
between in vivo placebo and progesterone-treated groups in either amplitude or frequency 
of contractions, nor was there any difference in the response to oxytocin or the tocolytic 
drugs. 
Conclusions: Progesterone exerts rapid inhibition of the amplitude of myometrial 
contractions in vitro but 17OHPC does not.  The action of progesterone does not appear to 
operate via potassium
 
channels nor does it enhance the activity of certain tocolytic drugs.  
INTRODUCTION 
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Preterm birth is the single biggest cause of perinatal morbidity and mortality with rates of 
preterm birth rising worldwide. The UK now has the highest rate of premature birth in 
Europe (2) with 5.3% of overall births in Scotland  occurring spontaneously before 37 
weeks gestation (1). It has long been established that progesterone is a pre-requisite for a 
successful pregnancy outcome, with functional withdrawal of progesterone now thought to 
underlie human labor. Consistent with this theory, recent clinical trials have demonstrated 
a beneficial effect of supplementation with either progesterone or the synthetic progestin, 
17 α-hydroxyprogesterone caproate (17OHPC), in the prevention of preterm labor (104, 
111). However, progesterone is not uniformly effective in preventing preterm labor and at 
present its principal mode of action on myometrium is unknown (48).  
 
Progesterone and its related progestins have both an indirect and direct, concentration-
dependent relaxant effect on spontaneous myometrial contractile activity (98, 105, 106).  
Progesterone is thought to modulate potassium channel activity. Potassium channels are 
widely expressed on the myocyte membrane surface (129); specifically adenosine 
triphosphate sensitive-potassium channels (KATP), BKCa (large conductance channel), IKCa 
(intermediate conductance channel), KV (voltage-operated channel) and SKCa (small 
conductance channel) are all present in pregnant myometrium (128).  Additionally, 
levcromakalim, a KATP opener, has been shown to exert a concentration-dependent 
inhibition of spontaneous myometrial activity in vitro (64, 92).Calcium channel blockers 
such as nifedipine have also been used widely as tocolytic agents to eliminate myometrial 
contractions in vivo (55). The opening of potassium channels or closure of calcium 
channels by progesterone could either hyperpolarise or prevent depolarisation of the cell 
respectively and would thereby potentially directly inhibit contractile activity.  In addition 
to these immediate effects on the myometrium, progesterone may also sensitise the uterus 
to tocolytics.  A clinical trial using vaginal progesterone  reported that patients responded 
more favourably to β-mimetics tocolysis when pretreated with progesterone compared to 
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placebo (104), despite no difference in the incidence of threatened preterm labor in the two 
groups. In vitro progesterone has been shown to sensitise myometrium to the relaxant 
effects of the β2-agonist, ritodrine (99).  
 
The purpose of this study was therefore to determine: 1) the effects of in vitro progesterone 
and its synthetic analogue, 17OHPC, on spontaneous myometrial contractility in vitro 2) 
whether in vitro progesterone exerts its myometrial effects via specific potassium channels, 
and 3) whether in vitro progesterone enhances activity of other tocolytic drugs.  
 
 
 MATERIALS AND METHODS  
Subjects and Preparation of tissues 
We recruited 84 women undergoing elective prelabor cesarean section between 37 and 41 
weeks gestation from three maternity hospitals within Scotland. The project was approved 
by North Glasgow University Hospitals Research Ethics Committee reference number 
05/S0705/18. All patients gave written informed consent to participate. At operation, a 
myometrial biopsy 2cm long, 1cm wide and 1cm thick was taken from the mid-upper lip of 
the lower segment cesarean section incision into the myometrium. This was done 
following delivery of the baby and prior to routine clinical administration of Syntocinon 5 
IU. Myometrial biopsies were immediately placed in a buffered Krebs solution (NaCl 133 
mM, KCl 4.7 mM, glucose 11.1 mM, MgS04 1.2 mM, KH2PO4 1.2 mM, CaCl2 1.2 mM, 
TES 10 mM), stored at 4°C and used within 12 hours of collection.  
 
In the laboratory, strips of myometrium 15mm long, 2mm wide and 2mm deep were cut, 
secured with silk and placed under isometric conditions with a 20 milliNewton (mN) 
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resting tension.  When suspended in this manner strips developed rhythmic activity which 
stabilised within 90 minutes to 3 hours. Once stable activity had developed with the 
amplitude and frequency having less than 5% variation between contractions then we were 
added drugs as relevant for each experiment. Each biopsy from a participant was divided 
into identical strips. One a strip from each participant was used to test each drug and a 
further strip was used as a control strip. Additionally multiple drugs were tested in parallel 
from each participant.  No participant provided more than one strip for each drug (or 
control). Contractility was recorded via a tension transducer (FT03, Grass Technologies, 
Slough, UK) attached to one end of the strip which was connected to a data acquisition 
system (PowerLab ML870/P, Chart, version 3.6, all AD Instruments). Each tissue strip was 
suspended in a separate 10ml organ bath filled with Krebs-Henseleit solution, gassed with 
95% O2/5% CO2, and maintained at 37 oC.  
Contractile analysis 
The amplitude of spontaneous contraction was taken as the mean amplitude of 3 
consecutive contractions recorded prior to the addition of drug. Stable activity was defined 
as a series of at least 3 contractions reaching the same amplitude and frequency after the 2-
hour equilibration period. The response to drug was defined as the effect on contraction at 
the time point of interest and recorded in milliNewtons (mN).  Frequency was recorded in 
contractions h-1 by measuring the interval between the peaks of two consecutive 
contractions occurring at the time point of interest. For time point analysis, contraction 
amplitude and frequency were recorded following the development of stable rhythmic 
activity, immediately prior to addition of drug (time 0) and at 30 minute periods thereafter 
for 4 hours. An integral measure of contractile activity was determined by the area under 
the tension curve for each contraction.  
 
Progesterone, 17OHPC experiments and water soluble progesterone 
Laurie Anderson, 2009  314 
Progesterone (10 nM-100 µM final bath concentrations) was added at 20-minute intervals 
to reach cumulative concentrations of 10 nM, 100 nM, 1 µM etc. Amplitude and frequency 
of contractions were recorded at the end of each time period. Similar experiments were 
then carried out with 17OHPC.  Both progesterone and 17OHPC were dissolved in a 70% 
ethanol vehicle with subsequent dilutions in Krebs. For progesterone and 17OHPC a 
parallel series of time matched experiments were carried out using ethanol (70%) vehicle 
control diluted in Krebs as appropriate. As will be seen from the results, the ethanol 
vehicle inhibited myometrial contraction, thus interfering with the actions of progesterone 
itself. Accordingly, a water soluble progesterone contained within a cyclodextrin was also 
examined which required no vehicle control as it was dissolved in Krebs solution. We 
subsequently tested the effects of the cyclodextrin compound which was used to make the 
progesterone water soluble on myometrial contractions. 
 
In order to assess the effects of progesterone for periods greater than 20 minutes, time 
course experiments were carried out. A single dose of water soluble progesterone, to reach 
a bath concentration of 100 µM, was added after the equilibration period. Thereafter the 
amplitude and frequency were recorded at 30 minute intervals over a period of 4 hours.  
 
Potassium channel experiments 
In view of the inhibitory effect of ethanol at high concentrations, these experiments were 
conducted with only water soluble progesterone. Each of the potassium channel blocking 
agents, glibenclamide 1.5 µM (blocks KATP channels), charybdotoxin 100 nM (blocks  
IKCa, BKCa and Kv channels), iberiotoxin 100 nM (blocks BKCa channels)  and apamin 100 
nM (blocks SKCa channels) were added to myometrial strips when spontaneous rhythmic 
activity had stabilised and progesterone was added after  20 minutes. Concentration-
response curves were then carried out adding water soluble progesterone as described 
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above.  Time matched controls were included for all agents and a DMSO vehicle control 
was also included for glibenclamide. Time course experiments were also repeated with 
progesterone 100 µM after treatment with each potassium channel blocking agent. 
 
In vitro progesterone incubation with oxytocin, levcromakalim, nifedipine and ritodrine 
We performed concentration-response curves to examine the effects on myometrial activity 
of oxytocin (which stimulates myometrial contractions in concentrations of 10 pM-10 
µM), levcromakalim (a KATP channel opener, 100 pM -10 µM), nifedipine (a calcium 
channel blocker, 100 pM-10 µM) and ritodrine (a β2-agonist, 0.01 µM-1 mM) all added to 
cumulatively to achieve final bath concentrations at these ranges, on separate strips from 
patients, n≥6. We also constructed parallel concentration-response curves on tissues 
incubated for 60 min with progesterone 1 µM . 
 
Drugs and solutions 
All concentrations stated are final bath concentrations. All drugs were obtained from 
Sigma (Poole) except for iberiotoxin and charybdotoxin which were obtained from 
Latoxan (France). All drugs were dissolved in saline except levcromakalim ( DMSO 
solvent), oxytocin ( acetic acid), nifedipine ( ethanol), progesterone ( 70% ethanol), 
17OHPC ( 70% ethanol) and  glibenclamide ( DMSO).The maximum concentration 
reached with ethanol was 0.2% of the total organ bath volume for all experiments except 
the progesterone (70% ethanol). The progesterone (70% ethanol) would have reached 
higher concentrations than appropriate for organ bath experiments and consequentially we 
used alternative progesterone. Water soluble progesterone, Sigma (Poole) is contained 
within a cylclodextrin (Sigma) compound. This enables hydrophobic molecules to be 
incorporated into the cavity of the cylclodextrin by displacing water, and when the water 
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soluble complex is dissolved in a larger volume of aqueous solvent the process is reversed 
thereby releasing the molecule into the solvent. 
 
Statistical analysis 
A reduction in the magnitude of the amplitude contractions was expressed as a percentage 
inhibition (mean ± SEM) of the contraction obtained immediately before the first addition 
of the drug. Statistical analysis was carried out using one-way analysis of variance with 
either Bonferroni correction or Kruskal-Wallis test for non parametric data or unpaired t 
test, for parametric data (Graph Pad Prism, Minitab). N is defined as the number of patients 
and myometrial strip number is stated separately. A value of p< 0.05 was considered to 
indicate statistical significance. 
 
RESULTS 
Effects of progesterone, 17OHPC and water soluble progesterone 
Following equilibration for 2 hours, myometrial strips contracted in a rhythmic manner 
(amplitude 46±1 mN, frequency 7.7±0.1 contractions h-1) for >4hours (figures 1a,1d), data 
obtained from 64 strips from 15 patients. Progesterone dissolved in ethanol (10 nM- 30 
µM) produced a concentration-dependent inhibitory effect on the amplitude of myometrial 
contractions (figure 1a, b). The vehicle 70% ethanol, at appropriate dilutions, also exerted 
an inhibitory effect on the amplitude of contractions. Maximum inhibition of amplitude 
was 93±2% and 67±14% for 30 µM progesterone and appropriate vehicle. 17OHPC also 
exerted an inhibitory effect on contraction amplitude but this was not significantly different 
from the vehicle (figure 1c). 
Given the demonstrable inhibitory effect of the ethanol vehicle at high concentrations on 
myometrial contractions, we used water soluble progesterone (which does not contain 
ethanol) for all subsequent experiments. The cyclodextrin compound encapsulating the 
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progesterone was tested alone, with 6 myometrial biopsies and had no effect on either the 
amplitude or frequency of myometrial contractions (data not shown). Time course 
experiments showed that water soluble progesterone (100 µM) exerted a 42±5% inhibition 
of contractile amplitude 30 minutes after addition to the bath, and reached a maximal 
inhibition of 82±10% at 1 hour (figure 1d). Water soluble progesterone also exerted a 
concentration-dependent inhibitory effect on amplitude (max of 82±10% at 100 µM (figure 
1e). Water soluble progesterone generally had no effect on the frequency of contractions 
(figure 1f); but in some cases a small rise was seen. Overall the activity integral (area 
under the curve) showed a clear decrease with progesterone compared with control (figure 
1g).  
Effects of potassium channel blockers on responses to progesterone 
Levcromakalim, a KATP channel opener, produced a concentration-dependent inhibition of 
the amplitude and frequency of spontaneous contractions. These effects were antagonised 
by the KATP channel blocker, glibenclamide (1.5 µM) (figure 2a, b). In contrast, 
glibenclamide had no effect on the progesterone-induced inhibition of myometrial 
contractility (figure 2c, d). Charybdotoxin 10 nM (which blocks IKCa, BKCa and Kv 
channels), iberiotoxin 100 nM (which blocks BKCa channels) and apamin 100 nM (which 
blocks SKCa channels) failed to affect the ability of progesterone to inhibit myometrial 
contractility (figure 3 a-f).  
 
Effects of progesterone 1 µM incubation in vitro on oxytocin and tocolytics 
Previous work has suggested sensitisation to tocolytics by progesterone (0.01 µM) in vitro 
(99). As expected, oxytocin (10 pM-10 µM) produced a concentration-dependent increase 
in both amplitude and frequency of myometrial contractions. Levcromakalim (100 pM -10 
µM), nifedipine (100 pM-10 µM) and ritodrine (0.01 µM-1 mM) each produced a 
concentration-dependent inhibition of the amplitude and frequency of spontaneous 
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contractions.  A short 60 minute water soluble progesterone (1 µM) incubation did not alter 
spontaneous amplitude or frequency of myometrial contractions. This progesterone 
incubation also failed to alter the concentration-dependent stimulatory effect of oxytocin or 
concentration-dependent inhibitory effects of levcromakalim, nifedipine or ritodrine n≥10 
(figure 4 a-d).  
 
DISCUSSION 
Our study clearly demonstrates that progesterone, albeit at high concentrations, exerts 
consistent, rapid and sustained inhibition of the amplitude of spontaneous myometrial 
contractions in vitro - consistent with effects observed in clinical studies of acute 
administration of progesterone at term (127). In contrast, 17OHPC did not exert any 
inhibitory effect on myometrial activity over and above that seen with its vehicle (70% 
ethanol). However, the concentrations of progesterone required to inhibit contractions in 
vitro (100 µM) are unlikely to be achieved with therapeutic doses of progesterone in vivo. 
However, it may not be the absolute concentration of progesterone that is important in 
vivo, given that it has been suggested that patterns of change as opposed to absolute 
concentrations of progesterone and other steroid hormones may be the important factor in 
affecting myometrial contractility  (157).  
Our observation that 17OHPC had no independent inhibitory effect confirms previous 
work from other groups(158). Despite this, a number of clinical trials administering 
intramuscular injections of 17OHPC have been successful in preventing preterm delivery 
in high risk women. Sexton et al suggests that this positive clinical outcome may well be 
mediated through long-term genomic pathways which cannot be reproduced under organ 
bath conditions (158). We were unable to test this as we were only able to conduct 
experiments for 8 hours in vitro before myometrial contractility began to decline 
(presumably due to cell death and lack of energy substrates in the tissue). It is possible 
therefore that 17OHPC requires either prolonged incubation (which cannot be tested in 
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vitro) or the contribution of other tissues or molecules that are present in vivo to exert an 
effect.  It also remains unclear as to whether 17OHPC is active itself or requires metabolic 
activation. One suggested pathway of activation is hydrolysis of 17 OHP by plasma and 
tissue esterases, but a recent study showed that this does not occur in vitro, suggesting 
again either different effects in vivo or alternative mechanisms of metabolism (159). 
Progesterone and 17OHPC may potentially act upon different receptors in vitro and in 
vivo. For example, 17OHPC has recently been found to have lower affinity than 
progesterone for the progesterone PR receptor (160).  These differences may account for 
the greater efficacy of progesterone compared with 17OHPC on contractility in vitro. 
In this study, the speed of the progesterone response suggests a non-genomic effect.  
However by use of selective inhibitors, we clearly demonstrate that progesterone does not 
exert its inhibition of myometrial contraction via a range of potassium channels, including 
KATP, BKCa, IKCa and SKCa, despite a key role for them in contractile responses. 
Alternative pathways in which progesterone may exert an effect could be via sodium or 
chloride channels. There is some evidence to suggest that sodium channels may be up 
regulated in myometrium at  late gestation (167) but the distinct roles of specific sodium 
channels is not clearly understood. Ion channels may well have regulatory pathways 
related to myometrial function but whether progesterone utilises them in its mechanism to 
prevent preterm labor remains unclear. 
There are several non-genomic pathways by which progesterone may inhibit myometrial 
contractility in vitro. We consider the most likely to be those operating through the cell 
membrane progesterone receptors α, β and γ, which themselves are similar to G-protein 
coupled receptors (109) . An alternative non-genomic pathway of progesterone action is 
interaction with gamma amino butyric acid A (GABAA) receptors. These receptors appear 
to be important in the emerging effects that progesterone has on the brain (97, 217). 
Additionally, initial studies of rat myometrium GABAA antagonists prevented progesterone 
induced inhibition of contractions, suggesting that progesterone might mediate its action 
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via the GABA receptor (107). These results could not be replicated in more recent studies 
of human myometrium. A prior study found that relaxation produced by the above steroids 
was not blocked by the GABAA receptor antagonists, picrotoxin or bicuculline, but was 
reversed by calcium, they suggest that blockade of calcium influx appeared to be 
responsible this relaxation (108).  
Thus the potential role of GABA receptors in the mechanism of action of progesterone in 
inhibiting myometrial contractions remains controversial, with progesterone’s main 
genomic action in maintaining uterine quiescence is considered to result via the PR-B 
receptor (48, 77).  
A previous study has reported enhanced responses to β-sympathomimetics following both 
in vivo and in vitro treatment with progesterone (104). However, we did not see an 
enhanced effect of any tocolytic, including levcromakalim (a KATP channel opener), 
nifedipine (a calcium channel blocker) and ritodrine (a β2- agonist) in our in vitro 
progesterone groups. This is in contrast to previous work carried out by Chanrachakul et al, 
where they demonstrated an enhancement of the tocolytic effect of ritodrine using a lower 
concentration of progesterone (0.01 µM)  in vitro (99). Their experimental design involved 
using oxytocin-induced contractions as opposed to spontaneous contractions in our study. 
Additionally, they used progesterone dissolved in ethanol (against appropriate ethanol 
controls) in contrast to our own study where we used progesterone in cyclodextrin. The 
differences between the Chanrachakul study and are own are hard to explain unless 
progesterone’s effect in enhancing the tocolytic effects of ritodrine require either ethanol or 
stimulation with oxytocin to become apparent. Their experimental design involved using 
oxytocin-induced contractions as opposed to spontaneous contractions in our study.  Lastly 
although a potential weakness of our study may be the use of lower segment myometrial 
biopsies, others have previously shown no difference between upper and lower segment 
biopsies in terms of myometrial contractility in vitro  (147) . 
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Progesterone has been demonstrated to suppress the immune response in early pregnancy 
(181). Elovitz et al demonstrated that the progestational agent, medroxyprogesterone 
acetate, reduced COX-2, IL-1β and TNF-α mRNA expression in the myometrium of 
pregnant mice pretreated with LPS. These studies demonstrated that progestational agents 
decreased the incidence of inflammation-induced preterm parturition and 
medroxyprogesterone completely prevented preterm birth compared to progesterone which 
decreased the overall rate of preterm birth (207).Although it is tempting to speculate that 
this inhibition of production of inflammatory genes may be part of the mechanism of 
action by which progesterone affects myometrial contractility, again this would be a 
genomic effect that would take longer than the rapid effects on contractility that we 
observed with progesterone. 
In conclusion we have clearly demonstrated that progesterone but not 17OHPC inhibits 
myometrial contractility in vitro, however, this affect is not achieved through the principal 
potassium channels.  Further we show that progesterone does not enhance the inhibitory 
response of tocolytics with respect to spontaneous contractions.  The mechanism of action 
of progesterone both in inhibiting myometrial contractility and in preventing preterm birth 
therefore continues to warrant further investigation. 
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Figure 1(a) Contractility trace showing the stability of rhythmic contraction of 
myometrial strips and inhibition of activity by progesterone (100µM). 
Concentration-response curves showing the effects of progesterone and the 
appropriate dilution of vehicle (70% ethanol) n≥9 (b) and 17OHPC n≥6(c). Time 
course assessment (d) of a maximal concentration water soluble 
progesterone,100µM over 4 hours on the amplitude of contractions. 
Concentration-response curves for amplitude of contractions (e) and frequency of 
contractions (f) both for water soluble progesterone n≥5. Activity integral 
assessment of control versus water soluble progesterone (g) *p<0.05 n≥6.  
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Figure 2. Concentration-response curves showing the effects of levcromakalim 
and progesterone on amplitude (a and c) and frequency (b and d) of myometrial 
contractions. The effects of glibenclamide (1.5 µM) on the actions of 
levcromakalim and progesterone are also shown n≥7.The right shift in the curve is 
evident, * p<0.05 indicates a difference between the response of contractile 
amplitude and frequency levcromakalim , and in the presence of its antagonist 
glibenclamide ( ANOVA). 
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Figure 3. Concentration-response curves showing how changes in amplitude and 
frequent of myometrial contractions induced by progesterone are influenced by 
the presence of charybdotoxin n≥6 (a, b), iberiotoxin n≥6 (c, d) and apamin n≥6 
(e, f). There was no significant difference in the response of contractions to 
progesterone in the presence of any of the potassium channel agents tested 
(ANOVA). 
Laurie Anderson, 2009  325 
 
Figure 4. Concentration-response curves showing the effects of oxytocin (a), 
levcromakalim (b), nifedipine (c) and ritodrine (d) on the amplitude of 
myometrial contractility in  vitro following incubation with progesterone 1 µM 
n≥6 . There was no significant difference in any of the drugs tested after the 
incubation with progesterone (ANOVA). 
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